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Clinical and immunological characterization of naturally occurring canine lymphoma: 
development and application of engineered recombinant antibodies for diagnosis and 
treatment 
Non-Hodgkin lymphoma (NHL) is one of the most common causes of cancer-related death 
worldwide. Although the outcome of NHL patients has improved with current therapies, the 
rate of mortality is still high. A plethora of new drugs is entering clinical development for 
NHL treatment; however, the approval of new treatments remains low due in part to the 
paucity of clinically relevant models for validation. Canine lymphoma (cNHL) shares 
remarkable similarities with its human counterpart, making the dog an excellent animal model 
to explore novel therapeutic options. Therefore, driven by the great success achieved by 
immunotherapies in human NHL, comparative research has focused on the development of 
similar immunotherapeutic approaches for dogs. However, the successful use of this animal 
model remains challenging, still lacking the characterization of the canine immune system, of 
common tumor epitopes, the development of canine-specific/cross-reactive agents and the 
establishment of preclinical models. Within this context, we aimed to develop novel antibody-
based therapies for cNHL, while contributing for the characterization and validation of the 
cNHL model for translational immune-oncology research.  For that purpose, a cNHL biobank 
was successfully constructed. The clinical cytokine patterns in patients with cNHL were 
investigated, confirming a local and systemic dysregulation in cytokine response. 
Furthermore, a positive correlation between intratumoral immune response and a favorable 
response to chemotherapy indicates that the modulation of the immune response might 
contribute to improve patient outcomes. With that in mind, a through characterization of 
canine CD20 expression was conducted and contributed for the validation of this receptor as a 
potential immunotherapeutic target for cNHL. This motivated the development and 
identification of a panel of single domain antibodies (sdAbs) with high binding activity and 
specificity to canine and human CD20. In addition, to develop a novel drug delivery system 
for cNHL treatment, we described novel methodologies to identify potential targets, while 
selecting highly specific sdAbs against NHL. This work allowed to select a promising pool of 
sdAbs that specifically target NHL tumor receptors for the development of a novel antibody 
drug conjugate (ADC).  Furthermore, we conducted a thorough investigation of a novel ADC 
payload – panobinostat - a potent histone deacetylase (HDAC) inhibitor with strong in vitro 
and in vivo antitumor properties in cNHL. Finally, we established a new bioluminescent 
murine model for monitoring tumor progression and treatment response in preclinical studies. 
In summary, the work presented herein allowed the establishment of a solid platform for the 
acceleration of the translational research of novel immunotherapeutic approaches for 
comparative oncology. 
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Caracterização clínica e imunológica do linfoma canino como modelo animal: 
Desenvolvimento de anticorpos recombinantes para tratamento e diagnóstico 
O linfoma não-Hodgkin (LNH) é uma das principais causas de morte por neoplasia em todo o 
mundo, representando 90% de todos os linfomas. O LNH abrange um grupo heterogéneo de 
tumores, caracterizado pela proliferação de linfócitos malignos, 85-90% dos quais de 
linfócitos B. Os anticorpos direccionados para o recetor CD20, combinados com 
quimioterapias convencionais revolucionaram o tratamento do linfoma de células B, 
melhorando o tempo de remissão e aumentando a taxa de sobrevivência. No entanto, 
independentemente da terapêutica utilizada, a taxa de mortalidade mantém-se elevada.  
Uma grande diversidade de novos fármacos encontra-se em fase de desenvolvimento clínico 
para o tratamento do LNH; no entanto, a aprovação de novos tratamentos permanece baixa 
devido, em parte, à escassez de modelos clinicamente relevantes para validação. O cLNH e o 
LNH humano (hLNH) partilham muitas características histopatológicas, moleculares, 
genéticas e clínicas, desta forma o cão é considerado um excelente modelo animal para 
explorar novas opções terapêuticas. Consequentemente, a investigação em oncologia 
comparativa, motivada pelo grande sucesso alcançado pelas imunoterapias no tratamento do 
hLNH, tem-se focado no desenvolvimento de abordagens imunoterapêuticas semelhantes para 
cães. Contudo, o sucesso do cLNH como modelo animal tem vindo a revelar-se desafiante, na 
medida que a validação do seu uso para o desenvolvimento de imunoterapias ainda carece da 
caracterização do sistema imune canino, das células imunitárias e das moléculas efectoras, da 
avaliação dos epítopos tumorais comuns, do desenvolvimento de agentes imunoterapêuticos 
específicos para a espécie canina com potencial reacção cruzada com a espécie humana e do 
estabelecimento de modelos pré-clínicos para oncologia veterinária. 
Neste contexto, o presente trabalho teve como principal objectivo validar o cLNH como 
modelo animal para o desenvolvimento de novas estratégias imunoterapêuticas para LNH, 
visando estabelecer uma linha de investigação inovadora para o desenvolvimento de 
anticorpos recombinantes para o tratamento do cLNH. Neste sentido, desenvolveu-se uma 
estratégia multidisciplinar constituída por etapas complementares de modo a construir uma 
sólida plataforma para o desenvolvimento de ensaios clínicos de imunoterapias em oncologia 
comparativa.  
Após uma breve sinopse no capítulo 1 com uma revisão bibliográfica das principais temáticas 
que contextualizam os objectivos deste trabalho, o capítulo 2 foca-se no papel das citoquinas 
no cLNH, importantes mediadores da interacção entre as células tumorais e o seu 
microambiente. No hLNH, diversas citoquinas foram associadas ao desenvolvimento de 
linfoma e demonstraram ser relevantes biomarcadores da resposta à terapêutica e de 
prognóstico. Em contraste, poucos estudos investigaram o seu papel no cLNH. Neste 
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contexto, um dos objectivos deste trabalho foi a avaliação da expressão e regulação das 
citoquinas no cLNH multicêntrico. Para este fim, foi construído com sucesso um biobanco de 
cLNH, composto por amostras colhidas de doentes seguidos no Hospital Escolar da FMV-
ULisboa. O perfil de ARNm de citoquinas pertencentes à resposta TH1/TH2/TH17 no tecido 
tumoral e nos PBMC circulantes foi investigado recorrendo à técnica de qRT-PCR e os 
resultados obtidos comparados com os do grupo de controlo constituído por cães saudáveis. 
As concentrações de citoquinas sistémicas foram também avaliadas usando um ensaio 
comercial multiplex canino, incluindo as citoquinas IL-2, IL6, IL-10 e TNF-α, e comparadas 
com o grupo de animais de controlo. Os resultados demonstraram uma desregulação da 
expressão de ARNm das citoquinas, representativa do microambiente tumoral e da resposta 
sistémica presente no cLNH. A regulação intratumoral de citoquinas revelou uma 
sobreexpressão do ARNm das citoquinas mediadoras da inflamação e uma diminuição 
significativa da expressão da resposta humoral e TH2 concomitante. Pelo contrário, a resposta 
sistémica demonstrou um padrão de expressão de ARNm distinto, com predomínio de 
imunossupressão e incapacidade de montar uma resposta TH1. Por sua vez, a quantificação 
serológica de citoquinas demonstrou um aumento significativo da concentração da IL-10 no 
cLNH. Foram descritas diferenças significativas nos parâmetros hematológicos e foi reportada 
uma correlação entre a concentração serológica da IL-6 e a contagem neutrofílica. De 
salientar ainda que foi observada uma correlação positiva entre a expressão de ARNm 
tecidular de IFN-γ pré-tratamento e o aumento do tempo de sobrevida. Ao confirmar e 
amplificar trabalhos prévios, este trabalho contribuiu para a avaliação de citoquinas com 
potencial diagnóstico, prognóstico e terapêutico e para a caracterização do sistema imunitário 
do modelo de cLNH. De destacar ainda a construção bem-sucedida do biobanco de cLNH 
representou uma importante mais-valia, uma vez que a sua manutenção garantirá a 
disponibilidade de diversas amostras adequadamente preservadas para trabalhos em curso e 
futuros projetos.  
Atendendo ao sucesso terapêutico do anticorpo monoclonal Rituximab no tratamento do LNH 
de células B em medicina humana, a comunidade médico-veterinária anseia por uma 
imunoterapia similar para o tratamento do cLNH. Deste modo, para ultrapassar a limitação da 
ausência de reactividade cruzada do Rituximab para o epítopo canino, alguns anticorpos 
monoclonais de primeira geração foram recentemente desenvolvidos, um dos quais obteve já 
aprovação clínica. No entanto, estes anticorpos têm vindo a apresentar resultados clínicos e 
científicos decepcionantes, sugerindo que o desenvolvimento de um mAb eficaz no 
tratamento cLNH poderá requerer uma abordagem mais complexa e inovadora.  
Neste contexto, no capítulo 3, procedeu-se ao desenvolvimento de anticorpos recombinantes 
para o diagnóstico e tratamento de cNHL. Assim, no sub-capítulo 3.1 descreve-se um estudo 
em que foi investigada a sequência do gene do CD20 canino e a sua expressão génica e 
proteica no biobanco canino. É reportada ainda uma nova estratégia para o desenvolvimento 
xiii 
 
de anticorpos anti-CD20 que reconhecem o receptor canino e apresentam reação cruzada com 
o humano. Os resultados obtidos demonstraram uma sobrexpressão deste receptor em células 
de linfoma canino, validando assim o CD20 como um potencial alvo de imunoterapia no cão. 
Para além disso, foi identificada uma nova sequência do CD20 canino, que diverge das 
sequências anteriormente reportadas. Adicionalmente, através do desenvolvimento de uma 
biblioteca variada de anticorpos de domínio único (sdAbs) de coelho contra a nova sequência 
do CD20 canino e da seleção dos melhores sdAbs pela técnica de “phage display” subtractivo 
em células, foi possível identificar um painel de sdAbs com elevada afinidade e 
especificidade para o CD20 canino, com reação cruzada com o CD20 humano. Estes sdAbs 
podem revelar-se promissores para o desenvolvimento de novas alternativas terapêuticas em 
oncologia comparativa. 
Apesar do sucesso do Rituximab, têm vindo a ser descritos vários mecanismos de resistência 
das células tumorais a este anticorpo, o que justifica a procura contínua por novos mAbs. 
Entre as terapêuticas baseadas em mAbs, os anticorpos conjugados com fármacos (ADCs) são 
considerados uma das estratégias mais promissoras, combinando a especificidade de 
reconhecimento tumoral, propriedades farmacocinéticas e de biodistribuição dos anticorpos 
com a potência citotóxica das moléculas pequenas. Considerando o potencial que representa o 
desenvolvimento de um ADC para oncologia comparativa, o subcapítulo 3.2 teve como 
objectivo explorar uma nova estratégia de selecção de anticorpos altamente específicos para o 
LNH, com o objectivo de desenvolver um sistema promissor de entrega de fármacos 
citotóxicos. Para isso, foi construída uma biblioteca de sdAbs de coelho anti-cNHL. A 
combinação de uma selecção por “phage display” subtrativa em células intactas e de uma 
análise com uma técnica de alta capacidade, possibilitou a identificação de um painel de 
sdAbs altamente específicos para o LNH. Este trabalho permitiu assim selecionar um 
promissor painel de sdAbs que reconhecem receptores de NHL in vivo, que no futuro 
esperamos acoplar a fármacos citotóxicos de modo a desenvolver um novo ADC. 
Por sua vez, o capítulo 4 teve como objectivo a identificação e caracterização de um agente 
citotóxico de elevada potência para o desenvolvimento de ADCs. Considerando o sucesso que 
os inibidores da histona desacetilase (HDACis) têm vindo a apresentar no tratamento 
oncológico no Homem, este trabalho visou assim investigar as propriedades antitumorais dos 
HDACis no LNH canino. Para este efeito, um painel de sete compostos (CI-994, 
panobinostat, SBHA, SAHA, scriptaid, tricostatina A e tubacina) foi testado quanto à 
capacidade de inibir o crescimento da linha celular CLBL-1 de linfoma canino difuso de 
células grandes tipo B. Os resultados obtidos demonstraram que todos os compostos testados 
apresentaram efeitos inibitórios dependentes da dose sobre a proliferação das células CLBL-1 
e promoveram o aumento da acetilação das histonas H3. De todos os HDACis estudados, o 
panobinostat provou ser o composto mais promissor tendo sido selecionado para posterior 
avaliação in vitro e in vivo. A citotoxicidade do panobinostat foi associada à histona H3, à 
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acetilação da α-tubulina e à indução da apoptose. É importante salientar que o panobinostat 
inibiu eficazmente o crescimento tumoral num modelo murino de xenotransplante de CLBL-1 
e induziu fortemente a acetilação da histona H3 e a apoptose in vivo. Em conclusão, estes 
resultados fornecem novos dados validando os HDACis em geral e especialmente, o 
panobinostat, como agentes promissores para terapêuticas antitumorais em medicina 
veterinária. 
Por fim, considerando que uma das maiores limitações para a integração do cLNH em estudos 
comparativos é a falta de modelos murinos adequados para estudos pré-clínicos, o capítulo 5 
dedicou-se ao desenvolvimento e caracterização de um novo modelo bioluminescente de 
cLNH de células B. Para este efeito, foi desenvolvida uma linha celular CLBL-1 que expressa 
luciferase exibindo fluorescência verde. Um estudo piloto com três densidades celulares 
diferentes (0,1 x 106, 0,5 x 106 e 1 x 106 células) em ratinhos imunodefiecientes, revelou que 
todos os ratinhos apresentaram indução tumoral 8 dias após a injecção subcutânea, com 100% 
de eficiência de enxerto e não foram observadas diferenças significativas no crescimento 
tumoral entre os grupos. Os tumores eram altamente agressivos e localizados no local de 
inoculação, reproduzindo características histológicas e imunofenotípicas compatíveis com 
LNH canino de células B. Além disso, os tumores foram detectados e quantificados por 
imagiologia bioluminescente. Consequentemente, foi realizado um ensaio terapêutico com o 
panobinostat, tendo-se observado que o tratamento com 20 mg/kg inibiu significativamente o 
crescimento tumoral, tendo a imagiologia bioluminescente permitido a monitorização e 
quantificação da resposta tumoral à terapêutica. Este estudo permitiu assim validar um 
modelo de cLNH de células B que oferece uma elevada eficiência de indução tumoral, 
preservação das características tumorais e monitorização da progressão tumoral através da 
utilização de um método não invasivo. 
Em suma, os trabalhos apresentados nesta tese constituem importantes pilares para a 
construção de uma sólida plataforma de aceleração da investigação translacional de 
inovadoras estratégias imunoterapêuticas em oncologia comparativa.  
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Bibliographic review and objectives 
 
1.1. Cancer immunotherapies – challenges and prospects 
 
In 2015 alone, cancer was responsible for 8.8 million deaths worldwide in countries of all 
income levels, ranking second place in the leading causes of death, behind cardiovascular 
diseases (Fitzmaurice et al., 2017). Owing to population growth, aging, and adoption of 
lifestyle behaviors associated with cancer risk, this number is expected to rise by about 70% 
over the next 20 years (Fitzmaurice et al., 2017; Torre, Siegel, Ward, & Jemal, 2016). Still, 
even though these impressive numbers demonstrate that cancer burden remains a major 
challenge worldwide, recent developments in personalized medicine and novel treatment 
approaches, such as immunotherapy, have raised hope of significantly improving cancer 
survival (Global Burden of Disease Cancer Collaboration, 2017). 
The concept of harnessing the host’s immune system to treat cancer can be traced back 
decades, however only in recent years immunotherapies have emerged as a clinically 
validated and effective treatment strategy (Yang, 2015). Nowadays, 
cancer immunotherapy positions as a fast-growing field and rapidly became the fourth pillar 
of cancer care, along with surgery, cytotoxic therapy and radiotherapy (Emens et al., 2017). 
More recently the successes of clinical breakthroughs, such as checkpoint inhibitors and 
engineered T cells, revitalized the field and highlighted the opportunities that 
immunotherapeutic approaches can offer, which culminated in the nomination of “cancer 
immunotherapy” as 2013’s Breakthrough of the Year by Science (Farkona, Diamandis, & 
Blasutig, 2016; Marks, 2017). 
However, by transforming the cancer therapeutic landscape, this complex modality brought 
unique challenges to the drug discovery and development industry. In fact, as more cancer 
patients have received immunotherapies, some of the major drawbacks of these treatments 
have become clear. One of the major issues is to determine the sub-populations of patients 
who will respond and who will experience at times significant toxicities (Ventola, 2017). As a 
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matter of fact, the challenge now is to extend the range of patients that benefit from 
immunotherapy while minimizing treatment-related adverse events. To address this, it is 
crucial to identify factors predictive of response that may help to properly select patients for 
treatment, identify rational combination therapies, and define progression and resistance 
(Klevorn & Teague, 2016). This is particularly critical when developing cancer 
immunotherapies, considering that the patient’s immune system is expected to be as 
significant as tumor-related aspects when determining response and toxicity (Park et al., 
2016).  
Clinical translation of cancer immunotherapy depends on preclinical investigation and rodent 
models have been the foundation of preliminary basic investigation and safety assays 
(Malaney, Nicosia, & Davé, 2014). However, these models underrepresent the heterogeneity 
and complex interaction between the human immune cells and cancers. As a matter of fact, 
laboratory mice rarely develop spontaneous tumors, are housed under specific-pathogen free 
conditions that markedly influences immune development, and incompletely model key 
characteristics of the tumor/immune microenvironment, creating challenges for clinical 
translation. As a result, these murine models have failed to correlate with clinical success 
rates, demonstrating an urgent need for innovative pre-clinical models (Biemar & Foti, 2013; 
Kohnken, Porcu, & Mishra, 2017; Kola & Landis, 2004). Thereby, the use of alternative 
animal models is pivotal to bridge the translational gap between murine models and human 
clinical studies. In particular, preclinical models with intact immune systems that closely 
mimic the human immune system, display comparable, spontaneous oncogenesis and immune 
interactions to humans, and that can model key immunotherapeutic outcomes such as 
efficacy, dose response, and toxicity, will be critical for progress in translational cancer 
immunotherapy research (Park et al., 2016). 
Thus, comparative medicine offers an important platform with innovative complex cross-
species models that allow the research of novel therapeutic strategies and agents for diseases 
that are common to animals and humans (Figure 1) (Henry & Bryan, 2013; Porrello, Cardelli, 
& Spugnini, 2006). In particular, the canine model represents a powerful resource of models 
for cancer immunotherapy research. Dogs are an appealing outbred combination of 
companion animals that experience spontaneous cancer development in the setting of an intact 
immune system (Park et al., 2016). Besides, naturally occurring tumors in dogs present many 
clinical, pathological, immunologic, molecular, diagnostic and therapeutic similarities to those 
observed in humans, that are difficult to reproduce in other models (Gardner, Fenger, & 
London, 2016; Pinho, Carvalho, Cabral, Reis, & Gärtner, 2012; Ranieri et al., 2013; Rowell, 
McCarthy, & Alvarez, 2011). This allows studying the complex immune interactions during 
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the course of treatment while also addressing long-term efficacy and toxicity of cancer 
immunotherapies (Park et al., 2016).  
Nevertheless, the integration of the canine model in immunotherapeutic approaches research 
requires diagnosis, staging and treatment response assessment optimization and 
standardization, to perform large and organized clinical trials and to achieve conformity when 
analyzing data (Marconato et al., 2017).  
 
Figure 1 - The remarkable similarity in cancers shared by human and dog 
 
The cancers shown are found in both human and canine populations, and several ongoing studies emphasize the 
similarities at the genomic level. The incidence of cancers in both species is shown, highlighting the more than 
2.5×number of cancers diagnoses in pet dogs each year. Comparative oncology is a growing trans-disciplinary 
field that harnesses these data, adding evidence to support a shared pathogenesis. Adapted from (Schiffman & 
Breen, 2015). 
 
1.2.  Non-Hodgkin Lymphoma 
 
Lymphomas are solid tumors of lymphoid cells and are divided into Hodgkin’s lymphoma 
and Non-Hodgkin lymphoma (NHL) (Hennessy, Hanrahan, & Daly, 2004). NHL is the fourth 
most common cancer and the sixth most common cause of cancer-related death in the United 
States and its incidence has nearly doubled since the early 70s (Kong, Barisone, Sidhu, 
O’Donnell, & Tuscano, 2015; Siegel, Miller, & Jemal, 2015). NHL represents 90% of all 
lymphomas and encompasses an heterogeneous group of cancers characterized by the 
proliferation of malignant lymphocytes, 85–90% of which arise from B lymphocytes, whereas 
the remaining derive from T cells or NK cells. This diverse group of malignancies usually 
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develops in the lymph nodes, but can occur in almost any tissue, ranging from the more 
indolent follicular lymphoma to the more aggressive diffuse large B-cell and Burkitt's 
lymphoma (Shankland, Armitage, & Hancock, 2012).  NHL patients typically present with 
persistent painless lymphadenopathy, but some patients may present with constitutional 
symptoms or with involvement of organs other than the lymphoid and hematopoietic system 
(Ansell, 2015).  
The basis of treatment selection requires an accurate diagnosis, a careful staging of the 
disease, and the identification of adverse prognostic factors. Regardless, NHL patients most 
commonly receive chemoimmunotherapy as initial treatment. Radiation therapy may be 
performed if patients have early-stage disease (Ansell, 2015). Response rates to conventional 
chemotherapy are generally greater than 50%; however, most patients eventually relapse. 
Moreover, the toxicity of conventional chemotherapy often limits its efficacy (Kong et al., 
2015).  In the last decades, the scientific community has been reporting cases of therapeutic 
success using monoclonal antibodies (mAbs) in the treatment of NHL in humans. One of the 
most successful examples has been the application of mAbs targeting the surface antigen 
CD20 (Rituximab®) (Figure 2) in combination with chemotherapy regimen CHOP 
(cyclophosphamide, doxorubicin, vincristine and prednisolone), which has revolutionized the 
treatment of B-cell lymphoma by significantly improving disease-free interval and overall 
survival, with minimal toxicity (Ito, Brewer, Modiano, & Beall, 2015; Motta et al., 2010). 
Even though current therapy strategies have significantly improved prognosis of patients 
diagnosed with NHL, a significant fraction of patients relapse or are refractory to these 
treatments. Several treatment shortcomings have been identified as research priorities, 
however rituximab resistance and refractory/relapsed disease represent major current and 






















The antibody labels B lymphocytes, which have the CD20 cell marker. These cells are then killed by one of three 
mechanisms: antibody-dependent cytotoxicity, complement-dependent cytotoxicity, or stimulation of apoptosis. 
 
1.3.  Rationale for a canine model of lymphoma 
 
For a long time, research in lymphoma has benefited from traditional mouse models, however 
the paucity of truly representative models has hindered complete understanding of disease 
biology and drug development. With the introduction of genomics technology, nontraditional 
animal models have been more accessible and the leverage of these opportunities may 
represent a novel strategy to accelerate disease research and new drug discovery (Richards & 
Suter, 2015). Furthermore, there is an increasing number of studies demonstrating that 
spontaneously arising lymphoma in dogs could be an invaluable resource to study the biology 
and treatment of this disease (Marconato, Gelain, & Comazzi, 2013). As such, the canine 
lymphoma (cNHL) model may help to bypass many of the limitations associated with the use 
of murine models while presenting other additional advantages (Ito, Frantz, & Modiano, 
2014; Khanna et al., 2006).  
The canine lymphoma  shares many remarkable similarities with its human counterpart (Ito et 
al., 2014; Kisseberth et al., 2007; Ponce et al., 2010; Rütgen et al., 2010, 2012). The incidence 
of cNHL of 15–30/100 000 is similar to human incidence (Hahn, Bravo, Adams, & Frazier, 
1994; Vail & MacEwen, 2000), though recent studies indicate that the incidence of cNHL 
may be higher (Hansen & Khanna, 2004). Classification and grading schemes of cNHL were 
designed to reflect the equivalent in people and facilitate comparison. In fact, the 2008 revised 
Figure 2 –Schematic illustration of the mechanism of action of rituximab. 
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World Health Organization (WHO) classification based on the Revised European American 
Lymphoma (REAL) classification system, which attempts to group lymphomas by cell type, 
phenotypic, genetic and molecular aspects, is the current standard for the diagnosis and 
classification of human lymphoma, also serves as the basis for the current canine 
recommendations (Seelig, Avery, Ehrhart, & Linden, 2016; Swerdlow, 2008). The use of 
these current WHO guidelines as a template, allowed to describe 20 cNHL entities, among 
nearly 50 discrete subtypes of human NHL (hNHL) (Figure 3). Moreover, B-cell lymphoma 
is more prevalent than T-cell lymphoma in both species and the most common type of NHL is 
the same in both humans and dogs is diffuse large B-cell lymphoma (Seelig et al., 2016). 
Finally, treatment modalities for cNHL are similar to those used for human lymphoma 
(radiation, corticosteroids, chemotherapy) and CHOP-based chemotherapy agents are 
typically used to treat it. Response to treatment and resistance also present clinical patterns 
similar to hNHL (Richards & Suter, 2015). 
 
Figure 3 - Relative distribution of common subtypes of cNHL and hNHL. 
 
DLBCL; diffuse large B-cell lymphoma, MZL; marginal zone lymphoma, BL; Burkitt lymphoma, PTCL; 
peripheral T cell lymphoma not otherwise specified, TZL; nodal T-zone lymphoma, LBT; lymphoblastic T-cell 
lymphoma, FL; follicular lymphoma, MALT; mucosa associated lymphoid tissue lymphoma (extranodal MZL), 
CLL; chronic lymphocytic leukemia, MCL; mantle cell lymphoma. Adapted from (Ito et al., 2014). 
 
From a drug development perspective, the canine model represents a large and long-lived 
animal model, evolutionarily more closely related to humans than rodents, that provides a 
more accurate assessment of the pharmacokinetic/pharmacodynamic (PK/PD) parameters, 
while determining safety and efficacy of new therapeutic agents and approaches (Lindblad-
Toh et al., 2005; Richards & Suter, 2015). Moreover, the relatively fast disease progression 
rate allows obtaining early conclusions from clinical trials. In fact, a randomized clinical trial 
in pet dogs requires approximately 1-3 years, whereas a human clinical trial takes about 15 
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years to be completed. This short timeline allows to integrate the findings of pet trials on 
human trials, including toxicity, response, pharmacodynamics, dose, regimen, schedule, 
biomarkers and responding histologies (Marconato et al., 2013) (Figure 4).  
 
Figure 4 -A comparative and integrated approach to cancer drug development.  
 
An optimal drug development path would integrate both preclinical and clinical components of drug 
development so that questions that emerge in the human clinic could be answered in animals. Translational drug 
development studies in the pet dog with cancer are optimal for such an integrated approach, being an 
intermediary between conventional preclinical models (mouse, research-bred dog and non-human primate) and 
the human clinical trial. Through this integrated approach it is likely that important questions about a new drug 
candidate can be answered before it enters human studies, for example, toxicity, dose, regimen, 
pharmacokinetics, pharmacodynamics and activity. Adapted from (Paoloni & Khanna, 2008). 
 
Another main advantage of the canine model is that cNHL is a spontaneously occurring tumor 
in an immune-competent host, in contrast to murine xenograft or genetically engineered 
mouse models. This natural occurring cancer setting offers genetic diversity similar to human 
lymphoma and allows to study biological mechanisms, such as tumor initiation and 
promotion. Moreover, the pet dog model harnessed by the evolutionary conservation allows to 
identify similarities between canine and human lymphomagenesis, for example in identifying 
key ‘driver’ gene mutations common to both species (Richards & Suter, 2015).  
In addition, the benefits of the cNHL model extend beyond the biological advantages of a 
spontaneously occurring tumor in a large animal. Pet dogs share the same living environment 
as their caregivers, allowing to study environmental risk factors of developing lymphoma 
(Marconato et al., 2013; Richards & Suter, 2015). For example, an epidemiological study in 
France demonstrated a correlation between the incidence of cNHL and hNHL and reported a 
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strong association between cNHL and the distribution of waste incinerators, radioactive waste 
or other polluted sites (Pastor et al., 2009). Moreover, there is an increased prevalence of 
lymphoma within specific dog breeds (Gamlem, Nordstoga, & Glattre, 2008) and a breed-
specific distribution of B-cell and T-cell lymphomas (Modiano et al., 2005).  This in 
association with the well-organized multi-generational pedigrees kept by many breeders, 
represents a unique genetic advantage that allows the genetic mapping of lymphoma 
predisposition genes with strategies that are not possible in humans (Marconato et al., 2013). 
The final rationale for using dogs with lymphoma as an animal model relies on the dual 
benefit concept of this comparative research approach. Improved current health care have 
promoted the increase dogs lifespan, allowing the diagnosis of late-in-life diseases such as 
cancer (Paoloni & Khanna, 2007). Lymphoma particularly is one of the most common 
malignancies in dogs (Marconato et al., 2013). In addition, the social status of dogs as 
companion animal allows them to benefit from high quality health care and the ethical 
exploration of translational approaches. Moreover, these initiatives are also motivated by the 
increasing healthcare standards demanded by pet owners, creating a need for novel cancer 
therapies in veterinary settings  (Henry & Bryan, 2013; Porrello et al., 2006; Weiskopf et al., 
2016). Altogether, the use of the cNHL  model represents a unique opportunity to strengthen 
the collaboration between human and veterinary medicine in lymphoma research, that 
ultimately will lead to advances in the care of people and dogs affected by NHL (Gardner et 
al., 2016; Richards & Suter, 2015). 
 
1.4.  Canine Lymphoma 
 
Lymphomas are among the most commonly diagnosed neoplasias in the dog and represents 
the most frequently managed neoplasia in veterinary medical oncology (Zandvliet, 2016). The 
generic term of cNHL comprises a heterogeneous group of lymphoid malignancies that have 
different cells of origin and biological behaviors (Ito et al., 2014). 
 
1.4.1. Epidemiology and etiology 
 
Lymphoma comprises 83% of all canine hematopoietic malignancies and 7-24% of all canine 
neoplasias and its frequency is increasing (Crow, 2008; Dobson, Samuel, Milstein, Rogers, & 
Wood, 2002; Ito et al., 2014; Jemal et al., 2004; Marconato et al., 2013). Lymphoma affects 
dogs of any age, but occurs most frequently in middle aged to older dogs (median age of 6 to 
9 years), with the incidence rate increasing with age from 1.5 cases per 100.000 dogs for dogs 
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10 years. Moreover, certain breeds show predisposition such as boxers, bull mastiffs, basset 
hounds, St. Bernards, scottish terriers, airedales and bulldogs. There is no apparent sex 
predisposition, but intact female dogs seem to have a reduced risk (Villamil et al., 2009; 
Withrow, Page, & Vail, 2013). 
The etiology of this neoplasia has a multifactorial character, emerging from genetic 
abnormalities, predisposition (breed, in the case of dogs) and environmental exposures 
(Modiano et al., 2005; Pastor et al., 2009). Although there is no definitive proof of a viral 
etiology similar to humans (Waugh et al., 2015), the detection of reverse-transcriptase activity 
in supernatants of lymph node cultures from dogs with lymphomas (Tomley, Armstrong, 
Mahy, & Owen, 1983), as well as the detection of a gamma-herpes (Epstein-Barr) virus in a 
proportion of cNHL cases (Chiou, Chow, Yang, Chiang, & Lin, 2005; Huang et al., 2012; 
Milman, Smith, & Erles, 2011) have supported the theory of a possible viral cause. Despite 
the association of Helicobacter-infections with the development of gastric mucosa associated 
lymphoid tissue lymphoma in humans, experimental infections in Beagles showed only the 
formation of lymphoid follicles and no progression to gastric lymphoma (Rossi et al., 2000). 
Observational and clinical studies have associated increased cancer risks with primary or 
acquired immunodeficiencies, autoimmunity, and use of immunosuppressive therapy for 
organ or stem cell transplantation and/or chronic inflammation (e.g. autoimmunity) (Ponce et 
al., 2014). There are few evidences supporting this association in the dog. Nevertheless, 
autoimmune disease (most likely secondary) is frequent in dogs with cNHL (Keller, 1992) 
and there is a case report of a dog diagnosed with cNHL after cyclosporine treatment 
(Blackwood, German, Stell, & O’Neill, 2004). 
 
1.4.2. Clinical presentation 
 
cNHL displays several histological subtypes and patients can manifest a wide range of 
symptoms. The most common clinical presentation of cNHL is multicentric (Ettinger, 2003).  
Extranodal forms include mediastinal, abdominal (gastrointestinal, hepatic, splenic, renal), 
cutaneous, ocular, central nervous system and pulmonary lymphoma. The clinical 
presentation of cNHL can be further complicated by the presence of paraneoplastic 







1.4.2.1. Multicentric lymphoma  
 
Multicentric lymphoma accounts for ±75% of dogs and is characterized by the presence of 
generalized superficial lymphadenopathy with splenic, hepatic and/or bone marrow 
involvement (Marconato et al., 2013; Ponce et al., 2010; Vezzali, Parodi, Marcato, & Bettini, 
2010). Most dogs with multicentric lymphoma are asymptomatic; however 20% to 40% of 
dogs will exhibit nonspecific clinical signs such as anorexia, weight loss, vomiting, diarrhea, 
emaciation, ascites, dyspnea, polydipsia, polyuria and fever (Ettinger, 2003; Marconato et al., 
2013). 
Multicentric lymphoma classification defined by WHO comprises five stages (Table 1). 
Sometimes, lymphoma involves only a single lymph node (stage I) or multiple lymph nodes 
localized in a region of the body (stage II), however generalized lymphadenopathy (stage III), 
with secondary involvement of liver and/or spleen (stage IV) or blood and/or bone marrow 
(stage V) are more frequent (Ettinger, 2003; Zandvliet, 2016). A substage may be used for 
clinical characterization using the suffix a when systemic signs are absent and b when signs 
such as fever, weight loss are present (Zandvliet, 2016). 
 







Single node or lymphoid tissue in single organ (except bone marrow) 
Regional involvement of multiple lymph nodes (±tonsils) 
Generalized lymph node involvement 
Stage I-III with involvement of liver and /spleen 




Absence of systemic signs 
Presence of systemic signs (fever, >10% weight loss, hypercalcemia) 
 
1.4.3. Diagnosis and staging 
 
Diagnosis of cNHL should routinely include a complete physical examination, as well as 
hematological, clinical chemistry profile (Gavazza, Sacchini, Lubas, Gugliucci, & Valori, 
2009) and in some cases urinalysis (Di Bella et al., 2013). Bone marrow involvement is 
observed in up to 55% of dogs (Raskin & Krehbiel, 1989) and cannot be assessed by 
peripheral blood counts (Martini, Melzi, Comazzi, & Gelain, 2015). Since bone marrow core 
biopsies or flow cytometry of bone marrow are not routinely performed, cytological of a 
single bone marrow aspiration sample remains the proved technique to assess bone marrow 
involvement (Aubry, Spangler, Schleis, & Smith, 2014). However, bone marrow biopsy is 
considered an invasive procedure, and the result has limited effect on prognosis (unless there 
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is massive bone marrow involvement) or treatment, as such it is presently not advised to 
routinely perform a bone marrow biopsy (Vail et al., 2010). 
Thoracic and abdominal radiographs are frequently non-specific and only suggestive of 
lymphoma as a differential diagnosis (Blackwood, Sullivan, & Lawson, 1997). Nonetheless, 
thoracic radiographs can reveal abnormal findings such as pulmonary infiltrates and 
lymphadenopathy in 70% of the cases (Starrak, Berry, Page, Johnson, & Thrall, 1997). 
Moreover, abdominal ultrasonography can be used to evaluate hepatic and/or splenic 
involvement and abdominal lymphadenopathy; however computed tomography (CT) scan is 
ideal to assess the disease extent (Zandvliet, 2016). Recently, it was proposed the use of 
scintigraphy with a radiolabeled peptide nucleic acid–peptide conjugate targeting Bcl2 mRNA 
for detection of neoplastic lymphocytes in dogs with B-cell lymphoma. Preliminary results 
reported advantages of using CT scan in the assessment the disease extent and monitoring 
treatment response (Statham-Ringen et al., 2012). 
A sample collected by fine needle aspiration (FNA) analyzed by an experienced pathologist 
can often suggest a diagnosis of lymphoma. However, histological examination of an 
excisional biopsy is the best choice for pathologic evaluation as a diagnostic method, since 
cytological examination of a FNA may be insufficient to complete the lymphoma 
characterization. An excisional biopsy (removal of a complete lymph node) is preferred, but 
in many cases an incisional (thru-cut) biopsy is sufficient. Flow cytometry of fine needle 
aspirates has demonstrated high potential for lymphoma diagnosis and might reduce the need 
for excisional biopsies (Comazzi & Gelain, 2011; Gelain, Mazzilli, Riondato, Marconato, & 
Comazzi, 2008; Zandvliet, 2016). 
 
1.4.4. Classification  
 
Classification of malignant lymphoma in dogs is based on anatomic location, histologic 
criteria and immunophenotypic characteristics.  
 
1.4.4.1. Anatomic classification 
 
Anatomically, lymphomas can be grouped according to the WHO classification (Owen, 










Clinical Presentation Incidence 
Most common 
immunophenotype 
Multicentric Bilateral and/or symmetrical peripheral 
lymphadenopathy; absence or presence of tumor 
metastasis to liver, spleen, tonsil, and bone marrow. 
75-80% B 
Alimentary Gut-associated lymphoid tissue involvement; single 
or multifocal/diffuse lesions, often with mesenteric 
lymphadenopathy. 
5-7% T 
Mediastinal Associated with an increase in craniomediastinal 
lymph nodes, thymus or both. Hypercalcaemia 
frequently occur as a paraneoplastic syndrome (10-
40% of the cases). 
5% T 
Cutaneous Multifocal or generalized skin involvement, may 
occur involvement of the oral mucosa and extra-
cutaneous involvement of lymph nodes, liver, 
spleen or bone marrow. 
6% T 
Extranodal Occur in any location outside the lymphatic system 
inclusing eyes, central nervous system, bone, testes, 
bladder, heart, and nasal cavity. 
  
 
1.4.4.2. Histologic classification 
 
Classifications developed for NHL in humans have been widely adapted and used by 
veterinary pathologists to classify cNHL. The Rappaport classification (Rapport, H, 1966; 
Teske, Wisman, Moore, & van Heerde, 1994) was one of the earliest classification systems 
applied to canine malignant lymphomas. However, with the increasing knowledge of the 
immunologic aspects of malignant lymphomas, a better understanding of maturation and 
differentiation of lymphoid cells and the advance of chemotherapy, this system was 
abandoned after the emergence of better classification systems, such as the Lukes-Collins 
classification (Lukes & Collins, 1974; Teske, Wisman, et al., 1994) in North America and the 
Kiel classification (Lennert, & Mohri, 1978; Teske, Wisman, et al., 1994) in Europe (Valli et 
al., 2010). The Kiel classification was easily adapted for canine malignant lymphoma (Valli, 
et al., 1981).  
Later, in an attempt to unify the European and North American classifications, the National 
Cancer Institute published the working formulation (Robb-Smith, 1982) - a translational 
system for the existing hNHL classifications, primarily oriented on the clinical outcome and 
less on cellular criteria (Valli et al., 2010). In addition, the original Kiel classification was 
revised, and a modified version (Stein et al., 1981) demonstrated to be applicable to canine 
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malignant lymphomas (Teske, Wisman, et al., 1994) with multiple studies reporting its 
prognostic utility (Kiupel, Teske, & Bostock, 1999; Teske, Wisman, et al., 1994). Both 
systems were widely accepted, and the working formulation became largely used in North 
America with animal studies based on this system (Carter, Valli, & Lumsden, 1986; Fry, 
Vernau, Pesavento, Brömel, & Moore, 2003; Greenlee et al., 1990), while the modified Kiel 
system became extensively used in Europe for both humans and animals (Fournel-Fleury et 
al., 2002; Teske, Wisman, et al., 1994). 
However, both classification systems presented major limitations, demonstrating the need for 
updating all of the previous systems (Valli et al., 2010). This prompted the foundation of the 
International Lymphoma Study Group (ILSG), which proposed the REAL classification 
system (Harris et al., 1994). The distinctive features of the ILSG proposal were that 
lymphomas were classified for the first time as diseases and not simply as cell types, with the 
diagnostic criteria including: cellular morphology and cell lineage, topography and general 
biology of each neoplasia that defined it as a specific disease entity (Valli et al., 2010). The 
REAL system was generally adopted, with a few exceptions, as the revised WHO system of 
classification (Harris et al., 1999). The validity of this latter system has been proven in 
lymphoma and human leukemia by the great consensus among pathologists and has been 
adapted for cNHL. According to this classification, most common subtype of cNHL are 

















Table 3 – Summary of Canine Malignant Lymphoma Revised From the Revised 




























Adapted from (Valli et al., 2010). 
 
1.4.4.3. Immunophenotypic classification 
 
 Immunophenotyping can be performed on a slide-based cytology (Caniatti, Roccabianca, 
Scanziani, Paltrinieri, & Moore, 1996) or on a histological section of biopsy samples (Milner, 
Pearson, Nesbit, & Close, 1996) or using flow cytometry (Culmsee, Simon, Mischke, & 
Nolte, 2001; Gelain et al., 2008).  The most regularly used antibodies include CD20, CD21, 
CD79α and PAX5 as B-cell markers and CD3, CD4 and CD8 as T-cell markers (Caniatti et 
B Cell Neoplasms 
Precursor B cell neoplasms  
Precursor B lymphoblastic leukemia/lymphoma 
Mature (peripheral) B cell neoplasms 
B cell chronic lymphocytic leukemia/prolymphocytic  
Leukemia/small lymphocytic lymphoma  
B cell prolymphocytic leukemia  
Lymphoplasmacytic lymphoma  
Splenic marginal zone B cell lymphoma 
Plasma cell myeloma/plasmacytoma  
Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type 
Nodal marginal zone lymphoma  
Follicular lymphoma 
Mantle cell lymphoma  
Diffuse large B cell lymphoma 
Mediastinal large B cell lymphoma  
Burkitt’s lymphoma/Burkitt’s cell leukemia  
Provisional entity: high-grade B cell lymphoma 
Burkitt’s-like  
Primary effusion lymphoma 
T Cell and Putative Natural Killer Cell Neoplasms 
Precursor T cell neoplasm  
Precursor T lymphoblastic 
     Lymphoma/leukemia  
Mature (peripheral) T cell and natural killer cell neoplasms  
T cell prolymphocytic leukemia  
Large granular lymphocyte leukemia  
     Aggressive natural killer (NK) cell leukemia 
     Peripheral T cell lymphomas, unspecified 
     Adult T cell lymphoma/leukemia 
     Intestinal T cell lymphoma (+enteropathy associated) 
Hepatosplenic γδT cell lymphoma 
Subcutaneous panniculitis-like T cell lymphoma 
Mycosis fungoides/Sezary syndrome 
Anaplastic large cell lymphoma, T and null cell primary cutaneous type 
Peripheral T cell lymphoma not otherwise specified 
Angioimmunoblastic T cell lymphoma 




al., 1996). For routine patient management, immunophenotypic analysis using two antibodies 
(typically CD3 and CD79α or CD20) is suitable, however this method can result in up to 20% 
unclassified lymphomas (Guija de Arespacochaga, Schwendenwein, & Weissenböck, 2007). 
More recently the use of the PCR-based clonality assay (PARR), a molecular technique that 
determines the clonality of a population of lymphoid cells by amplifying the DNA encoding 
the variable regions of the B cell receptors or T, has been proposed as an alternative for 
immunohistochemistry or flow cytometry. Flow cytometry proved to be superior over PARR, 
however in the absence of a fresh sample, PARR is an acceptable alternative (Thalheim, 
Williams, Borst, Fogle, & Suter, 2013).  
Regarding the immunologic phenotype, lymphomas may originate from B cells or cells T. 
About 60% to 80% of cNHL are from B-cell origin and T-cell lymphomas account for 10% to 
38%. There may also be lymphomas considered to be mixed, in which both B-cell and T-cell 
populations exist, that account for approximately 22% of the cases, or null, in which the cells 
are neither reactive for B-cell or T-cell markers, representing fewer than 5% of the cases 
(Fournel-Fleury et al., 2002; Greenlee et al., 1990; Ruslander, Gebhard, Tompkins, Grindem, 
& Page, 1997; Vail et al., 1996; Wilkerson et al., 2005). 
 
1.4.5. Conventional treatment 
 
Given the systemic nature, cNHL requires multiagent chemotherapy to achieve a temporary 
remission and prolonged survival (Ettinger, 2003; Withrow et al., 2013). Exceptions include 
lymphomas restricted to a single lymph node or extra-nodal cases in specific organs, in which 
a local modality, such as surgery or radiotherapy, may be indicated as the first approach. 
However, when considering a local modality, the pet owner and clinician must be committed 
to diligent reevaluation due to the possibility of subsequent systemic involvement (Vail, 
Young, & Pinkerton, 2007).  
Considering that the majority of therapy-related studies are directed towards intermediate to 
high grade multicentric lymphomas and that little is known about the optimal treatment for 
low-grade and extranodal forms, this review will focus on the treatment options available for 




Treatment response assessment of dogs with lymphoma relies on specific response criteria 
(Ettinger, 2003). The standardization of these response criteria allows for more consistent and 
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reliable comparisons of treatment protocols and outcomes. Recently, the Veterinary 
Cooperative Oncology Group published an integrated guidance from the response assessment 
criteria established for lymphoma in human using standards available in routine veterinary 
oncology practices that are simple, repeatable and consistently applicable. These guidelines 
are intended only for use in dogs with peripheral lymphadenopathy involvement and is not 
indicated for extranodal disease. In this document there are presented the general disease 
response definitions (Table 4) (Vail et al., 2010). 
 
Table 4 - General disease response definitions. 
Lesion response Definition 
Complete response (CR) Target lesions: Disappearance of all evidence of disease. All lymph nodes 
must be non-pathologic in size in the judgment of the evaluator(s). Non-
target lesions: Any pathologic lymph nodes must be considered to have 
returned to normal size in the judgment of the evaluator(s), and no new 
sites of disease should be observed. Spleen and liver should be considered 
within normal limits by the evaluator(s). 
Partial response (PR) Target lesions: At least a 30% decrease in the Mean Sum LD of target 
lesions taking as reference the baseline mean sum LD. Non-target lesions: 
Not applicable.a 
Progressive disease (PD) Target lesions: At least a 20% increase in the Mean Sum LD taking as 
reference the smallest mean sum LD at baseline or during follow-up (this 
includes the baseline mean sum LD if that is the smallest on study). The 
LD of at least one of the target lesions must demonstrate an absolute 
increase of at least 5 mm compared with its nadir for PD to be defined. For 
target lesions <10 mm at nadir, an increase in LD of any single 
previouslyidentified target lesion to >15 mm. Non target lesions: 
unequivocal progression of existing non-target lesions, in the judgment of 
the evaluator. (Note: the appearance of one or more new lesions is also 
considered progression). 
Stable disease (SD) Target lesions: Neither sufficient decrease to qualify for PR nor sufficient 
increase to qualify for PD. Non-target lesions: Not applicable.a 
 
Adapted from (Vail et al., 2010). 
 
1.4.5.2. Chemotherapy  
 
In the case of lymphoma, the fundamental goals of chemotherapy are to induce a complete 
durable (>6 months) first remission (termed induction), to reinduce a remission when the 
tumor recurs after achieving remission (termed reinduction), and, finally, to promote 
remissions when the cancer no longer respond to induction or reinduction using the initial 
protocols (termed rescue) (Withrow et al., 2013).  
Several protocols have been proposed for the treatment of cNHL, and generally, combination 
chemotherapy protocols have proved to be more effective compared to single-agent protocols. 
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In fact, induction therapy with single-agent chemotherapy does not normally result in durable 
remission as standard combination protocols (Withrow et al., 2013).  
 
1.4.5.2.1. Single agent protocols 
 
The most effective agents used as monotherapy against cNHL are doxorubicin (Hahn et al., 
1992; Simon et al., 2008), L-asparaginase (MacEwen, Rosenthal, Matus, Viau, & 
Abuchowski, 1987; Teske, Rutteman, van Heerde, & Misdorp, 1990), vincristine, 
cyclophosphamide, and prednisolone (R. Chun, Garrett, & Vail, 2000; Garrett, Thamm, Chun, 
Dudley, & Vail, 2002; Vail et al., 2007). Owing to their ability to induce 
apoptosis in lymphocytes (Smith & Cidlowski, 2010), synthetic glucocorticoids are widely 
used in the treatment of cNHL and may be instituted as a single therapy, when conventional 
chemotherapy is not available. Although most dogs present a good partial to complete 
response that normally persists for 60–90 days (Bell, Cotter, Lillquist, Sallan, & McCaffrey, 
1984; Squire, Bush, Melby, Neeley, & Yarbrough, 1973), this protocol should be considered a 
palliative treatment, as its use prior to chemotherapy is associated with tumor resistance, 
leading to shorter periods of remission and survivals (Gavazza, Lubas, Valori, & Gugliucci, 
2008; Marconato et al., 2011; Price, Page, Fischer, Levine, & Gerig, 1991; Teske, van 
Heerde, et al., 1994; Zandvliet, 2016).  
Other drugs that have reported activity are often considered second-line agents and include 
lomustine (Sauerbrey et al., 2007), vinblastine, actinomycin-D, mitoxantrone (Lucroy, 
Phillips, Kraegel, Simonson, & Madewell, 1998), mustargen, chlorambucil, methotrexate, 
dacarbazine, 9-aminocamptothecin, ifosfamide, cytosine arabinoside, and gemcitabine.  
The Lomustine® (CCNU) can be used as a single agent in the treatment of particular cases, in 
which the owners seek for a simple protocol but are willing to accept the shorter survival 
times. CCNU is most commonly used as a rescue therapy for multicentric lymphoma and in 
the treatment of cutaneous epithelial lymphoma (Moore et al., 1999; Risbon et al., 2006). 
Of all of these protocols, doxorubicin as a monotherapy, either as a continuous or an 
intermittent protocol, appears to be the most effective, however its efficacy is still inferior 
compared to a doxorubicin-based multi-agent protocol and this alternative should be reserved 







1.4.5.2.2. Combination agent protocols 
 
The selection of combination chemotherapy regimens for cancer treatment aims to delay as 
much as possible the onset of multidrug resistance (MDR), by using drugs with different 
mechanisms of action. As such, when designing a combination chemotherapy protocol, each 
drug in a combination should be effective as a single agent, should not share resistance 
mechanisms, and ideally, should not result in overlapping toxicities (Saba, Hafeman, Vail, & 




The COP protocol consists of a combination of cyclophosphamide (C), vincristine (O - 
Oncovin) and prednisolone (P). Despite being a well-tolerated and relatively inexpensive, the 
long-term treatment aspect of this protocol limits its use. This protocol includes a high and 
low dose dosage and presents remission rates of 60 to 70%, with a median survival of 6 to 7 




Presently, the CHOP based protocols represent the most successful therapies, yielding 
temporary remission (9–11 months) in approximately 85% of dogs (Meuten, 2008; Valerius, 
Ogilvie, Mallinckrodt, & Getzy, 1997; Withrow et al., 2013). CHOP refers typically to 
injection-protocols that combine Cyclophosphamide, vincristine (Oncovin), Prednisolone 
(COP) with doxorubicin (Hydroxydaunorubicin) (CHOP) and/or L-asparaginase (L-CHOP) 
(Zandvliet, 2016) (Table 5). In fact, just recently, a study has demonstrated that doxorubicin 
and vincristine strongly decreased the viability of cNHL cell lines, whereas 
cyclophosphamide induced the highest level of apoptosis (Pawlak, Rapak, Zbyryt, & 
Obmińska-Mrukowicz, 2014). By incorporating doxorubicin, the CHOP protocol and its 
derivatives resulted in the highest response rate and longest response durations and form the 
basis for most currently used treatment protocols for high-grade cNHL. Early proposed 
protocols consisted of two phases - an intensive induction phase using an intensive protocol 
that aimed at inducing complete remission, and a following maintenance phase using a less 
intensive protocol that aimed at maintaining the disease in remission (maintenance phase). It 
was later shown that a continuous maintenance phase following successful induction, offered 
no treatment benefit and decreased the probability of attaining a second remission after 
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relapse (Chun et al., 2000; Lautscham, Kessler, Ernst, Willimzig, & Neiger, 2017), as such 
the therapy duration was reduced. Although a 6 month protocol, such as the modified protocol 
of the University of Wisconsin of 25 weeks, is considered the standard of care (Chun et al., 
2000; Garrett et al., 2002), shorter  protocols (12-week (Simon et al., 2006) and 15-week 
(Burton, Garrett-Mayer, & Thamm, 2013)) have been reported and have shown similar 
effectiveness.  
A high-dose CHOP protocol has been fairly successful in improving the duration of first 
remission (Chun et al., 2000). However, toxicity has caused treatment delays or 
discontinuation in more than 44% of cases, leading to its abandonment. Finally, the 
association of other cytotoxic drugs with single-agent activity with CHOP-based protocols 
has not demonstrated significant advantages and most are reserved for subsequent rescue 
therapy purposes (Withrow et al., 2013). 
 
Table 5 - University of Wisconsin–Madison: 19-week combination chemotherapy 





















Vincristine: 0.5-0.7 mg/m2 IV; Prednisone: 2 mg/Kg PO 
Ciclofosfamide: 250 mg/m2 IV* ; Prednisone: 1.5 mg/Kg PO 
Vincristine: 0.5-0.7 mg/m2 IV; Prednisone: 1 mg/Kg PO 
Doxorubicin: 30 mg/m2 IV; Prednisone: 0.5 mg/Kg PO 
No treatment 
Vincristine: 0.5-0.7 mg/m2 IV 
Ciclofosfamide: 250 mg/m2 IV* 
Vincristine: 0.5-0.7 mg/m2 IV 
Doxorrubicin: 30 mg/m2 IV 
No treatment 
Vincristine: 0.5-0.7 mg/m2 IV 
Ciclofosfamide: 250 mg/m2 IV* 
Vincristine: 0.5-0.7 mg/m2 IV 
Doxorrubicin: 30 mg/m2 IV 
No treatment 
Vincristine: 0.5-0.7 mg/m2 IV 
Ciclofosfamide: 250 mg/m2 IV* 
Vincristine: 0.5-0.7 mg/m2 IV 
Doxorrubicin: 30 mg/m2 IV 
 
If the patient is in complete remission at week 9, treatment continues to week 11. If the patient is in complete 
remission at week 19, therapy is discontinued and the dog is rechecked monthly for recurrence. A complete 
blood count should be performed before each chemotherapy treatment—if the neutrophil count is less than 1500 
cells/mcL, the clinician should wait 5–7 days and then repeat the count; the drug is administered if the neutrophil 
count has risen above the 1500 cells/mcL cutoff. * Furosemide is given concurrently with cyclophosphamide to 





1.4.5.2.3. Chemotherapy side effects 
 
Generally, chemotherapeutic regimens designed for pets are well tolerated, presenting less 
than 5% incidence of severe, life-threatening complications. However, by possessing the 
lowest therapeutic indices among the different classes of drugs, these agents frequently cause 
predictable multisystemic toxicities, such as myelosuppression, gastrointestinal disturbances 
and alopecia (particularly in breeds with continually growing hair coats) (MacDonald, 2009). 
Most dogs will experience minimal side effects when treated with appropriate doses of 
chemotherapy and close monitored. However, depending on the side effect severity, some 
may require supportive care or a 20% reduction of drug dosage if gastrointestinal side effects 
or severe neutropenia occur. In addition to common chemotherapy side effects, drugs have 
varying capacities for unique toxicities including cardiotoxicity (doxorubicin), hepatotoxicity 
(lomustine), sterile hemorrhagic cystitis (cyclophosphamide), paralytic ileus (vincristine) and 
hypersensitivity reactions (doxorubicin and L-asparaginase). Lastly, chemotherapy drugs, 
such as doxorubicin and vincristine, are also potent vesicants (blistering agents) and can 
produce extensive and severe tissue injury if they leak out of the blood vessels (MacDonald, 
2009).  
It is important to mention that this relatively good tolerability to chemotherapeutic protocols 
in the treatment of dogs with lymphoma is reported using low dose intense protocols. 
Actually, considering the high response rates, it was reasoned that a dose intensification could 
improve remission and survival rates in dogs with lymphoma. However, the incidence of 
toxicity was high – 53,9% and 45% of the dogs needed dose reductions and treatment delays, 
respectively. In addition, 11% of the dogs in this study were hospitalized because of serious 
acute toxicity. As such, despite the lack of efficacy of the current chemotherapy protocols, it 
is unlikely that significant improvements can be attained through dose intensifications without 
increasing the incidence of serious toxicity or death (Sorenmo et al., 2010).  
 
1.4.5.2.4. Rescue protocols 
 
Rescue protocols are indicated when the patient fails to achieve a durable remission in the 
induction phase of the first-line protocol or relapse following treatment, and include both 
single-agent and multi-agent protocols. The treatment protocol choice is based on the timing 
of relapse in relation to the original (first-line) protocol, previously used drugs (e.g. 
cumulative cardiac toxicity of doxorubicin), and individual clinician's preferences. Regarding 
the moment of relapse, its occurrence during the first-line protocol typically requires the use 
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of alternative drugs (meaning drugs not included in the first protocol), while a relapse 
following completion of the first-line protocol allows to include drugs used in the original 
protocol (Zandvliet, 2016). Several alternative combination chemotherapeutic rescue 
protocols have been used to improve survival in dogs with refractory disease, including 
lomustine, L-asparginase, CCNU, DTIC (Dacarbazine), MOPP (methchlorathamine, 
vincristine, procarbazine, and prednisone), doxil, and prednisolone alone. Still, these 
protocols have mostly proven unsuccessful in significantly increasing survival beyond 2 to 3 
months, and tend to show more toxicity than first-line protocols (Back et al., 2015; Fahey et 




Even though lymphoid cells are sensitive to radiation, radiotherapy represents a second line 
treatment option for cNHL due to the systemic character of lymphoma (Zandvliet, 2016). In 
fact, radiotherapy as a monotherapy for multicentric cNHL (2x half-body irradiation, 7 Gy, 4 
weeks apart), demonstrated scanty results with objective response in 5/14 dogs of complete 
and partial response median duration of 102 and 54 days respectively. Moreover, side effects 
were frequent and particularly serious in dogs with an advanced stage of disease (Laing et al., 
1989). Therefore, radiotherapy is more often used in combination with chemotherapy, as an 
adjuvant and consists of irradiating the whole body, either in a single session of total body 
irradiation (TBI) or two sessions of half body irradiation (HBI). TBI is associated with severe 
and potentially fatal, bone marrow depression, which requires autologous bone marrow or 
peripheral blood stem cell transplantation. Although bone marrow transplantation was already 
implemented in the dog (Weiden, Storb, Deeg, & Graham, 1979) with promising preliminary 
results, morbidity and mortality were high (Appelbaum et al., 1986; Deeg et al., 1985). Even 
though, current work revealed less treatment-related morbidity and mortality (Willcox, Pruitt, 
& Suter, 2012), TBI has been progressively substituted by two HBI sessions . HBI with a high 
or low-dose rate has been assessed following conclusion of or within chemotherapy protocol. 
On one hand, a regular dose-rate HBI - 2x 8 Gy in 2 days, 3-4 weeks apart - performed during 
or after conclusion of a CHOP chemotherapy protocol lead to a moderate increase in first 
(median 311 respectively 455 days) and overall (median 486 days respectively 560 days) 
remission period (Gustafson, Lana, Mayer, & LaRue, 2004; L. Williams et al., 2004). On the 
other hand, a low-dose rate HBI - 10 cGy/min; 2x 6 Gy, 2 weeks apart – combined with a 
CHOP-based chemotherapy protocol resulted in lasting remission (410-455 days) and survival 





Without treatment, cNHL is highly fatal, resulting in death within 4 to 6 weeks (Marconato et 
al., 2013). For the most common form of intermediate to high grade lymphoma (DLBCL), 
treatment with the CHOP chemotherapy protocol typically results in a complete remission in 
up to 95% of patients. Unfortunately, most dogs that achieve remission will eventually relapse 
or present recrudescence of lymphoma within 6 to 9 months of diagnosis and treatment, 
resulting from the emergence of MDR clones - tumor clones or tumor stem cells that are 
naturally more resistant to chemotherapy or that become resistant following exposure to some 
chosen chemotherapy drugs. The median survival time following treatment with CHOP is 
approximately 12 months. Dogs that experience the most significant negative prognostic 
factors, such as stage IV or V, substage b, T-cell immunophenotype, presence of a mediastinal 
mass, anemia, prolonged pretreatment with corticosteroids and gastrointestinal involvement, 
are less likely to achieve a complete remission and more likely to have a shorter remission. 
Indolent lymphomas are associated with longer survival times because of slow progression of 
disease but are considered less chemoresponsive (Vail et al., 2007). 
 
1.4.7. Future goals and challenges 
 
Even though our understanding on the genetics, molecular biology, and diagnosis of cNHL 
has increased substantially over the past 25 years, this has had little effect on treatment and 
has only slightly improved prognosis. Chemotherapy still remains the mainstay for the 
treatment of cNHL and regardless of the numerous published chemotherapeutic protocols, it 
seems we have reached a stalemate concerning what this treatment modality has to offer in 
standard settings (Zandvliet, 2016). The 12 month median survival barrier and the 20% to 
25% 2 years survival rates demonstrate an urgent and unmet need in veterinary medicine to 
develop new treatment strategies for refractory disease (Back et al., 2015; Fahey et al., 2011; 
Flory et al., 2008; Zandvliet et al., 2013). Further advances in remission and survival times 
await the development of new methods of delivering or targeting traditional chemotherapeutic 
drugs, new generation of chemotherapeutic drugs, or novel nonchemotherapeutic treatment 
modalities. Mechanisms of avoiding or eliminating MDR, enhancing tumor apoptosis, tumor 
ablation, and immune-system reconstitution, as well as novel immunomodulatory therapies 






After decades of weakening or even eliminating the patient’s immune system with 
chemotherapy, now the trend is to harness the ability of the immune system to eradicate 
cancer (Klingemann, 2018).  Work from the last two decades has finally brought 
immunotherapy into the forefront of cancer treatment, with demonstrable clinical success for 
aggressive tumors where other therapies had failed (Anderson & Modiano, 2015). The field of 
veterinary immunotherapy holds similar promise for companion animals with cancer, and 
several efforts have been made in order to develop veterinary specific immunotherapies. In 
the nearby future, it is hoped that tumor immunotherapy will become a valid therapeutic tool 
in veterinary oncology, along with chemotherapy, radiotherapy and surgery (Zandvliet, 2016).  
Both passive and active modalities have been used to generate therapeutic anti-tumor immune 
responses in cNHL. Passive immunotherapy involves the transfer of biological reagents, such 
as mAbs or antigen-specific adaptive immune cells, into the cancer patient. Whereas, active 
immunotherapy seeks to elicit an anti-tumor response from the patient’s own immune system, 
typically through vaccination (Mellman, Coukos, & Dranoff, 2011). 
 
1.4.8.1. Passive immunotherapy: Antibodies 
 
The use of a mAbs targeting the human surface antigen CD20 (Rituximab®), expressed on B-
lymphocytes has revolutionized the treatment of B-cell lymphoma by significantly improving 
disease-free interval and overall survival, with minimal toxicity (Ito et al., 2015; Motta et al., 
2010). Rituximab is a chimeric antibody and was the first US Food and Drug Administration 
(FDA) approved mAb for the treatment of human cancer, being used for the treatment of most 
B-cell NHL and subtypes of acute lymphocytic leukemias (Chames, Van Regenmortel, Weiss, 
& Baty, 2009; Dimitrov & Marks, 2009; Waldmann, 2003). This immunotherapy provided 
significant enhancements in the efficacy of treatment versus existing non-mAb therapies, 
increasing the rate of durable remissions from 30% to 60% (Ito et al., 2015). As a result, since 
the approval of rituximab in 1997, multiple antibody-based therapies have been developed for 
human lymphoma . 
Although immunotherapy plays a major role in the treatment of many human B-cell 
malignancies, its role in cNHL is still limited. Whereas immunohistochemistry demonstrated 
the presence of CD20 in cNHL tissue samples (Jubala et al., 2005; Kano et al., 2005), 
Rituximab® failed to bind (Impellizeri, Howell, McKeever, & Crow, 2006). Interestingly, in 
1992, prior to FDA approval of Rituximab, the United States Department of Agriculture 
(USDA) approved the licensing of MAb 231 for use in cNHL. MAb 231 consists of a murine-
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derived mAb that showed both in vitro (Rosales, Jeglum, Obrocka, & Steplewski, 1988) and 
in vivo  activity and served as adjuvant therapy following remission induction with 
chemotherapy (Jeglum, 2009).  
A pilot study of anti-human leukocyte antigen (HLA)-DR mAbs in dogs with lymphoma was 
undertaken to verify the suitability of a canine model to address therapeutically relevant 
endpoints prior to a full trial in dogs, and ultimately human investigation. In vitro studies 
demonstrated that L243, a murine IgG1 anti-HLA-DR, binds to normal and malignant canine 
lymphocytes and induces apoptosis in cNHL cells. Moreover, L243 was administered safely 
to normal dogs and dogs with lymphoma, and bound to malignant cells in nodal tissue. 
Preliminary evidence of transient disease stabilization was observed in a subset of dogs with 
advanced-stage lymphoma following L243 immunotherapy. hL243γ4P (IMMU-114), a 
humanized IgG4 anti-HLA-DR, currently under evaluation preclinically for human trials, also 
shown to bind malignant canine lymphocytes, and safety and pharmacokinetic data from the 
administration of IMMU-114 to normal dogs indicated similar behavior to L243 in these 
assessments. These findings provide a rationale for the use of dogs with lymphoma in safety 
and efficacy evaluations of anti-HLA-DR mAbs for both veterinary and human applications 
(Stein et al., 2011). 
Considering the success achieved with Rituximab in human medicine, several studies focused 
on developing canine anti-CD20 antibodies. Interestingly, although the proposed rituximab 
binding epitopes are conserved between human and canine CD20, the canine mAb does not 
induce direct apoptosis of tumor cells. Studying the differences in the mechanism of action 
between human and canine anti-CD20 mAbs may yield insights to improve the engineering of 
mAbs. Despite these differences, each of the canine anti-CD20 mAbs has been shown to have 
diagnostic or clinical potential (Anderson & Modiano, 2015; Ito et al., 2015). 
A novel anti-canine CD20 mAb (6C8) that recognized the extracellular domain of canine 
CD20 and showed high-affinity binding to canine CD20 in solution and its native 
conformation on canine B-cells was developed. This mAb promoted phagocytosis of B-cell 
lymphoma cells by macrophages, but in its current framework did not induce direct 
cytotoxicity or complement dependent cytotoxicity (Ito et al., 2015). Likewise, a new anti-
CD20 mAb (NCD1.2) that binds both human and canine CD20 has been developed, in order 
to strengthen human-canine comparative model. NCD1.2 binds to clinically derived canine 
cells including B-cells in peripheral blood and in different histotypes of B-cell lymphoma. VH 
and VL genes from the NCD1.2 hybridomas were cloned and packaged as single chains (scFv) 
into a phage-display library Recombinant anti-CD20 scFv were identified and selected as a 
possible useful tool for evaluation in bioconjugate-directed anti-CD20 immunotherapies in 
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comparative  medicine (Jain et al., 2016). Moreover, a canine anti-CD20 mAb has been fully 
approved by USDA for clinical usage in dogs with B-cell Lymphoma and is currently being 
commercialized in the United States and Canada. Treatment with AT-004 anti-canine CD20 
was subject to a prospective randomized clinical trial and preliminary results suggest an 
improved median progression-free survival of dogs with B cell lymphoma (Killick, Stell, & 
Catchpole, 2015). Futhermore, another mAb, anti-CD47, has proved to increase the innate 
anti-tumor immune response of numerous human leukemias and lymphomas xenograft 
models in both in vitro and in vivo settings (Chao et al., 2010; Majeti et al., 2009). 
Preliminary results propose that anti-CD47 may also present these therapeutic effects on the 
canine B-cell lymphoma field (Anderson & Modiano, 2015). In addition, AT-005 (Aratana 
Therapeutics, Del Mar, CA, USA), a speciated mAb targeting CD52 on T cells, has received 
conditional USDA approval for the treatment of T cell lymphoma and is currently being 
evaluated in clinical trials (Klingemann, 2018). 
The development of technology to speciate antibodies has led to a variety of clinical trials in 
companion dogs since “caninization” of antibodies is crucial when approaching canine 
patients with cancer. With this goal in mind, work groups have already presented the 
technique to generate “caninized” antibodies, namely, a canine anti-EGFR IgG and nowadays 
is also a service offered by companies (Singer et al., 2014). 
The success of mAbs in human medicine strongly encourages veterinary medicine to develop 
similar therapeutics for our pets. Despite their potential, little speciated antibodies have been 
established for veterinary use or fewer were tested in veterinary clinical trials. mAbs have the 
capacity to treat a diversity of hematopoietic and solid tumors, do not need to be a 
personalized product and manufacturing techniques are well established, so that cost is not a 
major obstacle. Therefore, mAb therapy represents one of the most promising immunotherapy 




Figure 5 – Antibody therapeutics for cancer. 
 
Targeting mAbs to the tumor can result in the destruction of the tumor cells by antibody-dependent cellular 
cytotoxicity or complement-dependent cytotoxicity. Similarly, targeting cytokines or immunomodulatory 
molecules either by bispecific scFv or antibody–ligand fusion proteins to the tumor modulates the immune 
response against the tumor. In addition, antibody–ligand fusion proteins can induce apoptosis to targeted cells as 
well as bystander cells by, for example, presenting FasL. A more direct approach to kill the targeted cell is the 
conjugation of cytotoxic drugs, toxins or radionucleotides to the mAbs. The direct targeting approach requires 
the homogenous expression of antigen in the tumour cell population; depending on the radionucleotides used, 
however, radioimmunoconjugates can exert bystander effects and kill surrounding cells which do not express the 
antigen. The antibody-directed enzyme prodrug therapy approach specifically aims at causing bystander effects 
by targeting enzymes to the tumor cell and delivering a prodrug that is locally converted to a chemotherapeutic 
agent by the targeted enzyme. 
 
1.4.8.2. Passive immunotherapy: Adoptive T-cell transfer 
 
There is significant evidence suggesting the efficacy of cell-based therapies, such as, 
allogeneic transplantation, donor-lymphocyte infusion, and therapies using ex vivo expanded 
T and NK cells, such as lymphokine-activated killer cells, cytokine-induced killer cells, or 
CD3/CD2843 –expanded cells (Brody, Kohrt, Marabelle, & Levy, 2011). 
Adoptive cell therapy (ACT) consists of a treatment that uses a cancer patient’s own T 
lymphocytes with anti-tumor activity, expanded in vitro and reinfused into the patient (Figure 
6). This immunotherapeutic option represents the most effective treatment for patients with 
metastatic melanoma inducing visible cancer regression in approximately 50% of patients. 
ACT is also associated with clinical improvement in selected patients with post-transplant 
lymphoproliferative diseases caused by Epstein–Barr virus infection. Moreover, recent studies 
have reported that normal lymphocytes can be converted into lymphocytes with anti-cancer 
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activity through genetic modification caused by retroviruses that encode T-cell receptors.  
These data represented a possibility of extending ACT immunotherapy to patients with a large 
diversity of cancer types (Rosenberg, Restifo, Yang, Morgan, & Dudley, 2008). 
As dogs possess a fully intact immune system and genetic similarity to humans, tumor-
infiltrating lymphocytes (TILs) therapy in dogs has the potential to inform human trials and 
investigate the use of this therapy in other cancers, such as hematopoietic malignancies. In a 
recent clinical trial by O’Connor et al., non-specific, autologous T cells isolated from dogs 
with NHL were propagated ex vivo using a novel artificial antigen presenting cell system prior 
to reinfusion (O’Connor et al., 2012; O’Connor & Wilson-Robles, 2014a). The infused T cells 
persisted for greater than 49 days and trafficked to secondary lymphoid organs, demonstrating 
that the adoptive transfer of autologous T cells is safe in canine patients. Adoptive 
immunotherapy using non-specific autologous T-cells was demonstrated to be viable and 
effective in improving first remission and overall survival periods in dogs with multicentric 
lymphoma (Gavazza et al., 2013). 
TIL efficacy is based on T cells capacity to identify tumor antigens, consequently this therapy 
reports poor outcome when treating solid tumors with a low mutation character. Therefore, 
gene-transfer methods were established to apply artificial anti-tumor receptors into normal T 
cells collected from patient’s peripheral blood. In order to identify known tumor antigens 
expressed in a MHC (Major histocompatibility complex) molecule setting, TCR (T cell 
receptor) engineered T cells are produced expressing one α and one β chain (Rosenberg & 
Restifo, 2015). Chimeric antigen receptors (CARs) consist of artificial receptors formed by a 
tumor-antigen specific single-chain antibody variable fragment linked to an intracellular 
signalling domain and co-stimulatory molecules. CARSs don’t depend on patient APCs 
(Antigen presenting cell) to present antigen and do not require to be syngeneic to patient’s 
immune system, because they are non-MHC class limited molecules (Anderson & Modiano, 
2015). Canine T cells expressing a HER2 (Human epidermal growth factor receptor 2)-
specific CAR have been produced and showed anti-tumor activity in vitro targeting HER2+ 
canine osteosarcoma cells (Mata et al., 2014). Ongoing studies aim to develop canine CARs 




Figure 6 - Approaches to adoptive T cell therapy.  
 
In the top scheme, a resected tumor sample is digested into a single cell suspension and cultured in the 
presence of IL-2 to select for naturally occurring tumor-infiltrating lymphocytes (TILs). The TILs are then 
expanded, tested for anti-tumor activity, and reinfused into the patient. In the bottom scheme, autologous T 
cells are harvested from the blood and either a transgenic TCR or a chimeric antigen receptor (CAR) is 
introduced by viral or non-viral transduction. TCRs are capable of recognizing a specific tumor antigen 
presented in the context of an MHC molecule. CARs are MHC-independent and capable of directly 
recognizing an antigen on the tumor cell surface. Following transduction, the transgenic T cells are expanded 
and reinfused. 
 
1.4.8.3. Passive immunotherapy: Immunomodulators 
 
Cytokine therapy aims to enhance immune responses and tumor control in a variety of 
spontaneous oncologic diseases. In human medicine, modest success has been obtained with a 
low-dose IL-2 therapy delivered subcutaneously, with few side effects (Atzpodien & 
Kirchner, 1991; Burns et al., 2000, 2003; Dudek et al., 2008; Lissoni et al., 1994; Miller et al., 
1997) Additionally, subcutaneous GM-CSF (Granulocyte-macrophage colony-stimulating 
factor) therapy boosts cell-mediated immune responses and improves anti-idiotype vaccines 
efficacy in human lymphoma (Bendandi et al., 1999). In canine patients, IL-2 delivered 
subcutaneously, intralesionally, by inhalation and via liposome–DNA complexes encoding 
IL-2 gene, as a monotherapy or in combination with other modalities, promoted regression in 
dogs with oral melanoma, soft tissue sarcoma, squamous cell carcinoma and pulmonary 
metastases from osteosarcoma (Dow et al., 1998, 2005; Khanna et al., 1997; Moore, Theilen, 
Newell, Madewell, & Rudolf, 1991; Otter et al., 1999; Thamm et al., 2003). Likewise, in dogs 
with oral melanoma, combination therapy including GM-CSF delivered intralesionally, either 
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via liposome–DNA complexes or via GM-CSF secreting transgenic xenogeneic cells, resulted 
in regression (Dow et al., 1998; Finocchiaro, Fiszman, Karara, & Glikin, 2008).  
A phase I study enrolling 15 dogs with B-cell lymphoma tested a therapy with a combination 
of autologous tumour antigen-coated microbeads (large multivalent immunogen - LMI) with 
cytokine therapy including IL-2 and GM-CSF, following induction of remission with 
conventional chemotherapy. Results demonstrated no significant toxicity, no adverse effects 
in disease-free interval and half of the animals presented quantifiable delayed-type 
hypersensitivity reactions to intradermal LMI, suggestive of a specific cell-mediated immune 
response (Henson et al., 2011). 
 
1.4.8.4. Active immunotherapy: Vaccines 
 
Several attempts to use vaccines as a treatment for cNHL have been made (Figure 7) 
(Zandvliet, 2016). In the initial studies, Freund’s adjuvant was added to lymphoma cell 
extracts lysates. Despite de fact that these early studies reported some treatment benefit (Crow 
et al., 1977), this was later atributted to the use of the Freund’s adjuvant (Re et al., 1980).  
Jeglum et al. described an intralymphatic administration of an autologous tumor vaccine 
following induction of remission with chemotherapy thus results were conflicting (Jeglum, 
Winters, & Young, 1989; Jeglum, Young, Barnsley, & Whereat, 1988; Jeglum et al., 1986). 
Recently, an autologous vaccine consisting of hydroxylapatite ceramic powder with 
autologous heat shock proteins (HSP) purified from affected lymph node biopsy is currently 
available. On one hand, HSPs resultant from tumor cells, including gp96, hsp90, hsp70, 
calreticulin, hsp110, and hsp170, present strong immunogenicity (Marconato et al., 2014). 
The chaperone function of HSPs allows their combination with immunogenic tumor specific 
peptides (HSPPC), exposing the host to a large repertoire of tumor associated antigens (TAA) 
for immunization. On the other hand, hydroxylapatite vehicles and HSPPCs functions as an 
adjuvant. In order to reproduce the tumor heterogeneity, each vaccine is produced for each 
dog. Vaccination protocol consists of four administrations within four weeks and one 
injection a month for four months in combination with dose-intense chemotherapy. 
Preliminary results showed that the autologous vaccine is effective in prolonging overall 
survival and the time to progression in dogs with DLBCL and multicentric indolent B-cell 
neoplasia, without increasing treatment toxicity (Marconato et al., 2014, 2015).  
In a recent clinical trial, autologous CD40-activated B-cells loaded with total RNA from 
autologous lymphoma cells were administered to 19 dogs with NHL as an adjuvant, following 
induction of a complete response with chemotherapy. Vaccination stimulated an anti-tumor 
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immune response and increased a lasting second remission rate, although median time to 
disease progression and overall survival did not differ between groups (Sorenmo et al., 2011). 
Moreover, a new approach targeting canine telomerase reverse transcriptase via a DNA-
vaccine is reported. As telomerase confers immortality to cells, telomerase reverse is 
overexpressed in cancer cell lines and in several tumors and undetectable in the majority of 
normal tissues, establishing a possible target for translational cancer immunotherapy. A 
DNA-vaccine targeting canine telomerase reverse transcriptase can induce an immune 
response against telomerase in dogs with multicentric lymphoma, and conventional 
chemotherapty seems not to alter the immunotherapy effects (Peruzzi et al., 2010). The 
combination of this vaccine and chemotherapy (COP-protocol) resulted in a durable immune 
response, as well as prolonged survival in dogs with B-cell lymphoma (Gavazza et al., 2013). 
 
Figure 7 - Vaccination strategies and challenges.  
 
Vaccines utilize a variety of strategies to activate the immune system against tumor associated antigens 
(TAAs), including tumor cell lysates or peptide antigens, dendritic cells (DCs) activated with TAAs, and 
DNA plasmids designed to produce TAAs. The TAAs must then be presented by functional antigen 
presenting cells to T cells capable of recognizing the TAA. Once activated, T cells must travel to the tumor 
and induce tumor cell death. T cell tolerance to TAAs, dysfunctional antigen presentation, T-cell exhaustion 
induced by checkpoint inhibitors (such as PD-1), and immunosuppressive cells in the tumor 




1.4.8.5. Active immunotherapy: Checkpoint blockage 
 
There are several obstacles to the effective immunotherapy of cancer that may limit the 
success of treatment of cancer patients with minimal disease or may promote merely transient 
tumor responses. Some of these complications are tumor cell related, though the major result 
from a series of negative immunoregulatory elements (i.e. Tregs, myeloid-derived suppressor 
cells, tumor-associated macrophages, vascular endothelial growth factor, TGFβ, IL-10) that 
are normally responsible for the prevention of self-reactive destructive immune responses that 
lead to autoimmune disease (Guo et al., 2013; Pardoll, 2012).  
These immunoregulatory mechanisms correlate with poor clinical success in cancer patients 
and limit the outcome of vaccines in preclinical models. Therefore, a focus of recent 
preclinical tumor immunology has been to study various types of checkpoint blockade, either 
to improve vaccine-induced immunity or to reveal an underlying antitumor immune response. 
One approach is the use of mAbs directed to these checkpoints, and there is considerable 
preclinical evidence demonstrating the effect of agonistic antibodies specific for 4-1BB and 
OX4 mAbs or antagonistic mAbs specific for co-inhibitory receptors such as cytotoxic T-
lymphocyte associated protein 4 (CTLA-4) and programmed-death 1 (PD-1) (Armand, 2015; 
Berzofsky et al., 2004; Pardoll, 2012). 
Immune checkpoint inhibitors mAbs therapy, such as antibodies against CTLA-4 and PD-1 
mAbs, ligand PD-L1, have attracted notable attention due to reports in human phase-III 
clinical trials of inducing clinical responses in 20%–65% of patients with a diversity of 
tumors; a small subclass of patients have achieved complete and long-lasting remissions 
(Anderson & Modiano, 2015; Sharma & Allison, 2015). Briefly, binding of checkpoint 
receptors on the surface of T cells by their associated ligands (B7-1 and B7-2 for CTLA-4, PD 
ligand 1 [PD-L1] and PD-L2 for PD-1) promotes downregulation of T-cell function.  
Therefore, these molecules limit tumor´s ability to promote anergy or fatigue of activated T 
cells, by reactivating tumor-specific T cells (Figure 8) (Anderson & Modiano, 2015).  
Canine clinical trials with checkpoint inhibitors have yet to be conducted. Nevertheless, 
expression of canine PD-L1 has been reported on a variety of canine tumor types, including 
mastocytoma, melanoma and renal cell carcinoma (Maekawa et al., 2014). A preliminary 
study suggests that anti-PD-L1 might play a significant role in the treatment of dogs with 
tumors expressing PD-L1, by demonstrating that treatment of canine tumor infiltrating 
lymphocytes with this molecule improved IFN-γ production (Maekawa et al., 2014). 
Moreover, canine CTLA-4 has also been described and cloned (Shin et al., 2007) Even though 
anti-CTLA-4 has not yet been established, an agonistic recombinant canine CTLA has been 
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efficiently used to promote tolerance in a transplant model (Graves et al., 2009), suggesting 
that the mechanism of action of CTLA-4 in dogs is similar to humans and that CTLA-4 
checkpoint blockage could represent a novel immunotherapy for canine cancer. Hematologic 
malignancies such as lymphoma are likely targets for this type of treatment. Several clinical 
trials of checkpoint blockade have been performed in HM, with promising preliminary results 
suggesting the therapeutic benefit of this approach, namely results of PD-1 blockade in 
Hodgkin lymphoma (HL) (Armand, 2015).  
 
Figure 8 - Mechanism of action of immune checkpoint inhibitors.  
 
PD-1 is expressed on activated T cells and when it binds to its ligand PD-L1 on tumor cells leads to T cell 
exhaustion. CTLA-4 competes with CD28 (costimulatory T cell molecule) for B7 ligands (CD80 and CD86 that 
are not shown in the figure) and upon activation decreases T cell proliferation as well as activity. Blockade of 
CTLA-4 (by anti-CTLA-4) and PD-1 (anti-PD-1) or PD-L1 stimulates effector T cells to produce antitumor 
responses. PD-1: programmed death-1, PD-L1: programmed death-ligand 1, MHC: major histocompatibility 
complex, TCR: T cell receptor, and CTLA-4: cytotoxic T lymphocyte antigen. 
 
1.4.  Antibodies: The New Era of Biologics 
 
The discovery of hybridoma technology, described by Kohler and Milstein in 1975, and the 
subsequent ability to develop mAbs, initiated a paradigm shift in antibody research and their 
clinical development (Köhler & Milstein, 1975). Yet, despite representing a major 
breakthrough in antibody-based therapy, early clinical studies demonstrated that these 
unmodified murine mAbs presented properties that limited their use in a clinical context. One 
of the most important shortcomings was the high immunogenic character of these mAbs that 
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resulted in the production of anti-mouse antibodies and limited their therapeutic utility. 
Furthermore, murine mAbs demonstrate decreased serum half-life and inability to elicit 
human effector responses (Aires da Silva, Corte-Real, & Goncalves, 2008; Hwang & Foote, 
2005). To overcome these limitations,  murine mAbs were manipulated by recombinant DNA 
technology to turn their constant regions into human variants, which led to a reduction in 
immunogenicity while promoting an efficacy optimization, thus improving the grounds for  
the development of antibody-based therapies (Aires da Silva et al., 2008; Jones, Dear, Foote, 
Neuberger, & Winter, 1986). Since then, a total of 74 antibody-based molecules have been 
approved for a wide range of indications, of which 17 mAbs have been approved for the 
treatment of cancer by the FDA and 15 by the European Medicines Agency (EMA) (Figure 
9). In addition, a similar number of antibody candidates have reached late phase clinical trials, 
clearly demonstrating the potential of these biologic molecules as therapeutic agents (Strohl, 
2017).  
 
Figure 9 – Approved mAbs and Fc fusion proteins for therapeutic use.  
 
Adapted from (Strohl, 2017). 
 
1.5.1. Antibody structure 
 
Antibodies, also named as immunoglobulins (Igs), are heterodimeric glycoproteins produced 
by B cells during the adaptive immune response. In mammals, the antibody basic structure 
consists of two identical heavy chains (H) and two identical light chains (L) in a Y-shaped 
format. The L chains belong to kappa (κ) or lambda (λ) subtypes and H chains to α, δ, ɛ, γ or 
µ isotypes. Antibodies are divided in five different classes or isotypes: IgA, IgD, IgE, IgG and 
IgM, based on sequence and length of heavy-chain constant domains, each presenting a 
34 
 
specific structure and role in immunological processes. Due to its high prevalence in human 
serum, importance for immune response and excellent specificity, IgG represents the leading 
isotype being used in immunotherapy (Schroeder & Cavacini, 2010; Williams & Barclay, 
1988).  
In IgG class (Figure 10), each heavy chain is constituted by three constant domains (CH1, 
CH2 and CH3) and one variable domain (VH), while the light chain consists of a single 
constant (CL) and a variable domain (VL). The fragment antigen-binding (Fab) is composed 
by the variable domains positioned into antibody N-terminus and the CL and CH1 regions. A 
flexible sequence (hinge region) links this fragment to the CH2 and CH3 domains, 
components of the fragment crystallizable (Fc). Several inter-domain disulfide bonds along 
with the highly conserved intra-domain bonds maintain antibody integrity (Schroeder & 
Cavacini, 2010; Williams & Barclay, 1988). 
On one hand, the variable domains promote antibody specificity and affinity towards antigen 
mainly through three hypervariable loops, collectively known as complementary determining 
regions (CDRs). The conformation of the VH and VL chain CDRs result in six hypervariable 
loop structures (H1, H2, H3, L1, L2 and L3) that form the antigen-binding site. These 
domains also present four relatively conserved β-sheet strands, the framework sequences, 
which act as scaffolds that support the CDR loops. On the other hand, the Fc region plays a 
major role in mediating antibody effector functions through complement and gamma Fc 
receptor (FcγR) binding. Furthermore, this IgG region is responsible for the prolonged 
antibody half-life through a recycling mechanism dependent on neonatal Fc receptor binding 




Figure 10 – Antibody IgG structure. 
 
Antibody molecule is divided into three major fragments: two fragment antigen-binding (Fabs) and one fragment 
crystallizable (Fc). Each Fab comprises a variable fragment (Fv), constituted by antibody variable domains (VH 
and VL), one heavy-chain constant domain (CH1) and one constant light-chain variable domain (CL). Fc region 
comprises two heavy-chain constant domains (CH2 and CH3), represented in pink, responsible for complement 
and Fc receptor binding. The hinge region is located between CH1 and CH2.  
 
1.5.2. Antibody mechanisms of action 
 
In cancer therapy, the main purpose of antibody treatment is to promote the direct or indirect 
destruction of cancer cells and a number of strategies have been successfully employed. 
MAbs can bind to target cancer cells and directly promote signaling-induced death or can 
mediate an anti-tumor immune response by promoting antibody-dependent cellular 
cytotoxicity (ADCC) and inducing complement-dependent cytotoxicity (CDC) (Makkouk & 
Weiner, 2015). In ADCC responses, antibodies bind to target cells and the antibody Fc 
domains engage with FcγRs on the surface of effector cells, such as macrophages and natural 
killer cells. These immune cells cause phagocytosis or lysis of the target cell. In CDC 
responses, antibodies promote directly target cell death through the development of a 
complement chain membrane attack complex. Furthermore, mAbs based therapies can also 
block growth-promoting pathways in the tumor stroma, such as angiogenesis or can directly 
modulate the activity of anti-tumor adaptive immune cells by blocking inhibitory signals 
responsible for limiting T cell activation (Vacchelli et al., 2014). mAbs that interfere with the 
inhibitory signals are called checkpoint blockade mAbs. Likewise, mAb variable regions are 
also used to retarget immune effector cells towards cancer cells through the use of bispecific 
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or trispecific mAbs that recognize cancer cells with one arm and activating antigens on 
immune effector cells with the other arm (Gleason et al., 2014; Huehls, Coupet, & Sentman, 
2015; Kontermann & Brinkmann, 2015).  
Moreover, mAb based therapeutic approaches have been developed in which the 
immunoglobulin moiety serves for the selective in vivo pharmacodelivery of bioactive 
payloads such as cytotoxic drugs, bispecific antibodies, radionucleotides or cytokines to sites 
of disease, thereby sparing healthy tissues (Waldmann, 2003). Radio-immunoconjugates 
deliver radioisotopes to the cancer cells, whereas antibody–drug conjugates deliver highly 
potent toxic drugs to the cancer cells.  
 
1.5.3. Antibody Fragments and single domain antibodies 
 
Most marketed antibodies consist of a full-length IgG molecule. By providing a long half-life 
and effector functions, these molecules have been presenting a quite successful application in 
therapeutics. However, this conventional antibody format present some drawbacks that limit 
their clinical use and there is a range of therapeutic applications in which other antibody 
formats may be more appropriate. On one hand, due to high molecular weight (~150 kDa), 
IgG antibodies are known to penetrate poorly into densely packed tissues, to have an impaired 
reaching of difficult targets and to present a slow clearance rate. In addition, in some 
conditions, the long antibody serum half-life results in poor contrast in imaging applications.  
On the other hand, inappropriate activation of Fc receptor-expressing cells sometimes leads to 
massive cytokine release with subsequent toxic effects. To address these major issues, smaller 
antibody scaffolds such as the Fab or the single chain variable fragment (scFv) or single-
domain antibody (sdAb) are emerging as alternative therapeutic agents (Figure 11) (Hudson, 
1998; Presta, 2003). 
Fab (~50 kDa) and scFv (~30 kDa) can be obtained through the cleavage of the IgG molecule 
with papain or recombinant technology (Bird et al., 1988; Hudson, 1999; Hudson & Souriau, 
2003; Skerra & Plückthun, 1988). Both fragments are stable and exhibit properties similar to 
the whole antibody molecule. Fab contains the variable and CH1 domains of an antibody, 
whereas scFv is constituted by a VL-VH pair connected by a flexible peptide linker, in order 
to improve antibody folding and stability. The use of a short linker (typically 5 amino acids), 
allows to combine two scFv molecules and form a stable non-covalent dimer, named diabody 




Figure 11 - Schematic representation structure of a conventional IgG antibody 
and antibody fragments of biotechnological and clinical interest.  
 
(A)  IgG antibodies comprise a pair of identical heavy and light chains linked by disulphide bonds. Light chains 
contain one constant domain (CL) and one variable domain (VL), while heavy chains contain three constant 
domains (CH1, CH2 and CH3) and one variable domain (VH). The variable domains of both the heavy and light 
chains are responsible for the antigen-binding site of the molecule. The Fc constant region recruits effector 
functions of the immune system. Constant light (CL) and heavy (CH) chain domains are represented in orange 
and gray. Variable light (VL) and heavy (VH) chain domains are represented in green. B) The engineering of 
antibody fragments that can be generated from an intact conventional IgG: antigen-binding fragment (Fab), 
single-chain Fv fragment (scFv), heavy and light single domains antibodies (VL and VH sdAbs) and natural 
camelid variable domain (VHH) and shark variable domains (V-NAR). 
 
One of the most promising alternatives to conventional IgG´s are sdAbs. sdAbs are the 
smallest functional antigen-binding fragments of an antibody that can be isolated from 
conventional IgGs or obtained from naturally occurring antibodies devoid of light chain that 
were discovered in two types of organisms, the camelids (camels and llamas) and 
cartilaginous fish (wobbegong and nurse shark) (Aires da Silva et al., 2004; Greenberg et al., 
1995; Hamers-Casterman et al., 1993; Holliger & Hudson, 2005; Holt, Herring, Jespers, 
Woolven, & Tomlinson, 2003; Muyldermans, 2001). Due to their small size, sdAbs show 
improved tissue penetration and are able to reach targets not easily accessible by conventional 
antibodies, such as enzyme active sites or canyons in receptors molecules. Moreover, 
similarly to Fab and scFv, sdAbs lack the Fc domain of a full IgG antibody, presenting a low 
nonspecific uptake in tissues that highly express Fc receptors. Additional important 
advantages include their high stability, low immunogenicity, and lower manufacturing cost. 
Furthermore, sdAbs can be easily attached to other proteins, peptides, small molecules or 




We have been showing that rabbit derived sdAbs can be developed against several targets and 
that these minimal scaffolds show great potential for therapeutic applications (Goncalves & 
Aires-Da-Silva, 2008; Volker et al., 2016). The unique ontogeny of rabbit B cells promotes 
vastly distinctive antibody repertories rich in in vivo pruned binders of high diversity, affinity 
and specificity (Weber, Peng, & Rader, 2017). Furthermore, rabbits are evolutionarily distant 
from mice and rats, so epitopes that are not immunogenic in rodents can be recognized by 
rabbit mAbs, increasing the targetable epitopes and facilitating the generation of mAbs that 
cross react with other species (Weber et al., 2017) - a key aspect for clinical translational. 
Currently, 20–25% of the mAbs in clinical development for cancer and non-cancer indications 
are recombinant human antibodies derived from phage display libraries or from transgenic 
mice. This past year, five antibody “fragments” (scFv) were reported in clinical phase 2/3 
(Iezzi, Policastro, Werbajh, Podhajcer, & Canziani, 2018).  
 
1.5.4. Phage Display and immune libraries tailoring 
 
Antibody development relies on display technologies for the selection of therapeutic 
candidates. These in vitro platforms englobe three main phases: generation of a large 
repertoire of individual clones (library); display and selection rounds towards the target or 
desired feature, and functional screening and characterization of selected molecules. The 
principal display technologies are ribosome and mRNA/cDNA display, phage display and cell 
display (Galán et al., 2016). Phage display is one of the most effective molecular diversity 
techniques and is a well-established technology for in vitro selection of antigen-specific 
antibodies from recombinant antibody libraries. This technology is based on a direct linkage 
between phage phenotype and its encapsulated genotype, which leads to the successful 
presentation of antibody libraries on the filamentous bacteriophages (phages) particle surface 
(Bazan, Całkosiński, & Gamian, 2012).  
Phage display libraries can be successfully developed using a naïve or immunized source or 
developed synthetically or semi-synthetically. A naïve library is generated from the natural 
immune repertoire of a donor, which variability relies only in sources of sequence variation 
during B cell maturation. The main characteristic of a naïve library is the unbiased nature of 
the large repertoire. An immune library refers to antibody repertoires originated from a donor 
immunized with a desirable antigen or disease infected donors. Although this library approach 
narrows the repertoire spectrum, these antibody libraries mainly produce good affinities 
antibodies with high clonal diversity due to in vivo somatic hypermutation that contributes 
towards affinity maturation.  More recently, antibody libraries were developed synthetically 
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by replacing one or more of the CDR loops with artificial elements. The resulting antibody 
repertoire offers an highly diverse repertoire with unnatural variability that evades biases and 
redundancies of natural in vivo formed antibodies. A key subset of synthetic libraries is the 
production of semi‐synthetic libraries. The main difference between semi‐ and fully synthetic 
libraries is the source of the diversity. In semi‐synthetic libraries, the diversity is largely 
obtained from natural sources whereby the genes encoding the CDR are isolated. As such, the 
diversity is still natural, taking advantage of the maturation processes of antibodies in vivo, 
whereas in fully synthetic libraries the unarranged and randomized V‐gene segments are 
synthetically assembled ex vivo normally by polymerase chain reaction  (Ch’ng, Choong, & 
Lim, 2016; Frenzel et al., 2017). 
In the case of immunized libraries, cDNA is generated from the mRNA extracted from the 
spleen or bone marrow of an animal immunized with the desirable antigen. The heavy and 
light chain genes are amplified by polymerase chain reaction (PCR) and the antibody 
fragment inserted into one of the encoding genes for surface coat proteins. In general, M13 
and fd-based display continue to be the most widespread antibody phage display selection 
tools (Harel Inbar & Benhar, 2012) and with a few exceptions (pioneering work done at the 
Scripps Research Institute (Kang, Barbas, Janda, Benkovic, & Lerner, 1991) where Fab was 
displayed on p8), all known antibody phage display repertoires are fused to the minor phage 
coat protein p3 (Bradbury & Marks, 2004), which is involved in the bacterial infection 
process through the F pilus and is present in 3–5 copies per phage (Holliger & Riechmann, 
1997) and not to the major phage coat protein p8 which was found to be less efficient, though 
more prevalent with 2700 copies per phage (Figure 12) (Kretzschmar & Geiser, 1995).  
 
Figure 12 – Schematic of the M13 filamentous phage structure.  
 
 
Schematic representation of the phage structure showing how the five structural proteins are arranged around its 
ssDNA genome. Legend labeling the structural proteins. Adapted from iGEM. 
40 
 
The phagemid DNA is then transformed into competent E. coli cells and, after expression, the 
coat protein fusions are integrated into new phage particles assembled in the bacteria. This 
enables phage particles to be replicated as ssDNA in the presence of a helper phage. Helper 
phages provide the necessary viral tools for the initiation and packaging of phagemid DNA 
into phage particles. Helper phages contain a defective origin of replication thus limiting their 
own packaging ability to produce more helper phage molecules. This characteristic is 
important as it reduces the ability of helper phage to replicate resulting in dominant phagemid 
DNA production (Hoogenboom et al., 1998). Phage particles are harvested from the infected 
cells and positive clones with desired affinities selected by a process known as biopanning, 
whereas phages of interest are eluted, enriched by reinfection and re-growth in bacteria 
(Figure 13) (Smith, 1985). 
 
Figure 13 – Overview of the creation of the recombinant M13 phages carrying 
affinity body library and phage display biopanning.  
 
Phage display cycle with phagemid. A library of DNA sequences with random variations of the protein of interest (POI) 
displayed on the pIII coat protein is cloned into a phagemid vector. After transformation of E. coli cells and subsequent 
infection with helper phages, the phage library is created. Using an immobilized target molecule, rounds of selection and 
amplification are performed until phages with the highest affinity are isolated. DNA sequencing can be used to identify 







1.5.5. Single domain antibodies as targeting moieties for cancer therapy 
 
Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents 
that combine the tumor selectivity, pharmacokinetics and biodistribution properties of 
antibodies with the cytotoxic potency of small molecules (Figure 14) (Sievers & Senter, 
2013). This concept was first envisioned by Paul Ehrlich in the early 20th century who 
reasoned that if a compound could be made to selectively target a disease-causing organism, 
then a toxin for that organism could be delivered along with the agent of selectivity (Ehrlich, 
1913). Hence, such molecules named "magic bullets" would be created that only killed the 
targeted organism. As antibody-based therapies were developed, the idea that antibodies could 
be suitable moieties for the creation of these “magic bullets” gained scientific evidence.   
By attaching cytotoxic effector molecules to antibodies, ADCs are designed to improve the 
therapeutic index window of anticancer drugs as it promotes the selective delivery and uptake 
of the cytotoxic drug to the cancer cells to which the antibody binds, restricting its effect on 
normal cells. Additionally, ADCs draw on the in vivo distribution properties of the antibodies 
to reduce systemic toxicity of the cytotoxic agent. At the same time, ADCs enhance the anti-
tumor activity of the unmodified antibodies (Wu & Senter, 2005). 
 
Figure 14 - General mechanism of action of ADCs.  
 
The antibody of an ADC binds to tumor associated antigen. Upon binding, the ADC-antigen complex is 
internalized into the cancer cell. During the degradation of the complex, the released payload exerts its effects on 
the intracellular target leading to apoptosis. Adapted from Abbvie and (Chen & Cao, sem data). 
 
 The first generation of ADCs consisted of a mAb conjugated with clinically approved 
anticancer chemotherapeutic agents such as vinblastine, mitomycin, methotrexate and 
doxorubicin (Perez et al., 2014). Unexpectedly, the clinical trials demonstrated that these 
ADCs exhibited limited clinical sucess, possibly due to the low potency of the payload (Elias 
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et al., 1994; Petersen, DeHerdt, Schneck, & Bumol, 1991; Yang & Reisfeld, 1988). In turn, 
the second generation of ADCs resort to more potent payloads, namely calicheamicin, 
auristatin and maytansin analogs. This along with the optimization of the pharmacokinetics of 
the conjugation linker and the development of fully human in order to solve immunogenicity 
problems, led to the approval of the first ADC - gemtuzumab ozogamicin (Sievers et al., 
2001). As a result, in 2000, Gemtuzumab ozogamicin (MylotargR) received accelerated 
approval for the treatment of refractory acute myeloid leukemia (AML). Unfortunately, ten 
years later, gemtuzumab ozogamicin was withdrawn from the US market due to lack of 
clinical benefit (Petersdorf et al., 2009). Several issues have been associated with the limited 
clinical efficacy, including poor stability of the acid-labile conjugation linker, heterogeneous 
drug loading (approximately 50% of the antibodies are unconjugated) and sensitivity to 
multidrug resistance pumps that are often overexpressed in AML. More recently, two novel 
ADCs were approved by the FDA for the treatment of Hodgkin lymphoma and anaplastic 
large-cell lymphoma, brentuximab vedotin (AdcetrisR), and HER2 positive breast cancer, 
trastuzumab emtansine (KadcylaR) (Burris et al., 2011; Younes et al., 2010). These ADCs 
showed improved linker stability and pharmacokinetics. Though this recent clinical success 
has led to an impressive expansion of the clinical ADC pipeline, with more than 20 products 
being currently in clinical trials, many challenges remain related to ADC design and 
development, including the identification of ideal targets, antibody format, as well as linker-
payload combination. 
Most ADCs on the market and in clinical development are comprised of the complete IgG 
antibody, which is likely due to its favorable pharmacokinetics properties when compared to 
antibody fragments (Kim & Kim, 2015).  Nonetheless, there is also growing interest in using 
antibody fragments, such as sdAbs, as targeting agents for the delivery of therapeutic and 
imaging agents. As a matter of fact, the use of these small biomolecules may be the ideal 
format for cancer therapy as they present higher total tumor uptake, improved tumor to blood 
ratio and faster clearance rate than intact IgG or Fab (Chames et al., 2009). Moreover, a short 
serum half-life may be desirable in cases where the risk of toxicity in healthy tissues increases 
with prolonged exposure (Tijink et al., 2009).  
Owing to their solubility, stability, independent folding and versatility properties, sdAbs have 
been recently exploited as excellent frameworks for the development of novel diagnostic and 
therapeutic carriers, including toxins, radionuclides, dyes, peptides, proteins, nanostructures, 




Figure 15 – sdAb-associated strategies in targeting tumors and tumor accessory 
cells. 
 
VHH-associated strategies in targeting tumors and tumor accessory cells. Top, clockwise: bivalent bi-specific 
VHH; multivalent, high-avidity mono-VHH molecules; VHH fusions ranging from vascular penetration peptide-
VHH to engineered hu-Fab and albumin-binding domains; fluorescent dye fusions, for example, one 
spontaneously crossing the blood–brain barrier; radionuclide-VHHs; toxin-VHH theragnostics; chromogenic 
enzyme fusions: here an alkaline phosphatase-VHH may be applied in ELISA, dot blot, and transferred protein 
identification in western blot; oncolytic virus; VHH decorated nanoparticles for therapeutics delivery and in 
facilitating photothermal therapy; bacteriophage engineered to display VHH and deliver targeted therapeutics 
may also be developed for signal amplification in ELISA assays. Adapted from (Iezzi et al., 2018). 
 
Several payloads have been investigated for the development of drug-delivery nanobodies, 
however only two immunotoxins made use of cytotoxic compounds for cancer targeted 
therapy. Behdani and colleagues reported the development of a VEGFR2-specific nanobody, 
conjugated to the truncated form of pseudomonas exotoxin A (PE-A) that provided efficient 
inhibition of tumor cell growth (Behdani et al., 2013). More recently, a humanized CD7 
nanobody-based immunotoxins coupled with a derivative of the same PE-A toxin exhibited 
promising anti-T-cell acute lymphoblastic leukemia potential (Yu et al., 2017). As such, 
active research has been focusing on the development of promising highly potent payloads.  
In the area of natural products these efforts have led to the discovery of extremely potent 
cytotoxic compounds, which could be considered for ligand based pharmaco-delivery 
applications. These agents include potent tubulin agents, such as maytansinoids, dolastatins 
and cryptophicins (all strong inhibitors of tubulin polymerization with IC50 in the picomolar 
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range), but also duocarmycins (highly cytotoxic minor groove binders and DNA-alkylating 
agents). Despite these drugs failed to demonstrate clinical benefits on their own, 
demonstrating that the increase of the potency by itself does not increase the therapeutic index 
of chemotherapy, they represent attractive payloads for the preparation of ADCs (Aguiar et 
al., 2018). 
As the field of antibody fragments expands, novel and promising structures are being 
developed with unique and valuable characteristics. The combination of these innovative 
moieties with potent payloads may surpass many of the drawbacks associated with the use of 
IgGs and small molecules as targeting agents (Holliger & Hudson, 2005).  In addition, the 
interdisciplinary and synergetic investigation between chemistry, immunology and 
biotechnology may trigger a new era of ADC. As a result, the emergence of these 
biomolecules may represent a paradigm shift in cancer treatment as it can finally fulfill the 






1.5. Aims and Thesis outline 
 
Considering the great clinical potential that sdAbs as targeting moieties may represent in 
cancer treatment, this work aimed to develop a novel sdAb-based drug delivery system for 
canine NHL, which serves as an animal model of human NHL. However, the development of 
ADCs requires the careful selection of an appropriate antigen target, the screening of the most 
promising highly potent cytotoxic drugs and the development of stable linkers that can 
selectively release the cytotoxic payload. As such, to achieve the proposed objective, a 
strategic, multidisciplinary approach composed by a series of milestones was planned to 
tackle all these issues (Figure 16).   Furthermore, to overcome limitations associated with 
conventional preclinical models, we aimed to validate the naturally occurring canine B-cell 
lymphoma as an animal model for the development of immunotherapeutic strategies for NHL. 
 
Objectively, the main goals of this project can be summarized as follows: 
  
I - Characterization of the immune status of dogs diagnosed with B cell NHL (Chapter 
2): 
 
Despite the potential of using the dog as an animal model for the development of 
immunotherapies, efforts to develop such strategies for veterinary applications have been 
hampered by several limitations. Importantly, the canine immune system has not been 
sufficiently studied and characterized compared to the human immune system. We know 
relatively little, for example, about lymphocyte subtypes and expression and regulation of 
their receptors, or about canine cytokines that support their function.  In part, this lack of 
information is due to the limited availability of canine-specific reagents to characterize 
immune system components. This also implies that there are no predictive tests, to ascertain 
which dog may benefit from what type of immunotherapy. Moreover, tumors in dogs have not 
been as well characterized as their human counterparts with respect to genotype and 
phenotype. As such, the main goal of this chapter was to contribute to fill in this gap. Within 
this context, considering that high quality basic, clinical and translational cancer research 
requires prompt access to well-preserved biological samples, throughout this project multiple 
samples of dogs diagnosed with lymphoma were collected and used for the construction of a 
cNHL biobank. This samples supported the execution of the studies that allowed to 




II - Development of recombinant antibodies for the treatment and diagnosis of canine 
NHL (Chapter 3):  
 
Our research plan aimed at developing recombinant antibodies against cNHL, a promising 
animal model of immunotherapeutical approaches for NHL. Within this context, a 
comprehensive strategy was implemented to guarantee a successful project outcome, by 
developing sdAbs against canine CD20, a well-known clinically validated target, and by 
developing novel sdAbs against cNHL antigens using an innovative strategy. 
 
III - Selection of potent cytotoxic drugs against canine NHL (Chapter 4), 
 
One of the most important challenges when developing an ADC is the selection of a suitable 
payload. With that in mind, in this chapter we aimed to screen a panel of cytotoxic drugs with 
potent anti-tumor properties against cNHL. Panobinostat, a HDAC inhibitor revealed to be the 
most promising molecule and was further characterized under chapter 4. In the future, we 
expect to couple this molecule with our antibody candidates in order to develop an ADC.  
 
IV - Establishment of a xenograft murine model of canine NHL for monitoring tumor 
progression and treatment response in preclinical studies (Chapter 5). 
 
The integration of cNHL in comparative studies has been limited by the lack of suitable 
mouse models for preclinical studies. To overcome these limitations, we aimed to establish 
and characterize a localized subcutaneous bioluminescent canine DLBCL xenograft mouse 
model. This model will be a valuable preclinical tool for veterinary applications, while 




Figure 16 – Thesis at a glance. 
 
 
To properly address and discuss the above-mentioned objectives, this thesis has been divided 
in six chapters. The first Chapter consists of a detailed state of the art literature review. 
Chapter 2 to 5 were based in scientific manuscripts that were either published in international 
peer reviewed journals or are currently in preparation for submission. Finally, the last Chapter 
integrates the results presented in each of the previous Chapters with a complete discussion 
and conclusion. Importantly, results presented under Chapter 3 were subject to intellectual 
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NHL is among the most common neoplasias in dogs and humans. Owing to remarkable 
similarities with its human counterpart, the cNHL model has been proposed as a powerful 
framework for rapid and clinically relevant translation of novel immunotherapies. However, 
the establishment of cNHL as a predictive preclinical model has been hampered by the limited 
characterization of the canine immune system. Cytokines are key players of the interaction 
between tumor and its microenvironment. In human NHL, multiple cytokines have been 
linked to the development of lymphoma and are relevant biomarkers for treatment response 
and prognosis. In contrast, few studies have investigated cytokines in cNHL. Within this 
context, this study aimed to investigate cytokine regulation in cNHL.  
A multicentric cNHL biobank was successfully constructed. Cytokine mRNA profiles in 
tumor tissue and circulating PBMC were analyzed by qRT-PCR and compared to a healthy 
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control group. Specific primers were used to evaluate Th1, Th2 and Th17 responses. Systemic 
cytokine concentrations were measured using a commercial canine multiplex assay which 
included IL-2, IL6, IL-10 and TNF-α, and compared to a healthy control group. Our results 
demonstrated a dysregulation of cytokine mRNA expression, representative of the tumor 
microenvironment and systemic response in cNHL.  Intratumoral cytokine response revealed 
a significant downregulation of humoral and Th1 responses. The systemic response 
demonstrated a distinct mRNA pattern, however immunosuppression also prevailed. Cytokine 
serum quantification showed a significant increase of IL-10 concentration in cNHL. 
Significant differences in hematological parameters were described and a correlation between 
IL-6 protein serum levels and neutrophil count was shown. Finally, data analysis 
demonstrated that baseline pretreatment IFN-γ tissue mRNA levels were correlated to survival 
outcome, predicting a favorable response to chemotherapy.  
Altogether, these results revealed that cNHL presents a local and systemic dysregulation in 
cytokine response. By confirming and extending previous research, our work contributed for 
the evaluation of potential cytokine candidates for diagnostic, prognostic purposes and 




Non-Hodgkin Lymphoma (NHL) is among the most common neoplasias in dogs and humans. 
Owing to remarkable similarities with its human counterpart, the canine lymphoma (cNHL) 
model has been proposed as a powerful framework for rapid and clinically relevant translation 
of novel immunotherapies (Park et al., 2016). However, the establishment of cNHL as a 
predictive preclinical model has been hampered by the limited characterization of the canine 
immune system.  
Several efforts have been made to develop immunotherapeutic approaches for dogs. (Ito et al., 
2015; Jain et al., 2016; Marconato et al., 2015; O’Connor & Wilson-Robles, 2014b; Weiskopf 
et al., 2016). To date, two mAbs - CD20-positive B cell (Blontress®) and CD52 positive 
T cell lymphoma (Tactress®) - have been approved by the US Department of Agriculture and 
are commercially available in the USA and Canada (Regan & Dow, 2015). Nevertheless, the 
reported therapeutic efficacy of these mAbs is suboptimal and substantially inferior to results 
reported in human patients. These results show that, apart from the importance of developing 
specific and sophisticated immunotherapies for veterinary settings in order to surpass the lack 
of cross-species reactivity to human immunotherapies, the limited characterization of the 
immune system of these animals may also hinder recent efforts to develop novel therapeutic 
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tools, such as mAbs and chimeric antigen receptor  cells (Hartley et al., 2018; Maekawa et al., 
2017; Panjwani et al., 2016). Above all, the canine immune system has not been deeply 
studied and characterized compared to the human immune system. For example, relatively 
little is known about lymphocyte subtypes and expression and regulation of their receptors, or 
about canine cytokines that support their function. This also implies that there are no 
predictive tests to assess which patient may benefit from what type of immunotherapy 
(Klingemann, 2018).  
NHL are an heterogeneous group of lymphoproliferative malignancies with variable patterns 
of behavior and responses to therapy. NHL development and invasion depend on the dynamic 
and complex interplay between tumor cells and non-neoplastic cells and on their interaction 
with the surrounding stroma/matrix environment. Such interactions are usually modulated by 
several cytokines (Grant & Bollard, 2017; Malaponte et al., 2016). Immune dysregulation of 
the host cytokine environment has been associated with lymphoma pathogenesis in humans. 
In light of this, the evaluation of cytokine and immune stimulatory molecules prior to 
lymphoma diagnosis has provided insights into the etiology of these cancers and has been 
exploited as predictable biomarkers of increased risk of developing lymphoma in patients 
with primary and acquired immune deficiencies (Y.-H. Chiu et al., 2017; Purdue et al., 2013). 
Furthermore, changes in cytokine signaling and regulation have also been correlated with 
disease presentation, tumor progression, response to therapy and prognosis (Vaidya & Witzig, 
2014). By reflecting cytokine expression of nascent tumors cells and/or reactive tumor-
associated immune cells, these molecules have also been regarded as potential early 
biomarkers of human lymphoma (Vendrame & Martínez-Maza, 2011). 
An impaired cellular immunity in dogs with lymphoma has been evidenced by in vitro 
lymphocyte blastogenesis, survival of allogeneic skin grafts, and response to tuberculin 
challenge exposure after sensitization with Bacille Calmette Guérin (Calvert, Dawe, Leifer, & 
Brown, 1982; Dutta, Novilla, & Bumgardner, 1978; Weiden et al., 1974). Furthermore, a 
dysfunction in humoral response of dogs with lymphoma was also identified, suppressed 
antibody responses to sheep red blood cells and to primary and secondary immunization with 
bacteriophage, being reported (Medleau, Dawe, & Calvert, 1983; Weiden et al., 1974). In fact, 
serum IgG concentration of dogs diagnosed with lymphoma were significantly lower when 
compared with healthy control dogs (Weiden et al., 1974). Moreover, auto-immune diseases, 
such as immune-mediated thrombocytopenia, have been also associated with an higher risk of 
developing lymphoma in dogs, compared to a normal population (Keller, 1992). Nevertheless, 
the role of the immune system in the pathogenesis of canine lymphoma and its interactions 
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with the surrounding microenvironment have not yet been deeply investigated and few studies 
have addressed cytokine dysfunction (Bryan, 2016; Calvalido et al., 2016).  
Within this context, the present study aimed to gain better understanding of the systemic and 
intratumoral cytokine dysregulation/dysfunction in canine lymphoma. Considering that high 
quality basic, clinical and translational cancer research requires prompt access to well-
preserved biological samples, multiple samples were collected from dogs diagnosed with 
lymphoma to establish a biobank. These samples were used for the relative quantification of 
Th1/Th2/Th17 cytokine mRNA expression in paired tissue samples of affected lymph nodes 
and circulating peripheral blood mononuclear cells (PBMC). Its comparison with healthy 
control samples allowed assessing for the first time cytokine mRNA profiles associated with 
multicentric canine lymphoma. Moreover, the comparison of putative cytokine serum 
quantification of dogs diagnosed with lymphoma with those of healthy control dogs 
complemented mRNA expression studies. Systemic immune status evaluation included blood 
counts analysis and determine significant differences compared to healthy controls. These 
results were further correlated with serum cytokine levels. Finally, we evaluated whether 
intratumoral and systemic cytokine levels might predict a favorable survival outcome 
following CHOP protocol. Results demonstrated that there was a positive correlation between 
intratumoral immune response and prognosis. 
 
2.3. Material and methods 
 




Patients with canine multicentric lymphoma were followed at the oncology unit of the 
Veterinary Medicine Faculty – University of Lisbon (FMV/UL)’s -Teaching Hospital where 
clinical evaluations were conducted. On a preliminary phase, with diagnostic and staging 
purposes, a complete history, clinical signs and physical examination were assessed. 
Complete blood count and biochemistry profile were performed, as well as abdominal and 
thoracic imaging exams. Histopathological evaluation of lymph nodes was performed after 
node biopsy. This histopathological evaluation included a morphologic examination, 
classification of lymphoma into grade subcategories and immunophenotyping to determine 
the immunophenotype present – B or T. Immunohistochemistry markers included CD3, 
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CD20, CD79αcy and PAX-5. This clinical and laboratory examination allowed staging the 
dogs using the World Health Organization (WHO) system (Owen, 1980).  
Inclusion criteria comprised dogs recently diagnosed with multicentric lymphoma by clinical 
examination and cytological examination of lymph node fine-needle aspirate that have not yet 
begun therapy.  Exclusion criteria included dogs who have begun chemotherapy and who 
have received steroids or other immunotherapeutic agent within the last eight weeks of study 
enrollment or dogs who have become severely ill.  
 
• Establishment of a Canine Multicentric Lymphoma Biobank 
 
All sample collection was conducted with written pet owner consent in accordance with the 
principles and procedures outlined in the NIH Guide for the Care and Use of Animals and 
approved by the Animal Care and Use Committee of FMV/UL. Blood samples allowed the 
isolation of plasma and serum, as well as the extraction of DNA (DNeasy Blood & Tissue, 
Qiagen, Hilden, Germany) and mRNA (RNeasy Protect Animal Blood System, Qiagen), that 
were stored at -80ºC. Additionally, PBMC were isolated by Ficoll gradient method (Biocoll 
Separating Solution, BioChrom®, Fisher Scientific, New Hampshire, USA) and following 
cell viability was assessment, aliquots of 5 x 106 cells were suspended in 90% Fetal Bovine 
Serum (FBS) (Gibco, Life Technologies, Paisley, UK) and 10% dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich, Missouri, USA) and kept in liquid nitrogen. Sterile biopsy lymph nodes 
samples were divided, 1/3 was fined cut and stored at -80ºC in RNAlater® (Invitrogen, Life 
Technologies, Paisley, UK), 1/3 was formalin-fixed and 1/3 stored in liquid nitrogen after 
lymphoma cell isolation. Briefly, solid tissue was cut, passed through a cell strainer (Cell 
Strainer, BD Falcon®), suspended in Roswell Park Memorial Institute–1640 (RPMI-1640) 
medium (Gibco) supplemented with 20% FBS and penicillin 100 U/ml plus streptomycin 0.1 
mg/ml (Gibco), and isolated through Ficoll gradient method (Biocoll Separating Solution, 
BioChrom®). Cell viability were assessed and for storage, aliquots of 5 x 106 cells were 
suspended in 90% FBS and 10% DMSO and kept in liquid nitrogen. Clinical follow-up 
information about all cases was gathered from electronic medical records. All dogs that 
participated in this study were client-owned animals which joined the study during their 







• Control groups 
 
Whole blood samples were collected from 9 canine healthy donors and processed for serum 
and PBMC isolation and storage, as previously mentioned. All animals were submitted to 
clinical examination at FMV/UL’s-Teaching Hospital and their health status was screened 
through the execution of hematological and biochemistry profile and blood-borne parasites 
serology. Inclusion criteria included dogs aged between two and seven years, with a normal 
clinical examination and normal blood parameters. Exclusion criteria comprised dogs 
diagnosed with chronic diseases, such as heart disease, chronic kidney disease, endocrine 
disease or cancer, or whom have fall acutely ill and/or subjected to medications within the last 
60 days. All sample collection was conducted with written pet owner consent in accordance 
with the principles and procedures outlined in the NIH Guide for the Care and Use of Animals 
and approved by the Animal Care and Use Committee of FMV/UL. All dogs that participated 
in this study were client-owned animals which joined the study voluntarily. All sampled 
animals stayed with their owners after sample collection. Due to ethical concerns raised by the 
collection of lymph nodes from healthy animals without medical indication, sterile biopsy 
lymph nodes samples were collected from a healthy control group of 8 dogs housed at the 
animal facility of Faculty of Veterinary Medicine - Universiteit Utrecht. All sample collection 
was performed after donors were sacrificed by intravenous administration of 65 mg/kg 
sodium pentobarbital at the end of a non-related study. Lymph node samples were fined cut 
and stored at -80ºC in RNAlater®.  
 
2.3.2. Relative quantification of cytokine expression by Real-Time quantitative 
Polymerase Chain Reaction  
 
For total RNA extraction, lymph node samples stored in RNAlater® and PBMC samples were 
thawed and processed using RNeasy Mini Kit (Qiagen), according to the manufacturer’s 
instruction. To eliminate possible contaminant DNA, total RNA samples were subjected to 
DNAse treatment, using RNase-free DNase Set (Promega; Wood Hollow road, Madison, 
USA), following the manufacturer’s instructions. Thereafter, cDNA was synthesized using 
Transcriptor High Fidelity (Roche, Basel, Switzerland) following the manufacturer’s 
instructions and used as a template for Real-Time quantitative Polymerase Chain Reaction 
(qRT-PCR). Total RNA and cDNA purity were assessed by 1% agarose gel electrophoresis. 
The primers used for each gene were published in the literature and the respective authors and 
sequences are presented in Table 1. Despite the DNAse treatment, and to preclude genomic 
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DNA amplification, primers covered putative exon–exon junctions. Optimization experiments 
for each amplification system were previously performed (data not shown).  All qPCR 
amplification efficiencies exceeded 90%. Primers were obtained from a commercial 
manufacturer (Metabion International AG, Germany). The mRNA transcription of the 
Ribosomal protein L27 gene (RPL27) had no significant statistical differences (p > 0.05) 
regarding cNHL and control groups, therefore this gene was considered a suitable 
housekeeping gene (Table 6). qRT-PCR was performed in duplicate wells on StepOne Plus 
realtime analyzer (Applied Biosystems, Foster City, CA, USA). The PCR assays comprised, 
in each reaction, 2 μl of each primer (final concentration of 100 nM), 2 μl of cDNA (1ng), 4 
μl of sterile water and 10 μl of SYBr (Applied Biosystems, Warrington, UK) in a total volume 
of 20 μl per reaction. Thermocycling conditions consisted of an initial denaturation of 10 min 
at 95 °C, followed by 40 cycles of amplification (95 °C for 15 s and annealing at 60 °C for 1 
min). A final melting curve stage consisted of 95 °C for 15 s, 60 °C for 1 min followed by a 
ramp rate and heating of samples until 95 °C with a 0.3 °C/s ramp rate. The melting curves 
obtained were used to verify the specificity of each amplicon and finally PCR products were 
sequenced. The 2−ΔΔCT method was used as described by Perkin-Elmer Applied Biosystems to 
assess relative mRNA expression quantification between lymphoma group and control group 




















Table 6 - Detailed primers and conditions used for real-time PCR assays. 
 




























109 Peters et al. (2005) b 
IL-17ª NM 001165878.1 
FW-CACTCCTTCCGGCTAGAGAA 
RV-CACATGGCGAACAATAGGG 
















96 Henriques et al. (2016) a 
a (Henriques et al., 2016) b (Peters, Helps, Calvert, Hall, & Day, 2005) c (Schmitz, Garden, Werling, & 
Allenspach, 2012) 
 
2.3.3. Multiplex cytokine immunoassay 
 
Milliplex® MAP magnetic bead panel based on Luminex® xMAP® technology 
(CCYTOMAG-90K, Millipore GmbH, Am Kronberger Hang 5, 65824 Schwalbach/Ts., 
Germany) was used to measure the final product from four different cytokines in canine 
serum: IL-2, IL-6, IL-10 and TNF-α. The cytokine panel selection was based on previous 
works (Axiak-Bechtel et al., 2014; Calvalido et al., 2016) and on our cytokine mRNA panel 
assortment. The method was performed according to the manufacturer's instructions. All 
samples were analyzed in duplicates. The data were analyzed using the Bio-Plex Manager 4.0 
software (Bio-Rad, Hercules, CA). The observed concentration of each analyte for each 
sample was calculated using a standard curve generated from the seven standards and a blank 
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provided by the manufacturer. If a sample concentration was extrapolated outside the standard 
curve and designated as “Value extrapolated beyond standard range” by the software, that 
sample concentration was accepted as the calculated value (Levin, Romano, Matassa, & De 
Guise, 2014). The minimum detectable concentrations for the four cytokines according to the 
manufacturer was 12.2 pg/ml. Significance of differences of the median value of each serum 
cytokine concentration between cNHL group and control group was analyzed. 
 
2.3.4. Statistical analysis 
 
All the statistical analyses were carried out using R-software. Normality test was performed 
using Shapiro-Wilk test. The distribution of all cytokine concentrations and most clinical 
variables did not pass the normality test and groups were therefore compared using the Mann–
Whitney U-test. Parameters that demonstrated normal distribution within both the 
lymphoma group and the control group were analyzed with unpaired t-tests. Correlations of 
variables were evaluated using Spearman rank correlation. To avoid treatment related bias, 
survival correlation included animals submitted to CHOP protocol, excluding three non-




2.4.1. Establishment of a Canine Multicentric Lymphoma Biobank  
 
High quality clinical and basic cancer research, as well as the development of novel 
prevention, early diagnostics and treatment approaches, relies on prompt access to biological 
samples. Tumor samples are usually restricted to formalin-fixed paraffin-embedded tissues, 
which cannot meet the requirement of current research. In fact, most RNA and protein studies 
require samples to be cryopreserved. Thus, we have been successfully constructing a canine 
multicentric lymphoma biobank (Table 2). Canine lymphoma is an heterogeneous malignancy 
with several presentation forms, however multicentric lymphoma is the most diagnosed form 
(Ettinger, 2003), accounting for ±75% of the cases. Considering its high prevalence, we 
focused on constructing a naïve multicentric canine lymphoma. Twenty-two dogs were 
included in the multicentric lymphoma biobank consisting on thirteen males and nine females 
with the median age of 9.1 ± 3.4 years (range 3-17). The breeds represented were mixed-
breed, Labrador retriever and other breeds. Eight male dogs were enrolled in the tissue sample 
control group and nine dogs (four males and five females) were included in the PBMC control  
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Table 7 - cNHL patient clinical characteristics and corresponding tissue and blood samples. 
group. The samples collected will be used for current studies and are an important source for 
proposed and future research works. There was no significant difference between the 
lymphoma group and control group regarding age, sex, and weight (p > 0.05).  Based on 
staging evaluation, 45% (10/22) of the animals presented clinical stage V and 55% (12/22) 
presented clinical stage IV. All cases were classified into B and T cell subtypes as designated 
in the WHO classification system. Results are presented in Table 7. 
 
*Sex M – Male, F – Female; PBMC – peripheral blood mononuclear cells; DLBCL – Diffuse Large B Cell Lymphoma; 
PTCL – Peripheral T Cell Lymphoma; NK – Natural Killer;  a + tumor sample, - no tumor sample; b + PBMC sample, no 















1 12 M Schnauzer DLBCL + + + - 
2 15 M Mixed-breed PTCL + - + - 
3 8 M Labrador DLBCL + + + + 
4 12 M Golden Retriever 
Blastic NK 
Lymphoma 
+ + + + 
5 6 M Rottweiller DLBCL + + + + 
6 6 F Basset Hound DLBCL  + + + + 
7 12 F Pitbull Follicular + + + + 
8 12 F Husky DLBCL + - + - 
9 8 M Mixed-breed DLBCL + + + + 
10 11 F Mixed-breed DLBCL + + + + 
11 9 F Boxer DLBCL + + + + 
12 7 M Pointer DLBCL + + + + 
13 17 F Mixed-breed DLBCL + + + + 
14 3 F German Shepherd DLBCL + + + + 
15 8 M Mixed-breed DLBCL + + + + 
16 9 M Mixed-breed T Zone Lymphoma + + + + 
17 4 M Golden Retriever DLBCL + + + + 
18 8 M Beagle PTCL + + + + 
19 5 M Labrador DLBCL + - + + 
20 9 F Toy poodle DLBCL + - + + 
21 11 F Dobermann DLBCL + + + + 
22 9 M Afghan hound DLBCL + + + + 
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2.4.2. Blood cell counts analysis 
 
To assess the immune status of lymphoma diagnosed dogs and to better understand the 
relationship between cytokine expression and hematological parameters, comparison of red 
and white cell counts between cNHL and control group was conducted. This analysis 
demonstrated that cNHL patients presented a significant lower hemoglobin and hematocrit (p 
< 0,01) compared to the control group. All anemias were classified as non-regenerative, 
normocytic and normochromic, compatible with anemia related to inflammatory/chronic 
disease. Furthermore, cNHL group demonstrated a significant higher count of total leucocytes 
(p < 0,05) and monocytes (p < 0,05); and a significant lower count of eosinophils (p < 0,01). 
There was no significant difference in lymphocytes, neutrophils and platelets counts between 

























Figure 17 - Differences in blood cell counts of cNHL group compared to the control 
group. 
 
Data of hematological parameters, including hemoglobin, hematocrit, leucocytes, lymphocytes, 
neutrophils, monocytes, eosinophils and platelets are presented as box and whiskers (A-H). * p < 0,05; 







2.4.3. Transcriptional Profile of Cytokines Expression in Lymph nodes of cNHL patients 
 
To assess the immune changes of affected lymph nodes of cNHL patients, relative 
quantification of cytokine expression by qRT-PCR was performed. The analysis demonstrated 
a clear immune imbalance of cytokine mRNA expression in naïve cNHL patients, compared 
to healthy donor lymph nodes samples. As shown in Figure 18, cNHL presented a tendency of 
upregulation of IL1-β, IL-6, IL-8, IL-17A, TNF-α, transforming growth factor-β (TGF-β) and 
IFN-γ and a trend of downregulation of IL-2, IL-4, IL-10 and interleukin-12 subunit p40 (IL-
12p40). The downregulation of the mRNA expression of IL-2, IL-4, IL-10 and IL-12p40 was 
statistically significant (p < 0,05). There were no significant correlations between cytokine 
mRNA expression in the cNHL patients lymph nodes with clinical characteristics and blood 
counts.   
 
Figure 18 - Relative cytokine mRNA expression in cNHL tumor tissue. 
 
Results are expressed as a fold difference between mean ± SEM of mRNA expression level in cNHL 
affected lymph nodes samples and a control group with healthy donors. * p < 0,05. 
 
2.4.4. Transcriptional Profile of Cytokines Expression in Circulating PBMC of cNHL 
patients 
 
In order to evaluate possible differences in the transcriptomic profile of cytokine expression in 
circulating PBMC of cNHL patients and healthy donors, a relative quantification of cytokine 
mRNA expression by qRT-PCR was carried out. As shown in Figure 19, this experiment 
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demonstrated a distinct profile of cytokine expression compared with the former lymph node 
analysis, revealing a trend of upregulation of IL1-β, IL-8, IL-10 and IL-12p40 and a trend of 
downregulation of IL-17A, TNF-α and TGF-β. Importantly, the downregulation of IL-17A, 
TNF-α and TGF-β was statistically significant (p < 0,05).  Again, a low cytokine expression 
profile was detected. Moreover, the residual expression levels of IL-6, IL-4 and IFN-γ did not 
allow the subsequent analysis and comparison between circulating PBMC mRNA expression 
between cNHL and control/healthy groups. No significant correlation between cytokine 
mRNA expression in the circulating PBMC of cNHL patients with clinical characteristics and 
blood counts were found.  Finally, no significant correlation between cytokine mRNA 
expression between cNHL lymph node and circulating PBMC was displayed.   
 
Figure 19 - Relative cytokine mRNA expression in cNHL circulating PBMC. 
 
Results are expressed as a fold difference between mean ± SEM of mRNA expression level in cNHL 
PBMC and a control group with healthy donors. * p < 0,05. 
 
2.4.5. Serum Cytokine levels in cNHL patients 
 
Cytokines protein concentrations in sera collected from cNHL biobank dogs were analyzed by 
the selected canine cytokine multiplex panel and compared to those from the healthy donor 
group. The cytokine panel selection was based on previous works (Axiak-Bechtel et al., 2014; 
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Calvalido et al., 2016) and on our cytokine mRNA panel assortment. All samples presented 
low detectable values of IL-2, IL-6, IL-10 and TNF-α. The comparison of cytokine levels 
demonstrated that IL-10 concentrations in cNHL dogs were significantly higher compared to 
healthy donor samples (p < 0,05). No significant differences between sera concentration of 
IL-2, IL-6 and TNF-α of cNHL and control groups were found (Figure 20).  No significant 
correlation between cytokine mRNA expression in the lymph node or the circulating PBMC 
of cNHL patients with cytokine sera concentration were detected. Regarding correlation of 
cytokine sera concentration with hematological parameters and clinical characteristics, a 
positive correlation of IL-6 sera levels with neutrophil counts (p = 0,013; rho = 0,546) was 
found. 
 
Figure 20 - Differences in serum cytokine concentrations of cNHL group 
compared to control group. 
 
Data are presented as box and whiskers and a log10 scale was used for the y axis for an optimal 
visualization of results. * p < 0,05. 
 
2.4.6. Correlation of cytokine expression and patient survival 
 
To investigate whether pretreatment cytokine expression in intratumoral and systemic 
samples could predict whether patients would respond favorably to CHOP protocol, 
correlation analysis with survival clinical outcome was performed. This study demonstrated 
64 
 
that IFN-γ level was positively correlated with patient survival following chemotherapy 
(p=0,044). This correlation was considered moderate (rho=0,481) (Figure 21).  
 
Figure 21 - Correlation of IFN-γ mRNA expression and survival clinical outcome 
in cNHL tissue samples. 
 
Results are presented as Spearman rank test correlating survival days and CT values normalized to 




To the best of our knowledge, this is the first study addressing intratumoral cytokine 
dysregulation in lymphoma-bearing dogs, along with systemic cytokine dysfunction.  To date, 
a limited number of other studies have explored the immune status of dogs diagnosed with 
lymphoma, particularly cytokine expression (Axiak-Bechtel et al., 2014; Calvalido et al., 
2016). On one hand, Axiak-Bechtel and collaborators recently reported for the first time an 
imbalance in both pro- and anti-inflammatory cytokine production, however their work 
focused mainly on the chemotherapy induced remission effects on the immune response of 
dogs diagnosed with lymphoma as a risk factor for sepsis (Axiak-Bechtel et al., 2014). On the 
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other hand, Calvalido and collaborators investigated circulating cytokines in lymphoma-
bearing dogs as potential disease biomarkers (Calvalido et al., 2016). Even though these 
studies represented groundbreaking research about canine lymphoma immunity, many 
challenges remain. This is particularly true at a time when canine lymphoma model is being 
proposed as a powerful platform for rapid and clinically relevant translation of novel high 
impact immune therapies and immune combination therapies. 
Within this context, in the present study we aimed to investigate cytokine regulation in canine 
lymphoma. For this purpose, cytokine gene expression was evaluated in tumor samples and 
circulating PBMCs, and serum concentration of putative cytokines was measured using 
multiplex assay.  
Cytokines are molecular messengers that mediate immune intercellular communication to 
generate a coordinated, robust and rapid immune response to a target antigen (Lee & 
Margolin, 2011). In tumorigenesis, theoretically these cytokines directly promote immune 
effector and stromal cells at the tumor site and stimulate tumor cell recognition by cytotoxic 
effector cells (Anestakis et al., 2015). However, there is growing evidence that cytokine 
signaling in many tumors reveal an immune suppressive or anti-inflammatory function, being 
involved in tumor immunosurveillance evasion (Esquivel-Velázquez et al., 2015; Israelsson et 
al., 2017; Mager, Wasmer, Rau, & Krebs, 2016). As a result, the investigation of cytokine 
role in tumor-driven molecular mechanisms might provide opportunities to explore novel 
therapeutic approaches. 
Cytokine research can rely on measuring serum concentration of biologically active cytokines 
or by assessing their expression in the affected organs or in circulating leukocytes (Maissen-
Villiger et al., 2016). In this study, we chose to focus on the measurement of cytokine mRNA 
expression levels using qRT-PCR. The primary reason for that was the limited availability of 
validated canine assays that hampers the range of cytokines that can be evaluated (Maissen-
Villiger et al., 2016). In addition, the high specificity, sensitivity and stability of quantitative 
evaluation of cytokine expression by real-time PCR method enables the analysis of samples 
with very low mRNA expression and can be a valuable tool to establish disease-related 
cytokine profiles (Giulietti et al., 2001). The expression of mRNA does not necessarily reflect 
the real cytokine concentration but, being the result of the upstream path of activation leading 
to gene expression, it offers valuable insights into cytokine regulation pathways (Gygi, 
Rochon, Franza, & Aebersold, 1999). Furthermore, although the protein quantification 
provides a more predictive insight of its effect, it does neither evaluate its biological activity 
at the tissue level nor the effect of potential inhibitors (Cavaillon, Munoz, Fitting, Misset, & 
Carlet, 1992). As a result, our work aimed to fill in the gap in lymphoma cytokine mRNA 
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profile research considering that previous studies focused only on measuring serum cytokine 
concentrations. Our study also included a protein-based assay to complement cytokine gene 
expression studies and to allow correlation with previously published work. 
In this study, we assessed the mRNA profile of 11 cytokines in tissue samples of canine 
lymphoma affected lymph nodes compared to the mRNA profile of normal lymph nodes from 
healthy control dogs. Our results demonstrated a dysregulation of cytokine expression, 
representative of the tumor microenvironment in canine lymphoma.  Notably, key mediators 
of Th2 response, including IL-4 and IL-10 expression were significantly downregulated in the 
lymph node of dogs with canine lymphoma. Furthermore, IL-12 - required for Th1-cell 
differentiation and IL-2 - principal growth factor for T cells, were also significantly 
downregulated, indicating a component of immunosuppression in cancer microenvironment 
(Setrerrahmane & Xu, 2017).   
Although not statistically significant, there was a prominent tendency to the upregulation of 
IL1-β, IL-6, IL-8, and TNF-α, cytokines that mediate inflammatory response. Moreover, we 
found a trend of upregulation of IL-17A expression, another proinflamatory cytokine, 
associated with tumor cell proliferation and neoangiogenesis in hNHL (Ferretti et al., 2015). 
Finally, IFN-γ expression, the main cytokine implicated in cell-mediated immunity primarily 
through its effects on the monocyte/macrophage population, also shown a tendency of 
upregulated expression in canine lymphoma.  These results suggest that some dogs diagnosed 
with cNHL may present an higher inflammatory response, however this response was found 
to be heterogeneous and therefore not statistically significant.  
The downregulation of both Th2 and Th1 cytokine responses in cNHL is in line with the 
postulated hypothesis that the immunosuppressive nature of the tumor microenvironment is 
proving to be a major barrier for the treatment of B cell malignancies in human medicine 
(Nicholas, Apollonio, & Ramsay, 2016). 
Nevertheless, in the case of human NHL, the contribution of the tumor microenvironment to 
the pathogenesis and tumor survival remains poorly understood (Fowler et al., 2016). 
Moreover, cytokine expression was considered scarce and consequently it was never fully 
investigated, existing a lack of studies that evaluated mRNA cytokine expression in human 
NHL (Herreros, Sanchez-Aguilera, & Piris, 2008; Hsu, Waldron, Hsu, & Hough, 1993; E. A. 
Jones, Pringle, Angel, & Rees, 2002).  
Herein, we described for the first time a distinct systemic cytokine mRNA profile expressed 
by circulating PBMC. However, similarly to the immune response observed in tumor 
microenvironment, in the circulating PBMC a major immunosuppressive component of the 
immune response prevailed, with a significant downregulation of IL-17A, TNF-α and TGF-β. 
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The expression of IL-6, IL-4 and IFN-γ were undetectable in both groups, making the results 
for this cytokine negligible by this method. The significant downregulation of IL-17A 
documented herein is consistent with previous studies that report a significant decrease of 
Th17 cells in the PBMC of patients with NHL and B-cell NHL and a remarkably decreased 
IL-17AF plasma levels in B-NHL patients (Lu et al., 2016). Furthermore, although not 
statistically significant, IL-12p40 and IL-10 expression demonstrated a tendency to 
upregulation.  
In addition, we reported a significant increase of IL-10 serum levels in canine lymphoma 
patients. IL-10 is an immunosuppressive cytokine produced by many different cells of the 
immune system, including T and B lymphocytes, macrophages, monocytes, dendritic cells, 
and NK cells (Purdue et al., 2007) but can also be produced by neoplastic B lymphocytes 
(Mocellin, Marincola, & Young, 2005; Purdue et al., 2007). By suppressing antigen 
presenting cells, IL-10 enables tumor cells to escape immune system (Xiu et al., 2015). 
Moreover, IL-10 may promote the upregulation of bcl-2 expression, contributing for the 
protection of malignant cells from apoptosis (Blay et al., 1993). Elevated IL-10 levels have 
been found in patients with NHL and were associated with poor prognosis (Blay et al., 1993; 
Lech-Maranda et al., sem data). These results are in line with previous studies that also 
demonstrated an elevated IL-10 serum level and  an increased IL-10 production by circulating 
PMBC following peptidoglycan stimulation in canine lymphoma patients (Axiak-Bechtel et 
al., 2014; Calvalido et al., 2016). There were no significant differences between IL-6, TNF-α 
and IL-2 serum levels of canine lymphoma and control group. Calvalido and collaborators  
reported a IL-6 serum elevation only in T-cell lymphoma group (Calvalido et al., 2016). 
Considering that our studied lymphoma group is composed mainly by B-cell lymphoma 
cases, these findings are consistent with previously published data. In addition, the hypothesis 
of a systemic immunosuppression in canine lymphoma patients is supported by previous work 
that had observed a significant depression  of  CD4+ and  CD8+ T-cell  numbers  before 
initiation  of  chemotherapy (Walter, Biller, Lana, Bachand, & Dow, 2006).  
Remarkably, a moderate positive correlation between IFN-γ mRNA expression in lymphoma 
affected lymph node and survival following CHOP protocol treatment, was found. These 
results indicate that the promotion of an effective Th1 response may benefit cNHL patients, 
supporting the rationale for the use of immunotherapies that stimulate an effector T cell 
response. 
Considering the close relationship between cytokines and peripheral blood cells, we carried 
out a comparison between red and white blood cell counts of cNHL patient and control group. 
Similar to previous studies, our results demonstrated a significant higher count of leucocytes 
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and monocytes in cNHL patients (Calvalido et al., 2016; Perry, Thamm, Eickhoff, Avery, & 
Dow, 2011). Furthermore, our data revealed a significant lower eosinophil count, as well as a 
lower hemoglobin and hematocrit, compatible with a non-regenerative normochromic anemia. 
In fact, anemia is a well-known hematological finding in cNHL, being associated with poor 
prognosis (Calvalido et al., 2016; Madewell & Feldman, 1980). Moreover, a positive 
correlation between neutrophil count and IL-6 serum level was found in our cNHL patients. 
IL-6 regulates neutrophil trafficking during the inflammatory response by orchestrating 
chemokine production and leukocyte apoptosis. As such, this finding demonstrates that IL-6 
might be involved in the inflammatory response in cNHL (Fielding et al., 2008). In fact, in 
humans IL-6 has been associated with paraneoplastic inflammatory syndrome symptoms, 
such as weight loss, night sweats and fever (Burger, 2013).  
A major strength of this investigation was the careful criteria selection that allowed to include 
well-characterized naïve canine multicentric lymphoma cases in the lymphoma group and 
healthy donors in the control group. Indeed, the successful construction of multicentric cNHL 
biobank was a major output of this work. Maintaining the construction of this biobank will 
ensure the availability of multiple, properly preserved samples for future research studies. 
Furthermore, simultaneous analyses were done with paired tissue and corresponding PBMC 
samples thus opening a possibility to compare the cytokine mRNA expression at the local and 
systemic level. Furthermore, our own long-term experience and access to a well-established 
qRT-PCR assay allowed a parallel measurement of mRNA expression for a broad panel of 
cytokines that cover Th cytokine profiles of major interest. However, this study also presented 
several limitations such as the limited number of patients included and the heterogeneity of 
the lymphoma diagnosed cases. In the future, it will be important to include larger study 
groups categorized accordingly to cNHL subtypes. Lastly, a major drawback of this work was 
the inability to perform multiplex immunoassay on tumors extract due to kit specifications.  
Taken together, these results suggest that similarly to its human counterpart, cNHL reveals a 
local and systemic dysregulation in cytokine response. In fact, an immunosuppressive 
cytokine dysfunction appears to be a constitutive component of the immune status of cNHL.  
By confirming and extending previous investigations, our work contributed for the evaluation 
of potential cytokine candidates for diagnostic and prognostic purposes and therapeutic 
intervention by cytokine inhibition and/or immunomodulatory strategies. Nevertheless, future 
studies using larger cohorts are needed to elucidate in detail the role of cytokines in the 
establishment and disease progression of cNHL. Importantly, Axiak-Bechtel and collaborators 
reported that chemotherapy protocols appeared to fail to restore immune response in cNHL 
(Axiak-Bechtel et al., 2014). Although these results must be confirmed, it could indicate that 
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harnessing the immune system with immunotherapeutic approaches might be the long-waited 
solution to improve the prognosis of cNHL.  
In conclusion, this work contributes for the better understanding of cNHL immune status, 
essential for the establishment of this animal model as a predictive preclinical surrogate for 
human NHL, mutually benefiting these uniquely co-dependent species and opening up 





























Development of engineered recombinant antibodies for 





mAbs are leading agents in modern anti-cancer therapy, but have their use limited by the 
paucity of clinically relevant models for validation. Rodent models are the conventional 
preclinical test-bed, however they do not correlate with clinical success rates, demonstrating 
an urgent need for innovative pre-clinical models. Naturally occurring tumors in dog mimic 
features of those observed in humans, difficult to reproduce with other models. This 
represents a unique opportunity to study the complex immune interactions while also 
addressing long-term efficacy and toxicity of cancer immunotherapies. hNHL is one of the 
leading causes of cancer-related death. The use of a mAb targeting CD20 in combination with 
conventional chemotherapy has revolutionized the treatment of B-cell lymphoma by 
significantly improving disease-free interval and overall survival. However, regardless of the 
elected therapy, the mortality rate is still high. Therefore, there is a continuing need to 
develop novel therapeutic strategies, of which mAbs is one of the most promising. Canine 
lymphoma and human NHL share many histopathological, molecular, genetic and clinical 
features, making the dog an excellent animal model to explore novel therapeutic molecules 
and approaches.  
Within this context, under this chapter, we aimed to develop recombinant antibodies for 
cNHL treatment and diagnosis, as an animal model of hNHL. For that purpose, two divergent 
strategies were explored for the generation of mAbs for cNHL – a validated target-led 
discovery method and a platform for the identification of therapeutic mAbs directed to novel 
targets. The first approach relies on the conventional antibody development process that starts 
with the identification and characterization of a biological target. This discovery path has led 
to the isolation of the majority of antibody therapeutics that today are used in the clinic and 
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remains a reliable option. However, as the number of validated targets diminishes, and the 
target space becomes increasingly competitive with the development of many biosimilar and 
biosuperior candidates, alternative strategies are gaining favor. Indeed, it has become clear 
that the identification of the next generation of first-in-class antibody drugs against novel 
targets to address unmet medical needs will be crucial for the success of biotherapeutics. 
Considering the many strengths presented by each approach, we aimed to pursue both by 
developing sdAbs against canine CD20, a well-known clinically validated target, and by 






Our research plan aimed at developing recombinant antibodies against cNHL, a promising animal 
model of immunotherapeutical approaches for NHL. Within this context, a comprehensive strategy 
was implemented to guarantee a successful project outcome, by developing sdAbs against canine 
CD20, a well-known clinically validated target, and by developing novel sdAbs against cNHL 




Figure 22 – Chapter research plan. 
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Since its approval 20 years ago, the anti-CD20 monoclonal antibody (mAb) rituximab has 
changed the treatment landscape for patients with B-cell NHL and established a new standard 
care. By prolonging survival in a range of these diseases, rituximab has reduced mortality and 
improved the clinical prognosis for many patients with B-cell NHL. As a result, veterinary 
community have been pursuing similar immunotherapeutic approaches for canine B-cell 
NHL, a common disease that shares remarkable similiarlities with its human counterpart and 
remains essentially incurable. Moreover, comparative medicine is leveraging the spontaneous 
canine NHL as an highly translational model to investigate the clinical potential of novel 
immunotherapies, complementing conventional murine studies that have failed to predict 
results in human clinical trials. Hence, to surpass the lack of cross reactivity of rituximab to 
the canine CD20 epitope, a few 1st generation mAbs targeting canine CD20 were recently 
developed and one has obtained clinical approval. However, these mAbs have presented 
disappointing scientific and clinical results, demonstrating that the discovery of an effective 
antibody for the treatment cNHL may require a more complex and innovative approach.  
Within this context, we conducted an investigation on canine CD20 sequence gene and its 
protein and gene expression in a cNHL biobank. Furthermore, we report the use of a novel 
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strategy for the generation of recombinant anti-CD20 monoclonal antibodies that bind both 
human and dog epitopes. Data obtained under gene and protein expression studies on 
lymphoma and normal canine cells demonstrated an overexpression of this receptor on canine 
lymphoma cells. Additionally, a new sequence of canine CD20 was identified in our biobank 
samples, diverging from previous published sequences. Importantly, by successfully 
developing a highly diverse library of rabbit sdAbs against a novel canine CD20 sequence and 
by coupling subtractive antibody selection rounds on whole-cells with a high-throughput 
screening, we were able to identify a panel of sdAbs with high binding activity and specificity 
to canine and human CD20. In conclusion, these results provide new data validating the 
canine CD20 as a potential target for veterinary immunotherapeutic strategies. 
Furthermore, the exploitation of these sdAbs may become a useful tool for the development of 




Antibody-based therapies represent one of the most promising and exciting fields in modern 
anti-cancer therapy. Due to their high specificity, antibodies have the ability to selectively and 
efficiently target a single molecule and promote the direct or indirect destruction of tumor 
cells (Neves & Kwok, 2015). However, despite the success of recent clinical breakthroughs, 
including checkpoint inhibitors and engineered T cells, only a small percentage of patients 
durably respond to immunotherapy and/or do not present toxicity signs (Park et al., 2016). As 
such, the challenge now is to extend the range of patients that benefit from immunotherapy 
while minimizing treatment-related adverse events. To address this, it is crucial to identify 
factors predictive of response that may help to properly select patients for treatment, identify 
rational combination therapies, and define progression and resistance (Klevorn & Teague, 
2016). This is particularly critical when developing immunotherapies considering that the 
patient’s immune system is expected to be as significant as tumor-related aspects when 
determining response and toxicity (Park et al., 2016). 
Advances in cancer immunotherapy relies on faithful predictive preclinical investigation and 
rodent models have been the foundation of preliminary basic research and safety assays 
(Malaney et al., 2014). However, these induced-tumor models underrepresent the 
heterogeneity and complex interaction between the human immune cells and cancers. In fact, 
laboratory mice rarely develop spontaneous tumors, are housed under specific-pathogen free 
conditions that markedly influences immune development, and incompletely model key 
characteristics of the tumor/immune microenvironment, creating challenges for clinical 
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translation. As a result, these murine models have failed to correlate with clinical success 
rates (Biemar & Foti, 2013; Kohnken et al., 2017; Kola & Landis, 2004). Thereby, the use of 
alternative animal models is pivotal to bridge the translational gap between murine models 
and human clinical studies and the dog represents a powerful resource of models for cancer 
immunotherapy research. Dogs are an appealing outbred combination of companion animals 
that experience spontaneous cancer development in the setting of an intact immune system 
(Park et al., 2016). In addition, naturally occurring tumors in dogs present many clinical, 
pathological, immunologic, molecular, diagnostic and therapeutic similarities to those 
observed in humans, that are difficult to reproduce in other models (Gardner et al., 2016; 
Pinho et al., 2012; Ranieri et al., 2013; Rowell et al., 2011). This allows studying the complex 
immune interactions during the course of treatment while also addressing long-term efficacy 
and toxicity of cancer immunotherapies (Park et al., 2016). 
In the last decades, the scientific community has been reporting cases of therapeutic success 
using mAbs in the treatment of NHL in humans. The use of a monoclonal antibody targeting 
the surface antigen CD20 (Rituximab®) in combination with chemotherapy regimen CHOP 
has revolutionized the treatment of B-cell lymphoma by significantly improving disease-free 
interval and overall survival, with minimal toxicity (Ito et al., 2015; Motta et al., 2010). Even 
though current therapy strategies have significantly improved the prognosis of patients 
diagnosed with NHL, the rate of mortality is still high (Molina, 2008; Zappasodi et al., 2015), 
ranking 6th as the  most common cause of cancer-related death in the United States (US) 
(Kong et al., 2015; Siegel et al., 2015).  Consequently, there are current research lines focused 
on improving anti-CD20 modalities and the use of canine Diffuse Large B-cell and Marginal 
Zone lymphomas, that share a similar molecular fingerprint to the human counterpart, as an 
animal model is one of the most promising strategies (Ito et al., 2014; Mudaliar et al., 2013). 
cNHL represents an heterogeneous group of malignancies that are among the most common 
neoplasias of dogs. Despite a wide variation in clinical presentations and histological 
subtypes, most dogs present with generalized lymphadenopathy (multicentric form) and 
intermediate to high-grade lymphoma, more commonly of B-cell origin. Without treatment, 
this disease is associated with high mortality (Marconato et al., 2013), requiring prompt 
chemotherapy to achieve temporary remission and prolonged survival. Still, cure is rarely 
achieved and the majority of dogs relapse with lethal, drug-resistant disease (Vail et al., 2007; 
Zandvliet, 2016). Thus, there is an urgent and unmet need in veterinary medicine to develop 
new treatment strategies for refractory disease. 
Although immunotherapy plays a major role in the treatment of human B-cell malignancies, 
its role in canine lymphoma is still limited. Whereas immunohistochemistry using antibodies 
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that recognize the CD20 intracellular domains, demonstrated the presence of CD20 in canine 
lymphoma tissue samples (Jubala et al., 2005; Kano et al., 2005). Rituximab® and other anti-
human and anti-mouse antibodies specific to the extracellular domains failed to bind to canine 
CD20, even though the proposed binding epitopes are conserved between human and canine 
CD20 (Impellizeri et al., 2006). For that reason, technology to speciate antibodies is essential 
when developing similar passive immunotherapy strategies for canine cancer patients. 
Furthermore, these efforts were also driven by the emergence on the drug discovery landscape 
of a pet therapeutic industry that aimed to meet increasing healthcare standards demanded by 
pet owners and a large clinical need (Sinha, 2014). Indeed, anti-CD20 mouse mAbs that can 
target canine CD20  have been reported (Ito et al., 2015; Jain et al., 2016; Rue et al., 2015). In 
addition, an anti-CD20 mAb (Blontress®) has been approved for canine B-cell lymphoma by 
the US Department of Agriculture and are commercially available in the USA and Canada. 
Nevertheless, the 1st generation of these mAbs are demonstrating suboptimal therapeutic 
efficacy, substantially inferior to results reported in human patients. As a result, the company 
is currently working on 2nd and 3rd generation mAbs (Klingemann, 2018; Sinha, 2014). 
Interestingly, what initially seemed like a relatively straightforward approach to develop a 
canine mAb therapy, revealed itself to be a challenging task. In fact, the development of an 
effective anti-CD20 passive immunotherapy for cNHL may require a comprehensive target 
validation and a better understanding of antibody effector functions present in the canine 
immune system. 
Within this context and to fulfill these gaps, we conducted for the first time an investigation 
on canine CD20 sequence gene and its protein and gene expression in a cNHL biobank. 
Furthermore, we report the use of a novel strategy for the generation of recombinant anti-
CD20 monoclonal antibodies that bind both human and canine epitopes. Through this 
approach we intend to contribute for the development of more effective immunotherapies for 











3.1.2. Material and Methods 
 
3.1.2.1. Biological samples 
 
• Canine Multicentric Lymphoma Biobank   
 
Patients with canine multicentric lymphoma were followed at the oncology unit of the 
Veterinary Medicine Faculty – University of Lisbon (FMV/UL)’s -Teaching Hospital where 
clinical evaluations were conducted. On a preliminary phase, with diagnostic and staging 
purposes, a complete history, clinical signs and physical examination were assessed. 
Complete blood count and biochemistry profile were performed, as well as abdominal and 
thoracic imaging exams. Histopathological evaluation of lymph nodes after node biopsy was 
performed. This histopathological evaluation included a morphologic examination, 
classification of lymphoma into grade subcategories and immunophenotyping to determine 
the immunophenotype present – B or T. Immunohistochemistry markers included CD3, 
CD20, CD79αcy and PAX-5. This clinical and laboratory examination allowed staging the 
dogs using the WHO system (Owen, 1980). Inclusion criteria comprised dogs recently 
diagnosed with multicentric lymphoma by clinical examination and cytological examination 
of lymph node fine-needle aspirate that have not yet begun therapy.  Exclusion criteria 
included dogs who have begun chemotherapy and who have received steroids or other 
immunotherapeutic agent within the last eight weeks of study enrollment or dogs who have 
become severely ill. All sample collection was conducted with pet owner consent in 
accordance with the principles and procedures outlined in the NIH Guide for the Care and Use 
of Animals and approved by the Animal Care and Use Committee of FMV/UL. Blood 
samples allowed the extraction of plasma, serum, DNA (Dneasy Blood & Tissue, Qiagen, 
Hilden, Germany) and mrna (Rneasy Protect Animal Blood System, Qiagen) that were stored 
at -80ºc. Additionally, PBMC were isolated by Ficoll gradient method (Biocoll Separating 
Solution, biochrom®, Fisher Scientific, New Hampshire, USA), cell viability was assessed 
and for storage, aliquots of 5 x 106 cells were suspended in 90% FBS (Gibco, Life 
Technologies, Paisley, UK) and 10% DMSO (Sigma-Aldrich, Missouri, USA) and kept in 
liquid nitrogen. Sterile biopsy lymph nodes samples were divided, 1/3 was fined cut and 
stored at -80ºc in rnalater® (Invitrogen, Life Technologies, Paisley, UK), 1/3 was formalin-
fixed and 1/3 stored in liquid nitrogen after lymphoma cell isolation. Briefly, solid tissue was 
cut, passed through a cell strainer (Cell Strainer, BD Falcon®), suspended in RPMI-1640 
medium (Gibco) supplemented with 20% FBS and penicillin 100 U/ml plus streptomycin 0.1 
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mg/ml (Gibco), and isolated through Ficoll gradient method (Biocoll Separating Solution, 
biochrom®). Cell viability were assessed and for storage, aliquots of 5 x 106 cells were 
suspended in 90% FBS and 10% DMSO and kept in liquid nitrogen. Clinical follow-up 
information about all cases was gathered from electronic medical records. 
 
• Control group  
 
Due to ethical concerns, sterile biopsy lymph nodes samples were collected, fined cut and 
stored at -80ºC in RNA later™ from a healthy control group of dogs housed at the animal 
facility of Faculty of Veterinary Medicine - Universiteit Utrecht. 
 
• Cell lines and culture 
 
The canine B-cell lymphoma cell line CLBL-1 was provided by Dr. Barbara Rütgen 
(University of Vienna, Austria). The human Burkitt's lymphoma Raji cell line, the human T 
lymphocyte cells and the human cell line HEK293T cell line (appropriated for ectopic 
expression of mammalian proteins) were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). CLBL-1, Raji and Jurkat cell lines were maintained in 
RPMI-1640 medium (Gibco) supplemented with 10% FCS (Gibco) and penicillin 
100 U/ml/streptomycin 0.1 mg/ml (Gibco). 293T cell line was cultured in Dulbecco Modified 
Eagle Medium (DMEM) medium supplemented with 10% FCS (Gibco) and penicillin 
100 U/ml/streptomycin 0.1 mg/ml (Gibco). All cell lines cultures were maintained at 37 °C in 
a humidified atmosphere of 5% CO2 (T75-tissue culture flasks, Greiner Bio-One, 
Kremsmünster, Austria). 
 
3.1.2.2. Characterization of canine CD20 expression in a canine multicentric lymphoma 
biobank 
 
• Immunochemistry  
 
A representative area of each lymph node was selected and tissue sections of 3μm thickness 
were mounted on glass slides (Star Frost adhesive glass slides, Thermo Scientific, Rockford, 
USA), deparaffinized with xylene and hydrated in a graded ethanol series to distilled water. 
Except for anti-CD3 antibody, all protocol steps were carried out using the Novolink Polymer 
Detection System (Novocastra, Leica Biosystems, Newcastle, UK), according to the 
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manufacturer’s instructions. The antigen retrieval step was performed by microwave 
treatment (3 × 5 min) in Tris–EDTA buffer (pH 9.0). After endogenous peroxidase blocking 
and treatment with protein block solution (Protein Block Solution-Kit NovoLink™), tissue 
sections were incubated 1 h at room temperature with the following primary antibodies: 
mouse monoclonal anti-human anti-CD79 αcy (clone HM57, diluted 1:150; Dako) and mouse 
anti-human PAX5 (clone 1EW, 1:100, LEICA).  In turn, CD3 immunostaining included 
endogenous peroxidase blocking by incubating the slides in 3% hydrogen peroxide in water 
for 30 min followed by antigen retrieval in Tris–EDTA buffer (pH 9.0), as described above. 
Blocking was performed with blocking solution (PBS + 0.1Tween + 5% goat serum + 2.5% 
Bovine Serum Albumin (BSA)), for 1 h at room temperature followed by incubation with 
rabbit polyclonal anti-human CD3 (1:200; Dako, Glostrup, Denmark) for 2 h. The peroxidase 
conjugated goat anti-rabbit IgG polyclonal antibody (diluted 1:100, Dako) was used as 
secondary antibody. For all antibodies, the staining was developed by incubating the slides 
with the substrate diaminobenzidine (DAB kit, Zytomed Systems, Berlin, Germany). Staining 
without the primary antibody and staining with the isotype-matched irrelevant monoclonal 
antibody were used as negative controls. Human tonsil and dog spleen sections were used as 
positive control tissues. All slides were independently subjected to blind scoring by two 
independent pathologists. Discordant interpretations were further debated and settled using a 
multiobserver microscope. 
 
• Relative quantification of canine CD20 expression by real-time qPCR 
 
For total RNA extraction, lymph node samples stored in RNAlater® and PBMC samples were 
thawed and processed using RNeasy Mini Kit (Qiagen), according to the manufacturer’s 
instruction. To eliminate possible contaminant DNA, total RNA samples were subjected to 
DNAse treatment, using RNase-free DNase Set (Promega; Wood Hollow road, Madison, 
USA), following the manufacturer’s instructions. Thereafter, cDNA was synthesized using 
Transcriptor High Fidelity (Roche, Basel, Switzerland) following the manufacturer’s 
instructions and used as a template for Real-Time quantitative Polymerase Chain Reaction 
(qRT-PCR). Total RNA and cDNA purity were assessed by 1% agarose gel electrophoresis. 
The primers used for each gene were published in the literature and the respective authors and 
sequences are presented in Table 8. Despite the DNAse treatment, and to preclude genomic 
DNA amplification, primers covered putative exon–exon junctions. Optimization experiments 
and efficiency assessments for each amplification system were previously performed (data not 
shown). Primers were obtained from a commercial manufacturer (Metabion International AG, 
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Germany). The mRNA transcription of the Ribosomal protein L27 gene (RPL27) had no 
significant statistical differences (p > 0.05) regarding cNHL and control groups, therefore this 
gene was considered a suitable housekeeping gene (Table 8). qRT-PCR was performed using 
the StepOne Plus realtime analyzer (Applied Biosystems, Foster City, CA, USA). The PCR 
assays comprised, in each reaction, 2 μl of each primer (final concentration of 100 nM), 2 μl 
of cDNA (1ng), 4 μl of sterile water and 10 μl of SYBr (Applied Biosystems, Warrington, 
UK) in a total volume of 20 μl per reaction. Thermocycling conditions consisted of an initial 
denaturation of 10 min at 95 °C, followed by 40 cycles of amplification (95 °C for 15 s and 
annealing at 60 °C for 1 min). A final melting curve stage consisted of 95 °C for 15 s, 60 °C 
for 1 min followed by a ramp rate and heating of samples until 95 °C with a 0.3 °C/s ramp 
rate. The melting curves obtained were used to verify the specificity of each amplicon and 
finally PCR products were sequenced. The 2−ΔΔCT method was used as described by Perkin-
Elmer Applied Biosystems to assess relative mRNA expression quantification between 







• Analysis of canine CD20 protein expression by immunoblotting 
 
Lymph node cells were thawed and washed twice with PBS. Total protein was extracted using 
RIPA lysis buffer (25mM TrisHCL pH 7.6, 150mM NaCl, 1% NP-40, 1% 
sodiumdeoxycholate, 0.1% SDS) supplemented with fresh protease inhibitors (Roche) and 
phosphatase inhibitors cocktail (Sigma). Samples were quantified by the Bradford method. 
CD20 receptor expression was demonstrated by Western blot analysis. Total protein extract 
samples were separated by SDS-PAGE and transferred to nitrocellulose membranes. After 
blocking, proteins were incubated with Anti-CD20 antibody (polyclonal, rabbit, 1:500 
dilution, Thermo Fisher Scientific, Rockford, IL, USA) and then with Peroxidase-AffiniPure 
*RT-PCR – Reverse Transcriptase Polymerase Chain Reaction qRT-PCR – Real-Time Polymerase Chain Reaction  
Table 8 - Detailed primers and conditions used for reverse PCR and real-time 
PCR assays for CD20 analysis. 
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Anti-Rabbit IgG antibody (polyclonal, goat, 1:10000 dilution, Jackson ImmunoResearch, PA, 
USA) as a secondary antibody. Proteins were visualized using Luminata Forte Western HRP 
(Merck Millipore, Darmstadt, Germany) and acquired using the ChemiDoc XRS+ imaging 
system (Bio-Rad, California, USA). Beta-actin expression were used as protein loading 
control using an Anti-βactin antibody (AC-15 clone, mouse, 1:10000 dilution, Sigma-Aldrich) 
as a primary antibody and an Anti-Mouse IgG antibody (polyclonal, goat, 1:7500 dilution, 
Jackson ImmunoResearch) as a secondary antibody. Bioinformatic tools using Image Lab 
(Biorad) were used to quantify CD20 expression and demonstrate differences between 
samples. 
 
• Sequence analysis of the canine CD20 gene  
 
The canine CD20 was cloned by RT-PCR. For that purpose, mRNA was isolated from lymph 
nodes samples of the canine lymphoma biobank and control group using Rneasy Mini Kit 
(Qiagen GmbH; Hilden, Alemanha). To eliminate possible contaminant DNA, total RNA 
samples were subjected to DNAse treatment, using RNase-free DNase Set (Promega; Wood 
Hollow road, Madison, E.U.A.), following the manufacturer’s instructions. Thereafter, first-
strand cDNA was synthesized using Transcriptor High Fidelity (Roche) following the 
manufacturer’s instructions and used as a template for RT-PCR using primers presented in 
Table 8, designed at the ends of reported sequence of canine CD20.  Sequencing was 
performed by GATC. Translation to amino acid sequences, multiple sequence alignment and 
phylogenetic analysis were performed using the “Vector NTI” software. Canine CD20 protein 
secondary structure prediction was made using the InterPro platform on UniProt.  
 
• Statistical analysis 
 
All data are expressed as mean ± standard error of mean (SEM). All statistical analyses were 
carried out using R-software. Normality test was performed using the Shapiro-wilks test. The 
distribution of CD20 ct values passed the normality test and lymphoma and control groups 







3.1.2.3. Generation of monoclonal antibodies against canine CD20 
 
• Cloning of canine CD20  
 
The canine CD20 was cloned by RT-PCR from lymph node samples of a canine multicentric 
biobank case (B2) following the conditions previously mentioned above. PCR products were 
digested with SfiI (Roche) then purified and cloned into the FUGW at SfiI sites. Then, the 
ligated product was transformed into E.coli BL21 competent cells via thermal shock. 10 
colonies were picked and PCR colony was performed using primer cCD20-F and primer 
cCD20-R (Table 8). 
 
• Transfection of canine CD20 into HEK 293T cells 
 
The HEK 293T cells (ATCC) were transfected with plasmid DNA using the FuGENE® HD 
(Roche), according to the manufacturer’s instructions. HEK 293T cells were grown as 
monolayers in DMEM supplemented with 10% FCS and 3 μg of pFUGW vector CD20 was 
added. The HEK 293T transfected cells were incubated for 48 hours. Canine CD20 transient 
expression was confirmed by immunoblotting for canine CD20 expression (Thermo 
Scientific) and GFP staining with flow cytometry analysis. In parallel, a HEK 293ThCD20 cell 
line was simultaneously generated for cross-reactivity analysis purposes, using identical 
methodology. 
 
• Rabbit immunization 
 
A New Zealand White rabbit was immunized with HEK 293T cells transfected with canine 
CD20 vector. The injections were administrated subcutaneously at 2–3 week intervals during 
4 months.  
 
• Rabbits serum titer against canine CD20 
 
To evaluate the serum specificity and titer, before each immunization blood was harvested 
from the marginal ear vein for serum isolation. Serum was analyzed by enzyme-linked 
immunosorbent assay (ELISA) and immunoblotting using CLBL-1 cell line, Raji cell line and 
lymphoma primary cells and Peroxidase-conjugated goat anti-rabbit antibody (Jackson 
Immune Research) as secondary antibody. HEK 293T cells with canine CD20 vector, CLBL-
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1 cells, Raji cells and HEK 293T cells were separated by SDS-PAGE and transferred to 
nitrocellulose membranes. After blocking, proteins were probed with rabbit serum (dilution 
1:5000) and then with HRP conjugated anti-rabbit mAb as a secondary antibody. As a control, 
we used pre-bleed sera. 
 
• sdAbs immune library construction 
 
Five days after the final boost, spleen and bone marrow were harvested separately for total 
RNA using TRI Reagent (Molecular Research Center, Cincinnati, OH). First-strand cDNA 
was synthesized using Transcriptor High Fidelity (Roche) following the manufacturer’s 
instructions. PCR was performed to amplify the heavy-chain variable (VH) and light-chain 
variable regions (VL) from the rabbit’s cDNA using the set of primers presented at Table 9. 
PCR products encoding a library of antibody fragments (sdAbs) were then gel purified, 
restriction digested with SfiI and cloned into pCOMB3xSS. Subsequently, the ligated product 
was transformed into electro competent cells via electroporation and the library was tittered. 
To confirm library insert efficiency and diversity, PCR colony was performed using primer 
RSC-F (5´GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC 
3’) and primer RSC-B (5’GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC 



















Table 9 - Nucleotide sequences of primers used for the construction of a sdAbs 
library. 
 VH* Forward Primers sequences (5′–3′)  
SDVH1-F  GGGCCCAGGCGGCCCAGTCGGTGGAGGAGTCCRGG 
SDVH2 -F GGGCCCAGGCGGCCCAGTCGGTGAAGGAGTCCGAG 
SDVH3-F GGGCCCAGGCGGCCCAGTCGYTGGAGGAGTCCGGG 
SDVH4-F GGGCCCAGGCGGCCCAGSAGCAGCTGRTGGAGTCCGG 
 VH* Reverse Primers sequences (5′–3′)  
SDG-R CCTGGCCGGCCTGGCCACTAGTGACTGAYGGAGCCTTAGGTTGCCC 
 VL* Forward Primers sequences (5′–3′)  
RSCVK1-F  GGGCCCAGGCGGCCGAGCTCGTGMTGACCCAGACTCCA 
RSCVK2-F ’GGGCCCAGGCGGCCGAGCTCGATMTGACCCAGACTCCA 
RSCVK3-F  GGGCCCAGGCGGCCGAGCTCGTGATGACCCAGACTGAA 
RSCλ-F  GGGCCCAGGCGGCCGAGCTCGTGCTGACTCAGTCGCCCTC 
 VL* Reverse Primers sequences (5′–3′)  
SDVLj10-B CCTGGCCGGCCTGGCCTTTGATTTCCACATTGGTGCC  
SDVLj0-B  CCTGGCCGGCCTGGCCTAGGATCTCCAGCTCGGTCCC  
SDVL42j0-B ’CCTGGCCGGCCTGGCCTTTGACSACCACCTCGGTCCC  
SDVLλ-B CCTGGCCGGCCTGGCCGCCTGTGACGGTCAGCTGGGTCCC 
*VH – Heavy Chain variable domain, VL – Light Chain variable domain  
 
3.1.2.4. Selection of recombinant monoclonal antibodies against canine CD20 
 
• Selection of anti-CD20 sdAbs by Phage Display 
 
To display anti-CD20 sdAbs on M13 phage, sdAbs library was infected with M13 helper 
phage (1012 plaque-forming units/ml) during 1 h at 37 °C and grown overnight. Phages were 
precipitated, and titer was determined. The phage library displaying sdAbs was panned using 
a subtractive cell phage display protocol as described in Basbas studies, including a negative 
selection on HEK 293T cells followed by a positive selection on CLBL-1 cells (Barbas, 
Burton, Scott, & Silverman, 2004; Popkov, Rader, & Barbas, 2004). Three rounds of phage 







• In vitro binding and expression studies 
 
To express and select anti-CD20–sdAbs, phagemid DNA encoding selected anti-CD20 sdAbs 
was cloned into pT7-PL (pT7-peptide leader) vector and transformed into E. coli strain BL21. 
Library insert efficiency was confirmed by colony PCR. The colonies obtained were picked 
and incubated overnight at 30°C on 100 µl of Super Broth (SB) medium containing Overnight 
Express™ Autoinduction System 1 (Novagen®) and 100 µg/ml of Ampicilin. Next day, 40 µl 
of BugBuster (Roche) containing anti-protease cocktail-EDTA free inhibitors (Roche) were 
added and incubated for 30 minutes at 4°C. Next, the plates were centrifuged at 1200 rpm and 
the supernatant was used to perform an ELISA assay. Three different parameters were 
analyzed: binding of antibodies to the antigen, expression level and unspecific binding. To 
evaluate the binding to the antigen (CD20), plates with the total CLBL-1 extract attached 
were used, washed with PBS and blocked with BSA 3% for 1 hour at 30°C. Then, plates were 
washed and the supernatant containing VLs was incubated for 1 hour at 30°C. Plates were 
washed and incubated with anti-HA-HRP antibody (Roche) was added. After 1 hour of 
incubation, plates were washed, ABTS (Roche) substrate solution was added and optical 
density at 405 nm was measured at different time points. To evaluate the level of expression, 
the same process was carried out, except for the antigen coating. To evaluate the unspecific 
binding, in turn of the antigen, BSA 3% was added. Rabbit serum and anti-CD20 antibody 
were used as positive controls. BL21 cell extracts and SB medium were used as negative 
controls. 
 
• Sequencing of anti-CD20 sdAbs 
 
Sequencing was performed by GATC Biotech AG (Ebersberg, Germany) using the pComb3x 
ATG primer (5’ GGG CCC AGG CGG CCA TGA CAA CAC CCA GAA ATT CA 3’). To 
translate to amino acid sequences and to evaluate homology, the Vector NTI Advance 10 












3.1.3.1. Characterization of canine CD20 expression in a canine multicentric lymphoma 
biobank 
 
The selection of tumor antigens suitable for antibody targeting and immunotherapy demands 
an extensive investigation of tumor and normal tissue expression (Scott, Allison, & Wolchok, 
2012). CD20 is highly expressed by over 95% of B cell lymphocytes throughout their 
development, from the pre-B cell stage until their final differentiation into plasma cells, but is 
absent on the hematopoietic stem cell (Kosmas, Stamatopoulos, Stavroyianni, Tsavaris, & 
Papadaki, 2002). Thereby, CD20 is a lineage specific receptor, being expressed in both 
healthy and the majority of malignant B-cells (Einfeld, Brown, Valentine, Clark, & Ledbetter, 
1988). Its expression has been demonstrated to be heterogeneous between and within different 
subtypes of the human B-NHL and has been considered a predictor of response to rituximab 
containing treatment in patients with B-cell lymphomas (Prevodnik, Lavrenčak, Horvat, & 
Novakovič, 2011). As such, a comprehensive analysis of the expression of CD20 in both 
healthy and B-cell lymphoma diagnosed dogs might also have a critical role in the 
development of a similar canine anti-CD20 immunotherapy. Therefore, to further characterize 
CD20 gene and protein expression in canine lymphoma, relative quantification of gene 
expression by qRT-PCR and western blot analysis was performed. 
Following histopathological and immunochemistry analysis by a veterinary pathologist, 
canine lymphoma cases were divided in three different groups: B-cell lymphoma, T-cell 
lymphoma and non-B non-T cell lymphoma. CD20 immunophenotype was confirmed in all 
samples before gene and protein expression analysis (Figure 23C). 
Overall, qRT-PCR demonstrated that mRNA expression level of canine CD20 was 
significantly higher in B-cell lymphoma samples when compared with healthy lymph nodes 
and non-B-cell lymphoma samples, including T-cell and non-B and non-T cell lymphoma 
samples (p < 0,05). This increment was quantified as 8.2 ± 2.23 times fold, validating the 
CD20 mRNA overexpression in canine B-cell lymphoma samples (Figure 23A). Regarding 
CD20 protein expression by western blot analysis, all B-cell lymphoma samples demonstrated 
a CD20-positive phenotype. Moreover, CD20 expression was found to be heterogeneous on 
B-cell lymphoma samples. On the contrary, healthy samples presented a scanty CD20 
expression, as well as T-cell and non-B and non-T cell lymphoma samples (Figure 23B). 
These findings corroborated the qRT-PCR data, demonstrating a canine CD20 overexpression 
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in lymphoma samples and validating this receptor as an important lymphoma immunotherapy 
target. 
  





(A) Relative cytokine mRNA expression in cNHL tumor tissue. Results are expressed as a fold 
difference between mean ± SEM of mRNA expression level in cNHL affected lymph nodes samples 
and a control group with healthy donors. * p < 0,05. (B) Total protein was extracted from lymph nodes 
samples from cNHL biobank and healthy donor samples and CD20 expression were assessed by 
western blotting. β-actina was used for loading control. Representative blots are shown. B1-B18 refers 
to B-cell lymphoma samples, T1-T3 to T-cell lymphoma samples, N1 to a non-B non-T cell 
lymphoma and C1-C7 to control samples. (C) Upper panel – Diffuse growth pattern of large 
lymphocytes of a canine DLBCL (H&E, x40). Bottom panel – Nodular growth pattern of 
closely packed lymphocytes of a follicular lymphoma of a canine patient (H&E, x40).  (D) 
Imunohistochemistry of a canine PTCL showing positivity in virtually 100% of the tumor 
cells (anti-CD3 antibody, Gill’s hematoxylin, x100). Bottom panel – Immunohistochemistry 
of a canine DLBCL showing positivity in virtually 100% of the tumor cells (anti-CD20 
antibody, Gill’s hematoxylin, x 200). 
 
3.1.3.2. Sequence analysis of the canine CD20 gene  
 
The canine CD20 amino acid sequences exhibit 73 and 68% sequence similarities with human 
(X12530) and mouse (AB045181) CD20 sequences, respectively, suggesting that the CD20 
receptor might play a role in the immune system similar to other mammals. In fact, the 
canine CD20 was predicted to contain four membranes spanning domains, three intracellular 
domains including the N - and C – terminal domains and two extracellular loops as the human 
CD20 (Riley & Sliwkowski, 2000; Tedder et al., 1989). Moreover, potential differences in the 
coding sequence of the canine CD20 gene might explain the absence of cross-reaction 
between the two species, especially if these genetic alterations occur in the specific binding 
domains. The full-length of canine CD20 cDNAs was sequenced using canine mRNA from 
our biobank as a template. The full-length of the cDNA sequence of canine CD20 was 894 bp 
encoding 298 amino acids. Lymphoma lymph nodes, PBMCs and lymph nodes from healthy 
donors were analyzed and presented an analogous CD20 sequence. This canine sequence 
diverged by eight mutations when compared with previous published sequences (Ito et al., 
2015; Kano et al., 2005), of which six resulted in amino acid substitution and two 
corresponded to a silence mutations. As shown in Figure 24, the majority of the coding 
differences found are positioned on CD20 cytoplasmic and transmembrane portions, while 
differences in residues 147 and 159 are located in the larger extracellular loop. Importantly, 
our canine CD20 sequence presented an 82.2% similarity with human CD20 gene, 
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demonstrating that identified mutations resulted in a higher resemblance with human CD20 
gene. 
 
Figure 24 - Sequence analysis of the canine CD20 gene in a canine lymphoma biobank 
based on UniProt database prediction. 
 
 
Different amino acid residues between the canine CD20 sequences. The aminoacid residues that differ 
from the sequence reportated by Kano et al. 2005 are indicated in orange, while differences from the 
sequence reported by Ito at. 2015 are indicated in green. Detailed information about position and 





3.1.3.3. Development of monoclonal antibodies against canine CD20 
 
• Generation and screening of high-titered antisera against canine CD20 
 
The HEK 293T cell line was transfected with a pFUGW vector encoding canine CD20 and 
GFP reporters, as described in the material and methods section, for rabbit immunization. 
While flow cytometry analysis confirmed GFP expression in HEK 293TcCD20 cell line (Figure 
25A), immunoblotting analysis established CD20 expression (Figure 25B). In parallel, HEK 
293ThCD20 was simultaneously generated for cross-reactivity analysis purposes (data not 
shown). 
The canine CD20 antiserum was successfully produced from a female New Zealand white 
rabbit immunized with HEK 293T cells transfected with canine CD20 vector. Antibody titers 
and specificity were monitored by western blot and ELISA. As shown in Figure 25C, cell 
ELISA assays showed that final bleed serum recognized both HEK 293TcCD20 and HEK 
293ThCD20 cells contrarily to pre-bleed serum, confirming cross-reactivity against human 
CD20. Moreover, these data demonstrated that immunizations resulted in a strong immune 
response with a high serum titer (1:60.000). Similar results were obtained using CLBL-1 
cells, that express CD20 in its native form (Figure 25D).  
To further test binding specificity of rabbit serum against canine CD20 and human CD20, 
sera was evaluated by immunoblotting. After four immunizations, rabbit sera specifically 
recognized the 33 kDa canine CD20 protein expressed by CLBL-1 cells and HEK 293T cells 
transfected with canine CD20 vector and the 35 kDa human CD20 protein expressed by HEK 
293T cells transfected with human CD20 (Figure 25E). Importantly, western blot assays 
demonstrated that, with the course of immunizations, rabbit sera started presenting weaker 
signs against unspecific proteins expressed by HEK 293T cells and Jurkat (Figure 25F). 
These results were essential for the design of the phage display screening. In agreement, 
rabbit pre-bleed, harvested before starting immunizations, did not show any signal against 
immunized cell or control cells (Figure 25G). 
Altogether, these results allowed to confirm a high antisera titer against canine and human 
CD20, indicating a specific B-cell reaction and assuring a high-quality antibody gene library. 
As a result, the animal was sacrificed and the bone marrow and the spleen - major repositories 






Figure 25 - Generation and screening of high-titered antisera against canine CD20. 
 
(A) Histogram of HEK 293TcCD20 cell line construction, representing GFP expression analysis by 
FACS. (B) Canine and human CD20 phenotype was confirmed by western blotting analysis. Total 
protein extracts of both cell lines were probed with an anti-CD20 antibody using HRP-conjugated goat 
anti-rabbit Fc polyclonal antibody as secondary antibody. CLBL-1 extract, a canine B-cell lymphoma 
cell line with confirmed CD20 expression, was used as a positive control and HEK293T as a negative 
control.  (C) Titration and binding activity of serum antibodies corresponding to pre-bleed and final 
bleed. Antisera from the immunized rabbit was analyzed for binding activity to both HEK 293TcCD20 
and HEK 293ThCD20 cell lines by cell ELISA using HRP-conjugated goat anti-rabbit Fc polyclonal 
antibody as secondary antibody. Data were obtained by Abs measurement at 405 nm with reference a 
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492 nm. Values represent mean±standard deviation of triplicates (n=3) for each condition, and similar 
results were obtained in two independent experiments. (D) The same experiment was carried out to 
analyze binding activity to CLBL-1 cell line. (E) Immunized rabbit serum specificity was analyzed by 
Western blotting. Total protein extracts of HEK 293TcCD20, HEK 293ThCD20, CLBL-1 and HEK 293T 
cell lines were probed with the serum extracted during the 4th immunization. HRP-conjugated goat 
anti-rabbit Fc polyclonal antibody was used as secondary antibody. Representative blots are shown.  
Protein profiles recognized by rabbit polyclonal revealed specificity of the immune response. (F) 
Immunized rabbit final bleed specificity was analyzed by Western blotting. Total protein extracts of 
HEK 293TcCD20, CLBL-1, 17-71 (canine B-cell lymphoma cell line not expressing CD20), Jurkat (T-
cell leukemia cell line) and cell HEK 293T cell lines were probed with the final serum. HRP-
conjugated goat anti-rabbit Fc polyclonal antibody was used as secondary antibody. Representative 
blots are shown.  Protein profiles recognized by rabbit polyclonal revealed specificity of the immune 
response, as well as, an unspecific response against other targets. (G) Immunized rabbit pre-bleed 
specificity was analyzed by Western blotting, as mentioned above in panel E. No binding activity to 
protein extracts before the start of rabbit immunizations was confirmed.  
 
• Construction of a rabbit anti-CD20 sdAb phage display library 
 
A rabbit sdAb library was constructed using RNA from spleen and bone marrow cells of a 
rabbit previously immunized with HEK 293T cells transfected with canine CD20 vector.  For 
that purpose, specific oligonucleotide primers covering all known variable rabbit antibody 
family sequences were used to amplify VH and VL gene segments (Table 9). The 
recombinant phagemid pComb3X containing the VL sdAb genes was transformed into E. 
coli ER2538 cells to yield 2,25 x 106 and 6,42 x 106 individual clones for bone marrow and 
spleen, respectively. Rabbit repertoire presented an efficiency of 100% in all libraries. 
 
• Selection of recombinant monoclonal antibodies against canine CD20 
 
Selection of specific sdAbs for the CD20 receptor were performed using a subtractive cell 
phage display as described in the material and methods section. This cell phage display 
screening protocol was based on the previously Carlos Barbas studies, in which it is reported 
a novel whole-cell selection protocol with negative and positive selection steps (subtractive 
phage display) designed to remove antibodies reacting with common antigens (Popkov et al., 
2004). Phage display conditions implemented herein are summarized in Figure 26A. VL 
library was selected for phage display screening due to high diversity presented by VL 
repertoire compared to rabbit VH repertoire. Other advantages of the rabbit VL repertoire 
93 
 
includes its higher diversity and a larger complementarity-determining region (CDR)-L3 loop 
length, when compared to its mice and human counterpart. (Knight, 1992; Mage, Lanning, & 
Knight, 2006; Ros et al., 2004; Sehgal, Johnson, Wu, & Mage, 1999; Zhang, Liu, Guan, 
Wang, & Yuan, 2017). Briefly, four pannings were performed with a subtractive selection 
including a negative and a positive selection. To promote the elimination of non-specific 
antibodies, a negative selection was performed using the HEK 293T cell line, which do not 
express the CD20. In addition, the CLBL-1 cell line was used for the positive selection due to 
its stable expression of CD20 receptor. Over the course of selection, stringency was improved 
by increasing the number of washes in order to collect the sdAb-phage clones with greater 
target affinity or specificity. Different elution methods were performed to select for binders 
and internalized antibodies (Figure 26A). As shown in Figure 26B, the phage display rounds 
resulted in a lower number of phages in the output titers compared to the input titers (~1011-12 
to ~105-4 pfu). Furthermore, the biopannings profile indicates that the Phage Display protocol 






Figure 26 – Phage display selection of highly specific anti-CD20 sdAbs. 
 
(A) Schematic representation of subtractive whole-cell phage display. The antibody-phage library was 
initially subtracted on cell not expressing CD20 (HEK293T cells), and then the free phages were 
screened on cells harbouring CD20 receptor (CLBL-1 cells). A washing step was performed to remove 
all the non-specific and unbound phage. Cell surface bound phage were removed by tripsin elution, 
while the internalized phages were retrieved by cell lysis. The isolated phage particles were then 
amplified and used for subsequent panning rounds. (B) Graphic representation of amplified and eluted 
phage titers of each round of phage display selections. sdAbs with binding (binders) or internalization 





To further select the best candidates based on expression and binding features, the last 
panning was cloned into a pT7-PL vector. This vector possesses a peptide leader, which 
promotes the sdAbs expression to be directed to the periplasmic space, allowing to evaluate 
the expression level of sdAbs. Following, an high throughput screening was performed on a 
total of 528 clones, in which multiple ELISA assays were carried out to evaluate expression 
and binding to the protein extract from CLBL-1 cells. This study allowed to select 12% of 
clones that revealed the stronger signal regarding binding to protein cell extract and 
expression. Clone binding and expression activity were further tested and confirmed by 
ELISA (Figure 27A), which allowed to select the 11 best candidates.  In addition, to evaluate 
clones cross-reactivity against human CD20, ELISA assays were performed using Raji 
extract. As shown in Figure 27B, all selected clones presented cross-reactivity against human 
CD20. 
 
• Sequencing of anti-CD20 sdAbs  
 
To evaluate anti-CD20 sdAbs coding sequence, selected clones were sequenced by Sanger 
sequencing and sequence alignment and phylogenetic analysis were performed using the 



























(A) Relative binding activity of sdAbs. The lead candidates of high throughput selection were 
analyzed by ELISA to evaluate binding activity against CLBL-1 protein extracts and BSA and 
expression levels. HRP-conjugated anti-HA mAb was used as secondary antibody. Results were 
measured by optical density at 405 nm. BL21 extracts and a non-related VHH antibody were used as 
negative controls. (B) The same experiment was carried out to evaluate lead candidates binding 





Comparative medicine within the one world health framework offers an important platform 
with complex cross-species models that allows the research of novel therapeutic agents and 
approaches for human diseases (Gardner et al., 2016). Therefore, collaborative 
interdisciplinary efforts are being made in order to contribute for the development of 
innovative immunodiagnostic and immunotherapeutics models bringing canine and human 
diseases together (Park et al., 2016). Cancer remains a major cause of mortality and morbidity 
and its devastating consequences also affects our companion animals (Baioni et al., 2017; 
Fitzmaurice et al., 2017). Approximately 1 in 4 dogs will, at some stage in their life, develop a 
type of neoplasia and canine lymphoma is one of the most common neoplasias (Dorn, Taylor, 
Chaulk, & Hibbard, 1966; Dorn, Taylor, & Schneider, 1970; Dorn, Taylor, Schneider, 
Hibbard, & Klauber, 1968; Kidd, 2008; Merlo et al., 2008; Teske, 1994). Chemotherapy still 
remains the mainstay for the treatment of canine lymphoma and regardless of the numerous 
published chemotherapeutic protocols, it seems we have reached a stalemate concerning what 
this treatment modality has to offer in standard settings (Argyle & Pecceu, 2016). The 12 
month median survival barrier and the 20% to 25% 2 years survival rates demonstrate an 
urgent and unmet need in veterinary medicine to develop new treatment strategies for 
refractory disease (Vail et al., 2007). In the last decade, the scientific community has been 
reporting cases of therapeutic success using mAbs in the treatment of lymphoma in humans 
(Adler & Dimitrov, 2012). One of the most successful examples has been the application of 
the monoclonal antibody Rituximab towards a growing range of disease indications (Chames 
et al., 2009). Rituximab is a chimeric monoclonal antibody with humanized constant chains 
fused recombinantly to murine variable domains (Griffin & Morley, 2013). Since the approval 
of rituximab in 1997 five other mabs have been approved by the FDA for the treatment of B-
cell NHL and HL, including two anti-CD20 agents; tositumomab and ibritumomab; which are 
full-length mouse monoclonal antibodies that are conjugated to a radiochemical carrier (Cang, 
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Mukhi, Wang, & Liu, 2012). Although, therapeutic options for humans with NHL have 
improved remarkably and some of the more aggressive forms of lymphoma may at times be 
cured with combination chemo/immunotherapy, almost all patients with low-grade lymphoma 
and approximately 50% of patients with high-grade lymphoma die of this disease (Molina, 
2008; Zappasodi et al., 2015). Few chemotherapy agents were recently incorporated into the 
treatment of lymphomas and the interest over the last years has mainly focused on the 
development of targeted compounds, such as mAbs (Stathis & Ghielmini, 2012).  
The successful introduction of antibody-based proteins into the arsenal of therapeutics was 
highly promoted by the innovation in the production and engineering of antibodies (Chiu & 
Gilliland, 2016). The application of recombinant or synthetic biologic allows the construction 
of the most appropriate bio-conjugated to a specific platform, whether by using conventional 
antibodies with functional Fc domains, by developing antibody-drug conjugates that deliver 
targeted radiation or toxins or by constructing recombinant nanobodies that are suitable to 
selected manipulation (Jain et al., 2016). The latter have rapidly become one of the new-
generation of antibodies and are a promising alternative to conventional mAbs. 
We have been showing that rabbit derived sdAbs can be developed against several targets and 
that these minimal scaffolds show great potential for therapeutic applications (Corte-Real et 
al., 2005; da Silva et al., 2012). sdAbs are presently the smallest functional antibody 
fragment, only consisting of an antibody heavy-chain or light-chain variable domains (VH or 
VL). The small size of these fragments allows to improve tumor penetration and accessibility 
to targets not easily reached by IgGs (Aires da Silva et al., 2008; Goncalves & Aires-Da-
Silva, 2008; Volker et al., 2016). In addition to the reduced size, complementary-determining 
regions (CDRs; antigen-binding regions) of sdAbs can be easily engineered to develop 
specific and high-affinity binders. Moreover, sdAbs also present excellent properties such as 
high stability, solubility, low immunogenicity and low manufacturing cost (Aires da Silva et 
al., 2008; Volker et al., 2016). 
In our approach we explore the properties of these recombinant molecules for the 
development of rabbit sAbs towards canine CD20 protein, with cross-reactivity against 
human CD20. Our strategy comprised (i) the characterization of canine CD20 mRNA and 
protein expression and sequence analysis on a canine multicentric lymphoma biobank; (ii) the 
construction of a canine anti-CD20 library by amplifying the variable genes from cDNA 
derived from mRNA from the spleen and bone marrow of a rabbit immunized with HEK 
293T with canine CD20 vector cells (iii) the selection of specific sdAbs for the canine CD20 
receptor were performed using a subtractive whole-cell phage display followed by a high 
throughput screening.  
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To the best of our knowledge, we conducted for the first time a comprehensive target 
characterization of the canine CD20. This data is crucial to determine if tumor associated 
antigen specificity will guarantee high response rates and low toxicity (Scott et al., 2012). 
Data obtained under gene and protein expression studies on lymphoma and normal canine 
cells demonstrated an overexpression of this receptor on canine lymphoma cells, validating 
the canine CD20 as a potential target for veterinary immunotherapeutic strategies. 
Furthermore, when designing a passive immunotherapy similar to rituximab other clinical 
challenges must be considered, such as treatment resistance (Tsai, Hernandez-Ilizaliturri, 
Bangia, Olejniczak, & Czuczman, 2012). In fact, in human medicine only ~50% of patients 
with follicular lymphoma (FL) respond to initial treatment with single-agent rituximab 
(McLaughlin et al., 1998) and the majority of responders eventually become refractory to 
rituximab (Davis et al., 2000). Thus, there is a need to understand both the determinants 
responsible for de novo rituximab sensitivity as well as the mechanisms leading to acquired 
resistance.  
On one hand, a proven predictor of innate rituximab sensitivity is CD20 surface expression in 
rituximab–naïve B cells (Meerten, Rijn, Hol, Hagenbeek, & Ebeling, 2006), demonstrating 
the importance of CD20 expression analysis before implementing an anti-CD20 
immunotherapy. Indeed, lymphomas present heterogeneous levels of CD20 expression 
according to lymphoma types. For example, CD20 expression is higher in FL and lower in 
CLL (Chronic Lymphocytic Leukemia), which may explain the lower response rate to 
rituximab of CLL cell lines (Meerten et al., 2006).  Acquired rituximab resistance following 
therapy exposure has likewise been associated with reduced levels of CD20, that are 
correlated with CD20 mRNA levels, suggesting transcriptional-level control (Czuczman et al., 
2008; Small, McLeod, & Richards, 2013). Therefore, by characterizing gene and protein 
CD20 expression levels on a canine lymphoma naïve patient biobank, we hope to contribute 
for the research of predictive factor of response and possible mechanism of resistance that can 
overtime limit therapy responses, essential for the successful implementation of a canine anti-
CD20 antibody-based therapy.  
In addition, we have identified, for the first time, non-conservative amino acid differences on 
the canine CD20 protein sequence. Considering that these differences were observed in all 
canine lymphoma biobank, CLBL-1 cell line and healthy donors’ lymph nodes samples, we 
believed that this might be the most predominant sequence of the canine CD20 to present. 
Curiously, non-conservative amino acid differences recognized promoted a greater 
resemblance to human CD20 counterpart.  
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The human CD20 is a  nonglycosylated 30 to 35-kDa integral membrane non-glycosylated 
phosphoprotein (Perosa et al., 2009). The 16-kb gene encoding human CD20, consists of 8 
exons that have been mapped to chromosome 11 (11q12-q13) and belong to the MS4A 
(membrane spanning 4A) gene family (Henry et al., 2010). The physiological ligand and 
exact biological function remains unclear, although it is proposed that it may be involved in 
calcium signaling downstream of B cell antigen receptor activation (Boross & Leusen, 2012; 
Walshe et al., 2008). Initial analysis of CD20 deficient mice showed no immune-deficient 
phenotype (O’Keefe, Williams, Davies, & Neuberger, 1998), however, more recently CD20 
deficient mice and humans were found to exhibit decreased T-independent immune responses 
(Kuijpers et al., 2010). Although the crystal structure of CD20 has not been defined, the 
protein is predicted to be a tetraspan molecule with intracellular termini and two extracellular 
loops of 9 and 43 residues spanning from aa 72 to 80 and from aa 142 to 184, respectively 
(Polyak & Deans, 2002; Teeling et al., 2006). The larger extracellular loop, particularly 
nearby or between residues A170 and S173, contains the epitope recognized by rituximab and 
most other anti-CD20 mAbs (Polyak & Deans, 2002).  Moreover, the membrane orientation 
and topology of CD20 was confirmed using antisera generated against peptides near the 
amino and carboxyl termini and by proteolytic digestion of extracellular regions (Polyak, 
Tailor, & Deans, 1998). Rituximab binding was found to be imposed by both amino acid 
sequence and quaternary structure, justifying the heterogeneity in the fine specificity of CD20 
monoclonal antibodies (Polyak & Deans, 2002). While Rituximab binding is inhibited by 
reduction and alkylation of CD20, demonstrating that the epitope recognition is 
conformational (Ernst et al., 2005). Alanine-170 and Proline-172 were found to be critical 
determinants for extracellular CD20 epitopes, as their mutation in human CD20 abolished the 
binding of CD20 mAbs. Despite the proposed epitope(s) of rituximab in human CD20 to be 
relatively conserved in canine CD20, including residues 170 and 172, rituximab does not bind 
to canine CD20 (Impellizeri et al., 2006; Jubala et al., 2005). This might indicate that there are 
additional mechanisms involved in the lack of cross-reactivity, such as the structural 
formation of the large extracellular loop of canine CD20, which determine the binding avidity 
and function of anti-CD20 antibodies to canine CD20 in this region (Ito et al., 2015). On one 
hand, the lack of cross-reactivity of human anti-CD20 mAbs against other species, as mouse 
and dog, has made it challenging to improve mechanisms and pharmacology associated with 
targeting this antigen in naturally occurring animal models of B-cell lymphoma (Ito et al., 
2015). On the other hand, studying the differences in the mechanism of action between human 
and canine anti-CD20 mAbs may yield insights to improve the engineering of mAbs 
(Anderson & Modiano, 2015). 
101 
 
Finally, we used a novel strategy for the generation of recombinant anti-CD20 monoclonal 
antibodies against this novel coding sequence described herein, that bind canine CD20 and 
present cross-reactivity with human CD20  Indeed, the development and the implementation 
of anti-CD20 mAbs as a successful therapeutic strategy for canine lymphoma has revealed 
itself to be a challenging task, considering that the reported therapeutic efficacy of these 
mAbs demonstrated to be suboptimal and substantially inferior to results reported in human 
patients. Within this context, we described herein the development of recombinant mAbs 
against canine CD20 through the construction of a sdAb library from an immunized rabbit 
coupled with a phage display screening of the library on native-like receptor-expressed on 
cells. The rabbit antibody repertoire has been used for decades in diagnostic applications in 
the form of polyclonal antibodies. Now it also holds great promise as a source for generation 
of therapeutic mAbs (Rader et al., 2000). The unique ontogeny of rabbit B cells promotes 
vastly distinctive antibody repertories rich in in vivo pruned binders of high diversity, affinity 
and specificity (Weber et al., 2017). Furthermore, rabbits are evolutionarily distant from mice 
and rats, so epitopes that are not immunogenic in rodents can be recognized by rabbit mAbs, 
increasing the targetable epitopes and facilitating the generation of mAbs that cross react with 
other species (Weber et al., 2017) - a key aspect for clinical translational. Rabbit 
immunizations with HEK 293T cells transfected with canine CD20 vector resulted in a 
specific and selective high-titered antiserum against canine and human CD20. This strong and 
specific B-cell response allowed the construction of a high-quality antibody gene library. In 
addition, phage display screening of the library on native-like receptor-expressed on cells 
might have potentiated the diversity of antibodies againrformed by phage display, resulted in 
a specific pool of sdAbs-phages and high-throughput screening selected the best candidates.  
The availability of sdAbs against canine CD20, which binds both the large extracellular loop 
of canine and human CD20, offers a platform for translational immunotherapy investigation. 
In fact, the use of rabbit derived sdAbs allows to fully caninize the molecule and to promote 
ADCC responses after fusion to canine Fc constant regions as a traditional approach, or to 
develop more sophisticated recombinant molecules such as antibody-conjugates and 
bispecific antibodies. 
In conclusion, our work provides new data validating canine CD20 as a promising target for 
immunotherapeutic strategies for veterinary settings, while contributing to comparative 
oncology. Future studies will determine canine CD20 expression value as a predictive factor 
of anti-CD20 immunotherapy. Moreover, we report herein a panel of novel sdAbs that 
recognize both canine and human CD20, that may become a useful tool for exploring the 
development of novel therapeutic alternatives for comparative oncology. Future studies are 
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Sub-Chapter 3.2.  
 
A novel strategy to develop tumor-specific antibodies 




Cancer is among the leading causes of death worldwide and is still one of the most 
challenging diseases for the pharmaceutical industry to effectivally treat. With four ADCs 
already on the market and over 70 ADCs undergoing clinical studies, ADCs are becoming one 
of the most rapidly growing classes of human therapeutics for cancer. As a result, 
pharmaceuticals companies and academia are intensely focused in the development of novel 
highly specific and potent ADCs. However, the complexity of ADC components, conjugation 
methods, off-target toxicities still pose challenges for the strategic design of antibody-drug 
conjugates to achieve their fullest therapeutic potential. Tumor bearing murine models fail to 
predict ADC's clinical activity and tolerability, demonstrating an urgent and unmet need for 
better animal models for a fast, successful, and cost-effective drug development. Naturally 
occurring tumors in client-owned dogs closely recapitulate their human counterparts, making 
the dog an excellent animal model to explore novel therapeutic molecules and approaches. 
Using the potential of rabbit derived sdAbs technology, we aim to develop a highly selective 
and potent new anti-cancer ADC therapeutic molecule. Within this context, this work 
explores a novel strategy of tumor-specific antibodies selection against canine lymphoma, for 
the development of a drug delivery system. For that purpose, a highly diverse library of rabbit 
sdAbs against primary canine NHL cells has been successfully constructed, to ensure the 
presence of antibodies against any potentially relevant target. By coupling subtractive 
antibody selection rounds on whole-cells and a high-throughput screening, we have selected 
novel sdAbs targeting cNHL. In conclusion, the data presented herein validates a novel 
strategy for mAb selection and contribute for the development of a promising mAb-based 





3.2.2. Introduction  
 
In 2015 alone, cancer was responsible for 8.8 million deaths worldwide, second only to 
cardiovascular diseases as the leading cause of death (Fitzmaurice et al., 2017). Owing to 
population growth, ageing, and the adoption of lifestyle behaviors associated with increased 
cancer risk, this number is expected to rise by about 70% over the next 20 years (Fitzmaurice 
et al., 2017; Torre et al., 2016). These are impressive numbers that make cancer one of the 
major challenges of modern society. As such, the development of effective cancer treatments 
remains one of the biggest unmet clinical need of today’s biomedical research and 
pharmaceutical development. Conventional chemotherapy and radiotherapy appear to have a 
potent effect to kill tumor cells, but they also eliminate healthy cells. Therefore, massive 
attention went to the development of more effective curable options by targeted cancer 
therapy, of which monoclonal antibodies represents one of the most promising (Hu, Liu, & 
Muyldermans, 2017).  
Biological therapies play an increasing role in cancer treatment, however the number of naked 
antibodies showing clinical efficacy as single agent remains limited. One way to enhance 
therapeutic potential of antibodies is to conjugate them to small molecule drugs. This 
combination is expected to couple the benefits of highly potent drugs on one hand and 
selective binders of specific tumor antigens on the other hand. Nevertheless, the design of an 
ADC is complex, requiring thoughtful combination of antibody, linker, and drugs in the 
context of a target and a defined cancer indication (Sassoon & Blanc, 2013). Notably, of the 
2016 Nice Insight CDMO Outsourcing Survey respondents that have biologic drugs in their 
pipelines, 57% are developing ADCs and 56% are developing vaccines, compared to 51% 
with naked mAbs under evaluation (That’s Nice, 2016). Another source states that 182 
companies around the world have ADCs in their pipeline (Zhao, 2017). However, despite the 
increasing interest and investiment made in the last years, only four ADCs have been licensed 
to date (Drake & Rabuka, 2018). In fact, there are plenty examples of drugs that demonstrated 
potential in early pre-clinical stages but have failed to progress or have been terminated 
abruptly. Many of these failures were due to toxicity and incomplete characterization 
(Donaghy, 2016). So, it has become clear that conventional preclinical studies using tumor-
bearing murine models are not suitable in predicting ADC's clinical activity and tolerability. 
The main problem in this case is that the human tumor target is not commonly expressed in 
the animal host murine tissues. Consequently, the ADC molecule distributes exclusively to 
the tumor xenograft, resulting in high antitumor activity and complete tumor regression. 
However, when these ADC agents with strong preclinical activity enter clinical phases, 
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similar antitumor responses are unfortunatelly not observed, or non-target toxicity in normal 
tissue restricts dose-escalation to levels not particularly active. As such, for this promising 
platform to evolve successfully, lessons from past ADC history and critical re-evaluation of 
preclinical and clinical results must be undertaken (Tolcher, 2016). Naturally occurring 
tumors in client-owned dogs closely recapitulate their human counterparts, making the dog an 
excellent animal model to explore novel therapeutic molecules and approaches (Ito et al., 
2014; Marconato et al., 2013). By providing realistic opportunities to better evaluate 
therapeutic index, ADC mechanisms of action and ADCs off target toxicities, pet clinical 
trials can revolutionize this therapeutical field and contribute for the clinical success of these 
molecules. However, the development of a drug delivery system for comparative oncology 
settings requires a careful selection of targets, that present suitable caracteristics for ADC 
targeting in both species.  
Within this context, the present study aims to validate a novel strategy of tumor-specific 
antibodies selection against cNHL for the development a drug delivery system for the 
treatment of B-cell malignancies. We have been showing that rabbit derived sdAbs can be 
developed against several targets and that these minimal scaffolds show great potential for 
therapeutic applications (Corte-Real et al., 2005; da Silva et al., 2012; Goncalves & Aires-Da-
Silva, 2008). sdAbs are presently the smallest functional antibody fragment, only consisting 
of an VH or VL,  which  improves their tumor penetration and accessibility to targets not 
easily reached by IgGs (Aires da Silva et al., 2008; Corte-Real et al., 2005; Popkov et al., 
2004; Volker et al., 2016). In addition to the reduced size, complementary-determining 
regions of sdAbs can be easily engineered to develop specific and high-affinity binders. 
Moreover, sdAbs also present excellent properties such as high stability, solubility, low 
immunogenicity and low manufacturing cost (Aires da Silva et al., 2008; Volker et al., 2016). 
Owing to their advantageous properties, these scaffolds are being explored as targeting 
moieties for drug delivery systems. sdAbs can readily be linked genetically to Fc-domains, 
other antibodies fragments, peptide tags, or toxins and can be conjugated chemically at a 
specific site to drugs, radionuclides, photosensitizers, and nanoparticles. These properties 
make them particularly suited for specific and efficient targeting of tumors in vivo. 
With that in mind, a highly diverse library of rabbit sdAbs against primary canine NHL cells 
has been successfully constructed, to ensure the presence of antibodies against any potentially 
relevant target. By coupling a subtractive antibody selection rounds on whole-cells and a 
high-throughput screening, we selected sdAbs targeting NHL antigens in order to develop a 




Figure 28 – Schematic illustration of research methodology. 
Representation of a new strategy of NHL-specific antibodies selection. (A) An immune sdAb library 
was generated and selected by a subtractive whole-cell phage display. Rabbits were immunized with 
canine primary NHL cells and sdAb repertoire was constructed from B cell sources and cloned into a 
phage display vector system. Highly specific anti-NHL sdAbs were selected by phage display. (B) 
Schematic outline of the whole-cell phage display. Four rounds of biopanning were performed against 
the intact CLBL-1 cells, a canine B-cell lymphoma cell line. Binders were eluted using tripsin and 
internalizers were obtained after cell lysis using tween 20. After the third round of panning, eluted 
phages were subjected to a subtraction round against isolated lymph node cells from healthy donors 
(round 4).  
 
3.2.3. Material and methods 
 
3.2.3.1. Biological samples 
 
• Canine Multicentric Lymphoma Biobank   
 
Patients with canine multicentric lymphoma were followed at the oncology unit of the 
Veterinary Medicine Faculty – University of Lisbon (FMV/UL)’s -Teaching Hospital where 
clinical evaluations were conducted. On a preliminary phase, with diagnostic and staging 
purposes, a complete history, clinical signs and physical examination were assessed. 
Complete blood count and biochemistry profile were performed, as well as abdominal and 
thoracic imaging exams. Histopathological evaluation of lymph nodes after node biopsy was 
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performed. This histopathological evaluation included a morphologic examination, 
classification of lymphoma into grade subcategories and immunophenotyping to determine 
the immunophenotype present – B or T. Immunohistochemistry markers included CD3, 
CD20, CD79αcy and PAX-5. This clinical and laboratory examination allowed staging the 
dogs using the WHO system (Owen, 1980). Inclusion criteria comprised dogs recently 
diagnosed with multicentric lymphoma by clinical examination and cytological examination 
of lymph node fine-needle aspirate that have not yet begun therapy.  Exclusion criteria 
included dogs who have begun chemotherapy and who have received steroids or other 
immunotherapeutic agent within the last eight weeks of study enrollment or dogs who have 
become severely ill.  All sample collection was conducted with pet owner consent in 
accordance with the principles and procedures outlined in the NIH Guide for the Care and Use 
of Animals and approved by the Animal Care and Use Committee of FMV/UL. Blood 
samples allowed the extraction of plasma, serum, DNA (Dneasy Blood & Tissue, Qiagen, 
Hilden, Germany) and mrna (Rneasy Protect Animal Blood System, Qiagen) that were stored 
at -80ºc. Additionally, PBMC were isolated by Ficoll gradient method (Biocoll Separating 
Solution, biochrom®, Fisher Scientific, New Hampshire, USA), cell viability was assessed 
and for storage, aliquots of 5 x 106 cells were suspended in 90% FBS (Gibco, Life 
Technologies, Paisley, UK) and 10% DMSO (Sigma-Aldrich, Missouri, USA) and kept in 
liquid nitrogen. Sterile biopsy lymph nodes samples were divided, 1/3 was fined cut and 
stored at -80ºc in rnalater® (Invitrogen, Life Technologies, Paisley, UK), 1/3 was formalin-
fixed and 1/3 stored in liquid nitrogen after lymphoma cell isolation. Briefly, solid tissue was 
cut, passed through a cell strainer (Cell Strainer, BD Falcon®), suspended in RPMI-1640 
medium (Gibco) supplemented with 20% FBS and penicillin 100 U/ml plus streptomycin 0.1 
mg/ml (Gibco), and isolated through Ficoll gradient method (Biocoll Separating Solution, 
biochrom®). Cell viability were assessed and for storage, aliquots of 5 x 106 cells were 
suspended in 90% FBS and 10% DMSO and kept in liquid nitrogen. Clinical follow-up 
information about all cases was gathered from electronic medical records. 
 
• Control group  
 
Whole blood and sterile biopsy lymph nodes samples were harvested from a control group 






• Cell lines and culture 
 
The canine B-cell lymphoma cell line CLBL-1 was provided by Dr. Barbara Rütgen 
(University of Vienna, Austria). The human Burkitt's lymphoma Raji cell line, the human T 
lymphocyte cells and the human cell line HEK293T cell line (appropriated for ectopic 
expression of mammalian proteins) were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). CLBL-1, Raji and Jurkat cell lines were maintained in 
RPMI-1640 medium (Gibco) supplemented with 10% FCS (Gibco) and penicillin 
100 U/ml/streptomycin 0.1 mg/ml (Gibco). 293T cell line was cultured in DMEM medium 
supplemented with 10% FCS (Gibco) and penicillin 100 U/ml/streptomycin 0.1 mg/ml 
(Gibco). All cell lines cultures were maintained at 37 °C in a humidified atmosphere of 5% 
CO2 (T75-tissue culture flasks, Greiner Bio-One, Kremsmünster, Austria). 
 
3.2.3.2. Generation of monoclonal antibodies against canine NHL 
 
• Rabbit immunization  
 
Three female New Zealand White rabbit were immunized with 1 x 107 of cNHL primary cells 
from our biobank, as described in Figure 29. For that purpose, cells were thawed, washed in 
PBS and after confirmation of cell viability, resuspended in 1ml of PBS.  The injections were 





















(A) Under chapter 2, a canine lymphoma biobank was constructed with samples collected from lymph 
nodes collected from dogs submitted at the oncology unit of the FMV-UL’s teaching Hospital. Dogs 
diagnosed with multicentric lymphoma were followed and staged using the WHO system. In order to 
develop a rabbit antibody repertoire for the generation of antibodies against canine lymphoma 
antigens, we immunized rabbits using canine lymphoma primary cells from our biobank. (B) Three 
New Zeland White female rabbits were immunized with canine lymphoma primary cells from the 
biobank for 4 months, every 2-3 weeks. After thawing and celular viability evaluation, canine 
lymphoma cells (B1 e B2) were resuspended in PBS and injected subcutaneously. Before each 
imunization, blood was harvested from the marginal ear vein for serum isolation and serum titer 
evaluation by ELISA. (C) Description of cases included on our canine lymphoma biobank. Samples 
collected from B1 and B2 cases where used to immunize the rabbits. 
 
• Rabbits serum titer against canine cNHL 
 
To evaluate the serum specificity and titer, before each immunization blood was harvested 




immunoblotting using CLBL-1, Raji and Jurkat cell lines and cNHL primary cells from the 
biobank. Peroxidase-conjugated goat anti-rabbit antibody (Jackson Immune Research) as 
secondary antibody. HEK 293T cells with canine CD20 vector, CLBL-1 cells, Raji cells and 
HEK 293T cells were separated by SDS-PAGE and transferred to nitrocellulose membranes. 
After blocking, proteins were probed with rabbit serum (dilution 1:5000) and then with HRP 
conjugated anti-rabbit mAb as a secondary antibody. As a control, we used pre-bleed sera. 
 
• sdAbs immune library construction 
 
Five days after the final boost, spleen and bone marrow were harvested separately for total 
RNA using TRI Reagent (Molecular Research Center, Cincinnati, OH). First-strand cDNA 
was synthesized using Transcriptor High Fidelity (Roche) following the manufacturer’s 
instructions. PCR was performed to amplify the VH and VL from the rabbit’s cDNA using 
the set of primers presented at Table 9 in sub-chapter 3.1. PCR products encoding a library of 
antibody fragments (sdAbs) were then gel purified, restriction digested with SfiI and cloned 
into pCOMB3xSS. Subsequently, the ligated product was transformed into electro competent 
cells via electroporation and the library was tittered. To confirm library insert efficiency and 
diversity, PCR colony was performed using primer RSC-F and primer RSC-B. Phage library 
sequencing was performed by GATC Biotech AG (Ebersberg, Germany) using the pComb3x 
ATG primer. To translate to amino acid sequences and to evaluate homology, the Vector NTI 
Advance 10 software (Thermo Fisher Scientific) was used. 
 
3.2.3.3. Selection of recombinant monoclonal antibodies against canine cNHL 
 
• Selection of anti-cNHL sdAbs by Phage Display 
 
To display anti-cNHL sdAbs on M13 phage, sdAbs library was infected with M13 helper 
phage (1012 plaque-forming units/ml) during 1 h at 37 °C and grown overnight. Phages were 
precipitated, and titer was determined. The phage library displaying sdAbs was panned using 
a whole-cell phage display protocol on CLBL-1 cells as described by Barbas (Barbas et al., 
2004; Popkov et al., 2004). Four rounds of phage display panning were performed in order to 
select the best candidates. A subtractive strategy was used for the forth panning using primary 





•  In vitro binding and expression studies 
 
To express and select anti-cNHL–sdAbs, phagemid DNA encoding selected anti-CD20 sdAbs 
was cloned into pT7-PL (pT7-peptide leader) vector and transformed into E. coli strain BL21. 
Library insert efficiency was confirmed by colony PCR. The colonies obtained were picked 
and incubated overnight at 30°C on 100 µl of Super Broth (SB) medium containing Overnight 
Express™ Autoinduction System 1 (Novagen®) and 100 µg/ml of Ampicilin. Next day, 40 µl 
of BugBuster (Roche) containing anti-protease cocktail-EDTA free inhibitors (Roche) were 
added and incubated for 30 minutes at 4°C. Next, the plates were centrifuged at 1200 rpm and 
the supernatant was used to perform an ELISA assay. Three different parameters were 
analyzed: binding of antibodies to the antigen, expression level and unspecific binding. To 
evaluate the binding to the cNHL antigens, plates were coated with CLBL-1 extracts, washed 
with PBS and blocked with BSA 3% for 1 hour at 30°C. Then, plates were washed and the 
supernatant containing VLs or VHs was incubated for 1 hour at 30°C. Plates were washed and 
incubated with anti-HA-HRP antibody (Roche) was added. After 1 hour of incubation, plates 
were washed, ABTS (Roche) substrate solution was added and optical density at 405 nm was 
measured at different time points. To evaluate the level of expression, the same process was 
carried out, except for the antigen coating. To evaluate the unspecific binding, in turn of the 
antigen, BSA 3% was added. Rabbit serum and anti-CD20 antibody were used as positive 
controls. BL21 cell extracts and SB medium were used as negative controls. 
 
 3.2.4. Results 
 
3.2.4.1. Generation and screening of high-titered antisera against canine cNHL 
 
A highly specific sera against multiple cNHL antigens was successfully produced from three 
female New Zealand white rabbit immunized with cNHL primary cells from our canine 
lymphoma biobank, as described previously in the Material and Methods section. Antibody 
titers and specificity were monitored by ELISA, FACS and western blot analyses. As shown 
in Figure 30, cell ELISA assays showed that all three rabbits final bleed serum presented an 
highly specific and selective response against our biobank cNHL primary cells (Figure 30A 
and 30B) and CLBL-1 cell line (Figure 30C), a canine B-cell lymphoma. Furthermore, these 
data demonstrated that immunizations resulted in a strong immune response with a high 








(A) Rabbit #1 Rabbit #2 and Rabbit #3 sera analysis by cell ELISA for binding activity to B1 primary 
lymphoma cells from our biobank. All rabbits showed a selective and specific immunitary response 
against B1 cells. (B) Rabbit #1 Rabbit #2 and Rabbit #3 sera analysis by cell ELISA for binding 
activity to B2 primary lymphoma cells from our biobank. All rabbits showed a selective and specific 
immunitary response against B2 cells. (C) Rabbit #1, rabbit #2 and rabbit #3 serum analysis by cell 
ELISA for binding activity to CLBL-1, a canine B-cell lymphoma line. All rabbits showed a selective 





Figure 31 - FACS analysis of high-titered antisera against cNHL. 
 
                











(A) Cell viability and population analysis and background evaluation. (B) Rabbit #1, rabbit #2 and 
rabbit #3 serum analysis by FACS for binding activity to B1 primary lymphoma cells from our 
biobank. (C) Rabbit #1, rabbit #2 and rabbit #3 serum analysis by FACS for binding activity to B2 
primary lymphoma cells from our biobank. (D) Rabbit #1, rabbit #2 and rabbit #3 serum analysis by 
FACS for binding activity to CLBL-1, a canine B-lymphoma cell line. All rabbits showed a selective 
and specific immunitary response against CLBL-1, B1 and B2 cells.  
To evaluate the target protein profile recognized by the rabbit polyclonal sera, western blot 
analysis was carried out on cNHL cells and canine PBMCs from healthy donors. As shown in 
Figure 32, all three rabbits sera presented a distinct target profile. Moreover, receptors 
recognized on cNHL primary and CLBL-1 extracts were similar and differences between 
epitopes recognized in cNHL lymphocytes and PBMC from a healthy donor were 
demonstrated, revealing potential tumor-specific epitopes detected by rabbit polyclonal 
antibodies. In agreement, rabbit pre-bleed, harvested before starting immunizations, did not 
show any signal against immunized cells or control cells. These results enabled a better design 










Figure 32 - Evaluation of receptors recognized by rabbit policlonal sera.  
 
Protein profiles analysis by WB of lymphoma primary cells (B1 and B2 cells from our biobank), 
PBMC from healthy dogs (C1 and C2) and positive control cell line – CLBL-1. Representative blots 
are shown. Results allowed to identify potential receptors recognized by rabbits sera. 
 
Finally, to confirm that tumor-specific targets were recognized by polyclonal sera, ELISA 
analysis was performed using the CD20 receptor, a well-known immunotherapy target. These 
results showed that all three rabbits presented an immune response against CD20, however 
rabbit 1 presented the highest immune titer (Figure 33). Based on these results, rabbit 1 was 
selected as the most promising source of highly specific antibodies against cNHL and was 
therefore sacrificed for bone marrow and spleen extraction, further used for total RNA 
preparation and cDNA synthesis. 
 





(A) Evaluation of CD20 expression by Western blotting analysis on CLBL-1 cell line, lymphoma 
primary cells (B1 and B2 cells from our Biobank), PBMC from healthy dogs (PBMC1 and PBMC2) 
and negative control cell lines – Jurkat and 293T. This analysis confirmed CD20 expression in our 
cNHL biobank samples (B1 and B2), as well as on CLBL-1 cell line, whereas CD20 expression was not 
detected on PBMC from healthy donors and negative control cell lines such as Jurkat and 293T (B) 
Evaluation of rabbit polyclonal sera binding activity against human CD20 by ELISA. These results 
showed that all three rabbits presented an immune response against CD20, however rabbit 1 
presented the highest immune titer. 
 
3.2.4.2. Construction of a rabbit anti-cNHL sdAb phage display library 
 
A rabbit sdAb immune library was successfully constructed using RNA from spleen and bone 
marrow cells of a rabbit previously immunized with cNHL primary cells from our biobank.  
For that purpose, specific oligonucleotide primers covering all known variable rabbit antibody 
family sequences were used to amplify VH and VL gene segments. The recombinant 
phagemid pComb3X containing the sdAb genes was transformed into E. coli ER2538 cells 
(Table 10). Rabbit repertoire presented an efficiency ranging between 90% and 100%. 
Sequence analysis confirmed library diversity (Figure 34). 
 
Table 10 - Construction of a rabbit anti-cNHL sdAb phage display library. 
 
Library Bone Marrow Spleen 
VH 1 ,145x109 (100%) 4,51 x109 (100%) 
VL 2,1 x107 (90%) 3,6x106 (100%) 










Homology tree obtained from the homology analysis of selected the clones. 
Figure 34 – Sequence analysis of phage libraries. 
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3.2.4.3. Selection of recombinant sdAbs against cNHL 
 
Selection of specific sdAbs targeting cNHL epitopes were performed using a whole cell phage 
display as described in the material and methods section. This cell phage display screening 
protocol was based on the previously Carlos Barbas studies, in which it is reported a novel 
whole-cell selection protocol designed to select mAbs recognizing surface epitopes, that 
potentially internalize (Popkov et al., 2004). The last panning consisted of a subtractive 
screening on control cells, in order to remove sdAbs reacting with common antigens. Phage 
display conditions implemented herein are summarized in Table 11. Over the course of 
selection, stringency was improved by increasing the number of washes in order to collect the 
phage clones with greater target affinity or specificity. Different elution methods were 
performed to select for binders and internalized antibodies. As shown in Figure 35, the phage 
display rounds resulted in a lower number of phages in the output titers compared to the input 
titers (~1011-12 to ~103-4 pfu). Furthermore, the biopannings profile indicates that the phage 
display protocol successfully led to the enrichment for highly specific cNHL antibodies-
phages.  
 
Table 11 - Subtractive phage display conditions used in each panning. 
 1º Panning 2º Panning 3º Panning 4º Panning 
Conditions 
- 5 x 106 cells 
(CLBL-1) 
- 3 x wash 
- Trypsin 5 min 37ºC 
- TWEEN 20 10 min 
- 5 x 106 cells 
(CLBL-1) 
- 5 x wash 
- Trypsin 5 min 37ºC 
- TWEEN 20 10 min 
- 5 x 106 cells 
(CLBL-1) 
- 10 x wash 
- Trypsin 5 min 37ºC 
- TWEEN 20 10 min 
- Subtractive panning 
- 5x106 cells 
(CLBL-1; Lymph 
node) 
- 10 x wash 
- Trypsin 5 min 37ºC 
- TWEEN 20 10 min 
 
Figure 35 – Subtractive whole-cell phage display selection. 
 
Graphic representation of amplified and eluted phage titers of each round of phage display selections. 
sdAbs with binding (binders) or internalization (internalizers) properties for each VH and VL library 
are shown. The titers were determined by plaque forming units per milliliter measurement. 
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To further select the best candidates based on expression and binding features, the last 
panning was cloned into a pT7-PL vector. This vector possesses a peptide leader, which 
promotes the sdAbs expression to be directed to the periplasmic space, allowing to evaluate 
the expression level of sdAbs. Following, an high throughput screening was performed on a 
total of 744 clones of each VH and VL biopanning outputs, in which multiple ELISA assays 
were carried out to evaluate expression and binding to the protein extract from CLBL-1 cells. 
Clones that revealed the stronger signal regarding binding to protein cell extract and 
expression were selected. This allowed to identify 15,3 % and 9,7% of binders clones and 




Naturally occurring tumors in client-owned dogs are closely similar to their human 
counterparts, creating an excellent opportunity to incorporate pet dogs into the preclinical 
development path of cancer therapeutics. The use of pet dogs as animal models aims to 
surpass many of the bottlenecks associated with conventional models such as pharmacokinetic 
/ pharmacodynamics relationships, dose/regimen, expected clinical toxicities, and ultimately 
the potential for biologic activity, while also provides access to innovative cancer treatments 
to dogs (Garden, Volk, Mason, & Perry, 2018; Park et al., 2016). NHL remains one of the 
most common and deadly neoplasias in both dogs and humans. As a result, several initiatives 
have been focusing on the development of therapeutic strategies with mutually benefiting 
purposes, such as immunotherapies in the form of mAbs (Ito et al., 2014; Marconato et al., 
2013). As a result, a few mAbs directed against CD20 and CD52 were approved for the 
treatment of cNHL, however these naked mAbs have presented disappointing scientific and 
clinical results, demonstrating that the discovery of an effective antibody for the treatment 
cNHL may require a better understanding of antibody effector functions present in the canine 
immune system or the exploration of other ways of promoting a tumoral cytotoxic effect 
(Klingemann, 2018).  By using antibodies as targeting vehicules of potent payloads, ADCs 
may circumvent the lack of antitumor efficacy presented by naked antibodies when used on 
their own (Kim & Kim, 2015). Furthermore, the development of an ADC-based therapy for 
cNHL may also open perspectives for the use of the dog as a promising preclinical model to 
bridge the gap between conventional murine studies and clinical trials. Neverthertheless, the 
research of comparative immunotherapies has been limited by the scarcity of information 
regarding tumor epitopes common to both cNHL and hNHL (Park et al., 2016). This 
limitation is particularly relevant when developing ADCs, since target selection is the first 
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and most important determining factor for a successful ADC, directly affecting its efficacy, 
therapeutic window and toxicity profile. The ideal characteristics of a useful ADC antigen 
include up regulated expression in the tumor; internalization of antigen via endocytosis in the 
presence of ligand and its recycling back to the plasma membrane and homogeneous antigen 
expression in the tumor microenvironment with low antigen abundance in healthy tissues 
(Sau, Alsaab, Kashaw, Tatiparti, & Iyer, 2017).  Characteristics not easily found in most 
cancer targets. Moreover, target features that have not been investigated to date in 
comparative clinical oncology settings. 
Target-based screening has been the discovery platform of most therapeutic mAbs. 
Nonetheless, the decline in the number of validated targets and the intense competition around 
target space, demonstrated an urgent and unmet need for alternative strategies for the 
identification of new targets for the development of innovative mAb-based therapies and the 
maximization of their clinical efficacy (Gonzalez-Munoz, Minter, & Rust, 2016).  
Within this context, the present study aims to validate a novel strategy of tumor-specific 
antibodies selection against canine lymphoma for the development a drug delivery system for 
the treatment of B-cell malignancies. This approach relies on the use of intact cancer cells to 
display cancer-restricted antigens that can then be captured using multiple antibody-based 
technologies. Addressing the drug discovery process from this angle — the antibody / 
therapeutic activity side — provides an opportunity to discover new targets and target 
epitopes, use the antibody as a tool to validate the target, and rapidly evaluate the functional 
characteristics of the antibody itself as a possible therapeutic agent (Loo & Mather, 2008).  
For that purpose, a highly diverse library of rabbit sdAbs against primary canine NHL cells 
were successfully constructed, to ensure the presence of antibodies against any potentially 
relevant target. The rabbit antibody repertoire has been used for decades in diagnostic 
applications in the form of polyclonal antibodies. Now it also holds great promise as a source 
for generation of therapeutic mAbs (Rader et al., 2000). The unique ontogeny of rabbit B cells 
promotes vastly distinctive antibody repertories rich in in vivo pruned binders of high 
diversity, affinity and specificity (Weber et al., 2017). Furthermore, rabbits are evolutionarily 
distant from mice and rats, so epitopes that are not immunogenic in rodents can be recognized 
by rabbit mAbs, increasing the targetable epitopes and facilitating the generation of mAbs that 
cross react with other species (Weber et al., 2017) - a key aspect for clinical translational. 
Rabbit immunizations with isolated B-cell canine lymphoma primary cells from our biobank 
resulted in a specific and selective high-titered antiserum against canine epítopes. This strong 
and specific B-cell response allowed the construction of a high-quality antibody library. 
Following, a novel strategy of phage display screening on whole cells was used to select 
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sdAbs against membrane embedded target antigens in their natural environment and 
conformation to antibody-bearing phages, resulting in an enriched pool of sdAbs-phages 
(Stark, Venet, & Schmid, 2017). This technique was performed using two distinct steps of 
phage recovery in order to select both phages that bind to the cell membrane and internalize. 
Finally, an high throughput screening allowed to select the best sdAbs candidates targeting 
cNHL regarding binding activity and expression properties. The obtained data showed that 
these selected sdAbs have great promise. In fact, recently a final in vivo selection on a human 
and canine NHL murine model confirmed that these sdAbs populations were indeed highly 
selective and specific against NHL. With this novel approach the repertoire of targetable NHL 
tumor receptors may be expanded, while simultaneously confirming the availability of the 
epitope in vivo and generating new antibodies for targeting. In the future, we expect to use 
these promising sdAbs as moieties for the development of a novel ADC for NHL, by coupling 
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NHL is one of the most common causes of cancer-related death in the United States and 
Europe. Although the outcome of NHL patients has improved over the last years with current 
therapies, the rate of mortality is still high. A plethora of new drugs is entering clinical 
development for NHL treatment; however, the approval of new treatments remains low due in 
part to the paucity of clinically relevant models for validation. Canine lymphoma shares 
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remarkable similarities with its human counterpart, making the dog an excellent animal model 
to explore novel therapeutic molecules and approaches. 
Histone deacetylase inhibitors (HDACis) have emerged as a powerful new class of anti-
cancer drugs for human therapy. To investigate HDACi antitumor properties on canine diffuse 
large B-cell lymphoma, a panel of seven HDACi compounds (CI-994, panobinostat, SBHA, 
SAHA, scriptaid, trichostatin A and tubacin) was screened on CLBL-1 canine B-cell 
lymphoma cell line. Our results demonstrated that all HDACis tested exhibited dose-
dependent inhibitory effects on proliferation of CLBL-1 cells, while promoting increased H3 
histone acetylation. Amongst all HDACis studied, panobinostat proved to be the most 
promising compound and was selected for further in vitro and in vivo evaluation. Panobinostat 
cytotoxicity was linked to H3 histone and α-tubulin acetylation, and to apoptosis induction. 
Importantly, panobinostat efficiently inhibited CLBL-1 xenograft tumor growth, and strongly 
induced acetylation of H3 histone and apoptosis in vivo. In conclusion, these results provide 
new data validating HDACis and, especially, panobinostat as a novel anti-cancer therapy for 




It has become evident that the importance of small companion animals in the “One Medicine” 
concept goes beyond their role as reservoirs for infectious diseases and their contribution to 
human health through the human-companion animal bond. Pet dogs in particular are excellent 
models for the study of spontaneous degenerative, neoplastic, autoimmune and allergic 
disorders whose pathophysiology closely resemble their human counterparts (Sundberg & 
Schofield, 2009; Takashima & Day, 2014). Indeed, when compared with other animal 
models, the canine model presents unique advantages: diseases are naturally occurring in 
immune-competent hosts; the size of the animals allows testing therapeutic approaches similar 
to the ones used in humans; disease mapping and pharmacogenomics are simplified by the 
organization of dogs into isolated populations with reduced genetic variation (breeds); the 
relatively fast disease progression rate allows obtaining early conclusions from clinical trials; 
and the social status of dogs as companion animal allows them to benefit from high quality 
health care and the ethical exploration of translational approaches (Ito et al., 2014; Marconato 
et al., 2013; Rowell et al., 2011). Cancer is among the leading causes of death in both dogs 
and humans. Therefore, efforts towards bringing together veterinary and human medicine for 
the comparative research of cancer are being pursued (Fürdös, Fazekas, Singer, & Jensen-
Jarolim, 2015). These initiatives are also motivated by the increasing healthcare standards 
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demanded by pet owners, originating the need for novel cancer therapies in veterinary settings 
(Henry & Bryan, 2013; Porrello et al., 2006; Weiskopf et al., 2016). One of the most common 
neoplasias in both species is NHL, an heterogeneous group of cancers characterized by the 
proliferation of malignant lymphocytes (Fisher & Fisher, 2004; Seelig et al., 2016). Human 
NHL is the sixth most common cancer in the United States, and its incidence nearly doubled 
since the early 1970s (Fisher & Fisher, 2004; Siegel et al., 2015). Human NHL represents 
90% of all lymphomas and 85–90% of cases arise from B lymphocytes. This group of 
malignancies usually develops in the lymph nodes, but can occur in almost any tissue, ranging 
from the more indolent FL to the more aggressive DLBCL and Burkitt's lymphoma 
(Shankland et al., 2012). Even though current therapeutic options have resulted in improved 
response rates, the mortality rate is still high (Molina, 2008; Zappasodi et al., 2015). 
Moreover, the toxicity of conventional chemotherapy often limits its efficacy. Therefore, 
there has been an increasing interest in the design and development of novel target-specific 
molecules over the past years (Kong et al., 2015). Owing to shared molecular, incidence, 
genetic, histopathologic and clinical features, canine lymphoma has been proposed as a 
comparative animal model for the research of novel therapeutic agents and approaches for 
human NHL (Gardner et al., 2016; Pinho et al., 2012; Ranieri et al., 2013; Rowell et al., 
2011). Canine lymphoma displays several histological subtypes and patients can manifest a 
wide range of symptoms. However, most suffer from generalized lymphadenopathy 
(multicentric form) and are diagnosed with intermediate to high-grade lymphoma, more 
commonly of B-cell origin. Without treatment, the disease has high mortality (Marconato et 
al., 2013), requiring prompt chemotherapy to achieve temporary remission and prolonged 
survival. Yet cure is rarely achieved and the majority of dogs relapse with lethal, drug-
resistant lymphoma. Thus, there is an urgent need to develop new treatment strategies in 
veterinary medicine for refractory disease (Vail et al., 2007). 
Histone deacetylase inhibitors (HDACis) have emerged as an highly efficient new class of 
anti-cancer drugs (Chun, 2015). Histone deacetylases (HDACs) catalyze the deacetylation of 
histones (and other acetyl-lysine-containing proteins), leading to chromatin condensation and 
transcriptional repression (Bannister & Kouzarides, 2011). By inhibiting deacetylating 
enzymes activity, HDACis regulate aberrant deacetylation and modify gene expression in 
cancer cells, culminating in cytotoxicity (Mackmull et al., 2015; H. Miles Prince, 2010; W. S. 
Xu, Parmigiani, & Marks, 2007). Other putative mechanisms of action include cell cycle 
arrest, DNA repair inhibition, apoptosis induction and angiogenesis inhibition (Khan & La 
Thangue, 2012). Hematological malignancies seem to be particularly sensitive to HDACis 
(Ageberg, Rydström, Relander, & Drott, 2013). In fact, these agents have shown single-agent 
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activity against T-cell lymphomas, cutaneous T-cell lymphomas, mantle cell lymphomas, and 
Hodgkin disease (Zain, 2012). To date, four HDACis have been approved for cancer therapy 
by the FDA – vorinostat, romidepsin, belinostat and panobinostat (Stahl et al., 2016). 
Considering the high efficacy presented by HDACis in targeted human cancer therapy, we 
conducted the first investigation on their antitumor properties using a canine B-cell lymphoma 
model. For this purpose, a panel of seven HDACis was initially tested on the well 
characterized CLBL-1 canine B-cell lymphoma cell line (Rütgen et al., 2010, 2012) and 
panobinostat was identified as the most promising compound. Panobinostat was therefore 
deeply investigated and showed strong in vitro and in vivo antitumor properties.  
 
4.3. Material and methods 
 
4.3.1. Cell lines and reagents 
 
The canine CLBL-1 (Rütgen et al., 2010, 2012) and 17-71 (Steplewski, Jeglum, Rosales, & 
Weintraub, 1987) (kindly provided by Dr. Steven Suter, College of Veterinary Medicine, NC 
State, Raleigh, North Carolina, USA) B-cell lymphoma cell lines were cultured in RPMI-
1640 medium (Gibco, Life Technologies, Paisley, UK) supplemented with 10% heat 
inactivated fetal calf serum (FCS, Gibco) and penicillin 100 U/ml plus streptomycin 
0.1 mg/ml (Gibco). Cell cultures were maintained at 37 °C in a humidified atmosphere of 5% 
CO2 (T75-tissue culture flasks, Greiner Bio-One, Kremsmünster, Austria). The HDAC 
Inhibitor Set II, which includes CI-994, Panobinostat (LBH589), SAHA, SBHA, Scriptaid, 
Trichostatin A and Tubacin, was purchased from Sigma-Aldrich (St. Louis, MO, Cat # 
EPI009). HDACi stock solutions were prepared at 5 mg/ml, except for CI-994 (10 mg/ml) and 
SBHA (50 mg/ml) in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and stored at -20ºC. 
Panobinostat for the in vivo studies was purchased from Selleckchem (Houston, TX, Cat # 
S1030).  
 
4.3.2. Cytotoxic assay 
 
To determine the effect of HDACis on CLBL-1 and 17-71 cell proliferation, a cell viability 
assay was performed using the Cell Proliferation Reagent WST-1 (Roche, Basel, 
Switzerland). Briefly, cells were seeded at a density of 6 x 104 cells/well in 96-well plates in 
200 µl of culture medium plus 10% heat-inactivated FCS, and subjected to increasing 
concentrations (2.5 nM to 20 µM) of the HDAC Inhibitor Set II library or vehicle (DMSO at 
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0.2% final concentration). After 24 h of treatment, cell viability and proliferation were 
assessed using the WST-1 reagent, following the manufacturer’s instructions. Absorbance at 
450 nm was measured using a plate reader (BMG LABTECH GmbH, Germany). Two 
replicate wells were used to determinate each data point and three independent experiments 
were carried out in different days.  Best-fit IC50 values were calculated using GraphPad 
Prism software (version 5.00; San Diego, CA, USA), using the log (inhibitor) vs response 
(variable slope) function. 
 
4.3.3. Immunoblotting  
 
After HDACis treatment, cells were harvested, washed twice with PBS and lysed using RIPA 
lysis buffer (25mM TrisHCL pH 7.6, 150mM NaCl, 1% NP-40, 1% sodiumdeoxycholate, 
0.1% SDS) supplemented with protease inhibitor cocktail (Roche). Protein extract samples 
were quantified using the Bradford method (Bio-Rad Protein Assay Dye Reagent 
Concentrate, Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions. 
Total protein extract samples were separated by 15% SDS-PAGE and transferred to 
nitrocellulose membranes. After blocking, proteins were probed with the following primary 
antibodies: anti-acetylhistone H3 (Lys9, Lys14) antibody (polyclonal, rabbit, 1:2500 dilution, 
Thermo Fisher Scientific, Rockford,IL, USA), anti-histone H3 (polyclonal, rabbit, 1:1000 
dilution, Thermo Fisher Scientific), and then with Peroxidase-AffiniPure Anti-Rabbit IgG 
antibody (polyclonal, goat, 1:10000 dilution, Jackson ImmunoResearch,  PA, USA ) as a 
secondary antibody. Proteins were detected by chemiluminescence using Luminata Forte 
Western HRP (Merck Millipore, Darmstadt, Germany) and acquired using the ChemiDoc 
XRS+ imaging system (Bio-Rad).  
 
4.3.4. Evaluation of caspase-3/7 activity 
 
Caspase-3 and 7 activity levels were measured using the Caspase-Glo 3/7 Assay (Promega, 
Madison, WI, USA). For this purpose, CLBL-1 cells were seeded and treated with 1-20 nM 
panobinostat as mentioned above. After 24 h of treatment, 100 μL of each cell suspension 
were transferred into a white 96-well plate, and then mixed with 75 μL of Caspase-Glo 3/7 
reagent by orbital shaking for 30 s. Subsequently, the mixture was incubated at room 
temperature for 30 min, allowing complete cell lysis, stabilization of proluminescent substrate 
cleavage by caspases, and accumulation of luminescent signal. The resulting luminescence 
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was measured using the GloMax-Multi+ Detection System (Promega). Three independent 
experiments were carried out in different days.  
 
4.3.5. Evaluation of apoptotic cell death  
 
The percentage of apoptotic cells after panobinostat treatment was assessed by flow 
cytometry using the Guava Nexin Assay (Merck Millipore, Darmstadt, Germany), according 
to manufacturer’s instructions. This assay relies on Annexin V-PE and 7-AAD staining to 
distinguish between viable (Annexin V/7-AAD double negative), early-apoptotic (Annexin V 
positive/7-AAD negative), and late-apoptotic/dead cells (Annexin V/7-AAD double positive). 
Briefly, CLBL-1 cells were seeded and treated with 1- 20 nM panobinostat. After 24 h of 
treatment, cells were collected, centrifuged at 500 g for 5 min, and resuspended in PBS 
containing 2% FBS. Next, 50 μL of each cell suspension were stained with an equal volume 
of Guava Nexin reagent for 20 min, at room temperature, protected from light. Sample 
acquisition and analysis were performed in a Guava easyCyte 5HT flow cytometer using the 
Nexin software module (Merck Millipore). Three independent experiments were carried out 
in different days.  
 
4.3.6. Immunofluorescence microscopy 
 
CLBL-1 cells (6 x 104) were treated with increasing concentrations of panobinostat as 
described above. After 24 h treatment, cells were fixed in methanol/acetone (1:1) at -20ºC for 
20 min, washed in PBS, incubated with 0.1% Triton X-100 for 15 min, washed, blocked with 
BSA 1%/PBS TWEEN 0,2% for 30 min, washed and probed with anti-α-tubulin antibody 
(clone DM1A, 1:200 dilution, Sigma Aldrich) or anti-Acetyl-Tubulin antibody (clone 6-11B-
1, 1:200 dilution, Sigma Aldrich) in PBS for 1 h at room temperature. Then, cells were 
washed with PBS for 10 min and incubated with anti-mouse IgG alexa 594 secondary 
antibody (polyclonal, goat, 1:300 dilution, Invitrogen) in PBS for 1 h at room temperature. 
Nuclear staining was obtained by mounting with DAPI Vectashield (Vector Labs, CA, USA). 
Cells were visualized using an Olympus IX-50 inverted microscope (Olympus Portugal, 
Lisbon, Portugal) equipped with Ludl Bio-Point filter wheels, and a 12-bit PCO (Kelheim, 
Germany) Sensicam QE cool CCD (Ludl Electronic Products, New York, NY, USA). 
Integrated control of the filter wheel and image acquisition was achieved by Image-Pro Plus 
4.5 and Scope- Pro 3.1 (Media Cybernetics, Rockville, MD, USA). Settings for image 
acquisition (camera exposure time, filters and time interval) were determined by custom-made 
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macros. Images were collected with Olympus 10x or 100x plan objectives (Numerical 
Aperture = 0.95 and 1.4, respectively). 
 
4.3.7. Xenograft studies 
 
All animal-handling procedures were performed according to EU recommendations for good 
practices and animal welfare, and approved by the Animal Care and Ethical Committee of the 
Veterinary Medicine Faculty. Female 6–8-wk-old SOPF/SHO SCID mice (Charles River 
Laboratory) were maintained in microisolation cages under pathogen-free conditions. Mice 
were allowed to acclimatize for at least two weeks prior to the start of the experiment. 
Suspension of 1 x 106 CLBL-1 cells in PBS with matrigel® (Corning, NY, USA, Cat # 
354248) (1:1) were injected subcutaneously into the dorsal interscapular region to induce 
tumors. When tumors reached a minimum volume of 100 mm3, mice were randomly assigned 
to one of three groups: not treated (vehicle only, n=5), 10 mg/kg panobinostat (n=5) and 20 
mg/kg panobinostat (n=5). The tested doses (Catalano et al., 2012; Crisanti et al., 2009; Imai 
et al., 2016) and the vehicle selection (2% DMSO + 48% PEG300 + 2% Tween 80 + ddH2O) 
(Hennika et al., 2017) were based on previously published studies and following 
manufacturer’s recommendation. Treatment consisted of intraperitoneal injections 5 days per 
week, over two weeks. Tumor volume and body weight was measured three times per week. 
Tumor volume was calculated as (width)2 x length. Compound activity was determined by 
tumor growth inhibition (TGI). TGI was determined as the percent change in tumor volume of 
treated over control animals (%T/C). In the end of the study, tumor samples were finely cut, 
and either stored at -80ºC in RNAlater™ (Invitrogen, Life Technologies, Paisley, UK) or 
formalin-fixed. Main organs including the liver, kidney, lung, spleen and intestine were 
collected and formalin-fixed. For immunoblotting and caspases 3/7 detection, RNA later™ 
(Invitrogen) preserved tumor samples were thawed and processed using tissueLyser II 
(Qiagen, Hilden, Germany) for tissue disruption, and RIPA lysis buffer supplemented with 
fresh protease inhibitors (Roche) for total protein extraction. Samples were quantified using 
Bradford method (Bio-Rad Protein Assay Dye Reagent Concentrate) according to the 
manufacturer’s instructions, and then evaluation of H3 histone acetylation was carried out as 
described above. Additionally, tumor protein extracts (15 μg) were used for caspase activity 





4.3.8. Histology  
 
Tissues, including tumors, were fixed in 10% buffered formalin were embedded in paraffin, 
using a Leica tissue processor. Four µm sections were cut from paraffin blocks and stained 
with H&E. Sections were mounted onto superfrost ultra plus slides (Menzel-Glaser, 
Braunschweig, DE), for immunohistochemistry.  
 
4.3.9. TUNEL staining 
 
Apoptotic cells were quantitated in tumor tissue sections, excluding areas of necrosis, using 
the transferase mediated deoxyuridine triphosphate (dUTP)-digoxigenin nick-end labeling 
(TUNEL) assay (ApopTag® Red In Situ Apoptosis Detection kit; Merk Millipore, Darmstadt, 
Germany), following the manufacturer's instructions. Specimens were then counterstained 
with Hoechst 5 µg/ml, for 10 min, at room temperature. Finally, slides were rinsed and a glass 
coverslip was mounted using Fluoromount-GTM mounting media (Beckman Coulter Inc., 
Fullerton, CA). Specimens were examined by fluorescence microscopy using an 
AxioScope.A1 microscope (Carl Zeiss Microscopy GmbH, Jena, Germany). Images were 
acquired under 630x magnification, using an AxioCam HRm camera with the ZEN 2012 
software (Blue Edition, version 1.1.2.0). Only areas with dense tumor cell mass displaying 
similar cell density were considered. Quantitation of TUNEL-positive cells was performed 
using Image J software (http://rsbweb.nih.gov/ij/). Apoptosis frequency was expressed as the 
number of TUNEL-positive cells per field. 
 
4.3.10. Statistical Analysis 
 
All data are expressed as mean ± SEM from at least three independent experiments. For in 
vitro and in vivo assays, statistical significances were determined using two-tailed Student’s t-











4.4.1. HDACis suppress cell proliferation and present cytotoxic effects on canine 
lymphoma   
  
Aiming to evaluate the potential cytotoxic effects of HDACis on canine lymphoma we have 
tested a panel of seven compounds with HDACi activity - CI-994, panobinostat, SBHA, 
SAHA, scriptaid, trichostatin A and tubacin - in the well-characterized CLBL-1 cell line. 
CLBL-1 was selected for our study as it is the well-known canine cell line that faithfully 
represents DLBCL, reproducibly inducing tumors and preserving its phenotype in the 
xenotransplantation setting (Rütgen et al., 2010, 2012; Weiskopf et al., 2016). The effect of 
the tested compounds on cell viability was measured using the WST-1 reagent as described in 
material and methods section. As shown in Figure 36, all tested HDACi compounds exhibited 
dose-dependent inhibitory effects on the proliferation of CLBL-1 cells. On the contrary, no 
evidence of toxicity was detected for vehicle-treated cells. The data obtained clearly 
demonstrated that panobinostat (IC50 = 5.4 ± 0.5 nM), scriptaid (IC50 = 218 ± 8.4 nM) and 
trichostatin A (IC50 = 67 ± 7.5 nM) exhibited the higher antiproliferative and cytotoxic 
activity (Figure 36). The remaining HDACis (CI-994, SBHA, SAHA and tubacin) 
demonstrated a lower susceptibility to interfere with CLBL-1 proliferation and showed IC50 
values in the µM range (Figure 36).  
 





CLBL-1 cells (6 × 104) were subjected to the indicated concentrations of HDACis - CI-994, 
panobinostat, SBHA, SAHA, scriptaid, trichostatin A and tubacin (A-G). After 24 h treatment, cell 
viability and proliferation were evaluated with WST-1 reagent. Two replicate wells were used to 
determinate each data point and three independent experiments were carried out in different days. 
Best-fit IC50 values of each HDACis were calculated using the log (inhibitor) vs response (variable 
slope) function (H). 
 
4.4.2. HDACi cytotoxicity is associated with histone acetylation  
 
The primary molecular mechanism of HDACis action is to modify the acetylation status of 
core histone proteins, leading to chromatin remodeling with consequent alteration in gene 
expression and cell differentiation. Therefore, to elucidate the mechanism of action of 
HDACis in the CLBL-1 cell line, we evaluated the acetylation status of H3 histone protein by 
western blot analysis. As shown in Figure 37, immunoblot analysis demonstrated that CLBL-
1 cells presented an hyperacetylation status of the H3 histone protein following 24 h treatment 
with 20 µM of HDACis, when compared with control vehicle treated cells. Importantly, the 
H3 histone acetylation levels were consistent with cytotoxic effects of the different HDACis 
and the compounds that showed the higher potency (Figure 36) promoted the higher effect on 
acetylation status (Figure 37). Considering the strong anti-proliferative activity and high 
degree of histone acetylation induction, panobinostat demonstrated to be the most promising 
therapeutic molecule. To confirm the strong activity in canine B-cell lymphoma, a different 
cell line, namely 17-71, was also tested with panobinostat. Again, the data obtained (Figure 
38) demonstrated that panobinostat presents a similar activity profile and histone acetylation 
induction as shown in CLBL-1. Panobinostat presented therefore a consistent and potent anti-




Figure 37 - Cytotoxic effect of HDACis correlates with histone acetylation . 
 
CLBL-1 cells (6 × 104) were exposed to 20 µM of HDACi compounds. After 24 h treatment, cells 
were harvested for total protein extraction and acetylation of H3 histones were assessed by western 
blotting with anti-acetyl-histone H3 polyclonal antibody (Ac-H3). DMSO was used as vehicle control 
and loading was controlled with anti-histone H3 polyclonal antibody (H3). Representative blots are 
shown. 
 
Figure 38 - Panobinostat presents cytotoxicity on 17–71 canine lymphoma cells 
and is correlated with histone acetylation. 
 
(A) 17–71 cells (6 × 104) were subjected to the indicated concentrations of panobinostat. After 24 h 
treatment, cell viability and proliferation were evaluated with WST-1 reagent. Two replicate wells 
were used to determinate each data point and three independent experiments were carried out in 
different days. Best-fit IC50 values were calculated using the log (inhibitor) vs response (variable 
slope) function. (B) 17–71 cells (6 × 104) exposed to 20 µM were harvested for total protein extraction 
and acetylation of H3 histones were assessed by western blotting with anti-acetyl-histone H3 
polyclonal antibody (Ac-H3). DMSO was used as vehicle control and loading was controlled with 
anti-histone H3 polyclonal antibody (H3). Representative blots are shown. 
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4.4.4. Panobinostat cell death is associated with apoptosis induction 
 
To clarify the nature of CLBL-1 canine lymphoma cell death induced by panobinostat, we 
measured the levels of caspase-3 and -7 activities and Annexin V/7-AAD staining following 
24 h treatment. As shown in Figure 39A, panobinostat treatment induced high levels of 
caspase activity in a dose-dependent manner. The maximum level of caspase-3/7 activity was 
seen at 20 nM. Accordingly, a higher percentage of apoptotic cell death was also determined 
at 20 nM by flow cytometry analysis of Annexin V/7-AAD staining (Figure 39B and 39C). 
These results are in agreement with the cell viability and proliferation data upon panobinostat 
treatment, indicating that the cytotoxic activity of panobinostat in the CLBL-1 cell line is 
consistent with the induction of apoptosis. 
 
Figure 39 - Panobinostat induces apoptosis on canine lymphoma. 
 
CLBL-1 cells (6 × 104) were subjected to the indicated concentrations of panobinostat. DMSO was 
used as vehicle control. After 24 h treatment, cells were harvested for apoptosis studies. (A) Caspase-
3/7 activity was determined using the Caspase-Glo 3/7 assay. Results are expressed as mean ± SEM 
fold-change to vehicle control cells. (B) The percentage of apoptotic cells was determined according 
to Annexin V/7-AAD (Guava Nexin Assay) staining. Results are expressed as mean ± SEM. (C) 
Representative flow cytometry plots of cells stained for Annexin and 7-AAD are shown. *p < 0.05 
and ** p < 0.01 from vehicle control cells. 
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4.4.3. Panobinostat cytotoxicity is linked to α-tubulin acetylation 
 
The activity of HDACis extends beyond chromatin remodeling, and has been associated with 
the acetylation of non-histone proteins, such as the α-tubulin. The hyperacetylation of α-
tubulin results in the stabilization of microtubules and subsequent cytotoxicity (Bolden, Peart, 
& Johnstone, 2006; H. M. Prince & Prince, 2009). Therefore, to further characterize the 
mechanism of action of panobinostat, we have assessed the levels of acetylated tubulin (ac-
tubulin) in the CLBL-1 cells by immunofluorescence labeling. As shown in Figure 40, 
immunofluorescence studies revealed an α-tubulin immunolabeling throughout the cytoplasm 
of both vehicle and panobinostat treated cells, evidencing a normal microtubule network, 
radiating from the perinuclear microtubule-organizing center. On the contrary, acetylated α-
tubulin immunofluorescence studies demonstrated a clear labelling of cells after panobinostat 
treatment for 24 h, whereas vehicle treated cells exhibited a low basal α-tubulin acetylation 
(Figure 40).  Thus, panobinostat treated cells displayed robust acetylation of α-tubulin with 





Figure 40 - Panobinostat cytotoxicity is linked to α-tubulin acetylation. 
 
 
CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized 
by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) 
using the appropriate excitation and emission filters as described in the material and methods section. 
Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-




4.4.5. Panobinostat induces tumor regression in a canine lymphoma xenograft mouse 
model 
 
The antitumor effect of panobinostat on canine B-cell lymphoma was further tested in a in 
vivo murine xenograft model. CLBL-1 suspensions (1×106 cells) were injected 
subcutaneously into the dorsal interscapular region of SOPF/SHO SCID mice. When tumors 
reached ~100 mm3, mice were randomized into three groups: not treated (controls/vehicle 
only, n = 5), panobinostat at 10 mg/kg (n = 5) and panobinostat at 20 mg/kg (n = 5) as 
described in the material and methods section. After two weeks of treatment, panobinostat at 
10 mg/kg and 20 mg/kg doses inhibited tumor growth by 82.9% and 97.3%, respectively, 
when compared to vehicle control treated mice (p < 0.05) (Figure 41A and 41B). All 
xenografts were nodular; infiltration was macroscopically evident, and tumors were highly 
adherent to surrounding tissues. Microscopically (H&E staining) tumors showed infiltration 
of the dermis, hypodermis, muscular paniculus and muscle striated by large lymphoid cells of 
indistinct cytoplasm and nucleus containing several little evident nucleoli (Figure 41C). 
Moreover, pathologic evaluation described a high degree of necrosis and mitotic activity. 
These pathological features are characteristic of an high grade lymphoma (Rütgen et al., 
2012). No histological alterations were identified in main organs examined (data not shown). 
Nevertheless, it is important to mention that in the majority of treatment groups, the animals 
lost an average of 5-10% of their starting body weight, and that some mice from the 20 mg/kg 











Figure 41 - Panobinostat treatment strongly inhibits in vivo tumor growth in a 
canine NHL tumor xenograft murine model. 
 
SOPF/SHO SCID mice (6-8 weeks-old) were injected subcutaneously with 1 × 10
6 
CLBL-1 cells in a 
matrigel suspension. When tumors reached ~100 mm3, mice were randomized into three treatment 
groups: not treated (controls/vehicle only), panobinostat at 10 mg/kg and panobinostat at 20 mg/kg (n 
= 5 per group). Mice were treated with intraperitoneal injections for 2 weeks, 5 days per week. (A) 
Tumor volumes were measured prior to drug administration and after the initiation of therapeutic 
interventions, three times a week, using a caliper and calculated as (width)2 × length (±SEM). The 
tumor growth curve showed that both treatment groups had a statistically significant tumor growth 
inhibition compared to vehicle group. *p < 0.05 when compared to the vehicle control treatment. (B) 
Representative images of xenografted tumors were captured at the end of 2 weeks of therapy. Scale 
bar =5 mm. (C) - Representative images of the hematoxylin and eosin (H&E) stained xenograft tumor 
sections. Upper panel - magnification = 20x, scale bar = 200 µm. Bottom panel - magnification = 
400x, scale bar = 20 μm. 
 
4.4.6 Panobinostat in vivo effects on canine lymphoma xenograft tumors 
 
To evaluate the panobinosat effects in vivo, the acetylation status of the H3 histone protein 
was evaluated in the tumor xenograft samples by western blot analysis. As shown in Figure 
42A, the data obtained demonstrated an increase of H3 histone acetylation on treated tumor 
samples, compared with control/vehicle treated samples. These differences were strongly 
evident in 20 mg/kg treated tumor samples. To further characterize panobinostat mechanism 
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of action, apoptosis was evaluated according to caspase activity in tumor protein extracts and 
TUNEL analysis in histological sections. Consistent with the in vitro observations, caspase-
3/7 activity was significantly increased up to 4-fold in tumors from treated animals (Figure 
42B). Taking that into consideration, TUNEL analysis of in vivo tumors was performed after 
selection of fields without apparent necrosis by the pathologist. Tumor sections from mice 
receiving panobinostat treatment demonstrated an increase of TUNEL-positive cells as 
compared to vehicle treated tumors (p < 0.05). As shown in Figure 42C, panobinostat 
treatment at 20 mg/kg was associated with an increase up to 30% of TUNEL-positive cells. 
Altogether, these results demonstrate that panobinostat exhibits strong antitumor activity in a 
canine B-cell lymphoma xenograft murine model. 
 
Figure 42 - Panobinostat promotes strong in vivo anticancer activity. 
 
(A) H3 histone acetylation in total protein extracts from xenograft tumor samples were evaluated by 
western blot with anti-acetyl-histone H3 polyclonal antibody. Loading was controlled with H3 histone 
using anti-histone H3 polyclonal antibody. Representative blots are shown. (B) Caspase-3/7 activity 
was evaluated in tumor protein extracts using the Caspase-Glo 3/7 assay. Results are expressed as 
mean ± SEM fold-change to vehicle treated tumors. (C) Apoptosis was evaluated in tumor sections 
and quantified according to TUNEL-positive cells per high power-field (HPF) (left panel). 
Representative microphotographs of TUNEL analysis (630× magnification), with apoptotic cells (red) 
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and Hoechst stained-nuclei (blue) are shown (right panel). Scale bar, 15 m. Results are expressed as 




Lymphoma is responsible for significant morbidity and mortality in pet dogs. Its remarkable 
similarities to human NHL prove clinically realistic opportunities to explore therapeutic 
protocols that may translate to human clinical trials (Ito et al., 2014; Marconato et al., 2013). 
To the best of our knowledge, this is the first study exploring HDACis antitumor therapeutic 
properties for treatment of canine B-cell lymphoma. HDACis have demonstrated anticancer 
efficacy in both in vitro and in vivo studies across a range of malignancies, and most 
impressively in hematological cancers. Consequently, they have undergone a rapid phase of 
clinical development either as a monotherapy or in combination with other anticancer agents 
(Chun, 2015; Dickinson, Johnstone, & Prince, 2010). Indeed, four HDACis have been 
approved by the FDA for cutaneous T-cell lymphoma and multiple myeloma treatment - 
vorinostat, romidepsin, belinostat and panobinostat (Stahl et al., 2016). Regarding the 
veterinary clinical setting, it has been previously reported by Kisseberth et al. the in vitro 
effect of two HDACis, OSU-HDAC42 and SAHA, on a panel of canine cancer cell lines, 
including canine T-cell lymphoma (Kisseberth, Murahari, London, Kulp, & Chen, 2008). In 
this study, the authors showed that the HDACis induced cytotoxicity, histone acetylation and 
apoptosis when cells were treated under µM doses (Kisseberth et al., 2008). In another study, 
Wittenburg et al. also described that the HDACi valproic acid sensitizes human and canine 
osteosarcoma cells to the anti-tumor effects of the topoisomerase-II inhibitor doxorubicin. 
The pharmacokinetics and pharmacodynamics features of this combination treatment was 
further assessed during a Phase I clinical trial in tumor-bearing dogs, demonstrating the safety 
and clinical utility of this class of drugs for veterinary oncological applications (Wittenburg, 
Gustafson, & Thamm, 2010).  
Within this context, in the present study we aimed to investigate the HDACis antitumor 
properties on canine diffuse large B-cell lymphoma. For this purpose, a panel of seven 
HDACis was initially tested on the well-characterized CLBL-1 canine B-cell lymphoma cell 
line. The antitumor properties of the tested compounds observed here is in line with previous 
studies from other authors, both in hematological [37–40] and solid malignancies in other 
species (Bluethner et al., 2007; Catalano et al., 2012; Edwards, Li, Atadja, Bhalla, & Haura, 
2007; Fortunati et al., 2010; Haefner et al., 2008). Indeed, all seven HDACis exhibited dose-
dependent inhibitory effects on the proliferation of CLBL-1 cells. Nevertheless, and 
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importantly, with our study we were able to identify three HDACis (panobinostat, trichostatin 
A and scriptaid), which presented a high cytotoxic activity under the nM range. Moreover, our 
data demonstrated that the entire panel of HDACis evaluated was able to induce histone H3 
acetylation on the CLBL-1 canine lymphoma cell line. Importantly, the levels of acetylated 
histone status were correlated with the IC50 values of the HDACis tested. 
Based on the potent cytotoxic activity and induced histone acetylation, panobinostat revealed 
to be the most promising HDACi against canine B-cell lymphoma (CLBL-1 and 17-71) and 
was selected for further in vitro and in vivo studies. Panobinostat is a pan-HDACi, with low 
nanomolar concentration and high inhibitory activity against all Class I, II and IV HDACs 
both in vitro and in vivo, which has undergone extensive preclinical and clinical scrutiny 
(Prince & Prince, 2009). Panobinostat appears to be at least 10-fold more effective in vitro 
against Class I, II and IV HDACs when compared with vorinostat, the first FDA approved 
HDACi (Cea et al., 2013). A marked anti-tumor activity of panobinostat has been 
demonstrated across a broad range of cancer cell lines from hematologic malignancies, 
including cutaneous T cell lymphoma (CTCL), acute myeloid leukemia (AML), chronic 
myeloid leukemia (CML), multiple myeloma, HL, as well as in solid tumors such as breast, 
colon, prostate and pancreatic cancer (Cea et al., 2013; Prince & Prince, 2009). Importantly, 
despite its strong antitumor activity at nanomolar concentrations, panobinostat only resulted 
in apoptosis of normal human cell lines at far greater concentrations, indicating a selective 
toxicity for cancer cells (Anne, Sammartino, Barginear, & Budman, 2013). In addition, other 
potential uses for panobinostat include maintenance therapy, its use as a potential radio-
sensitizing agent and, combinatory therapy with other immunomodulatory drugs (Prince & 
Prince, 2009).  
Noteworthy, the results presented herein have shown that the high efficacy of panobinostat 
against canine diffuse large B-cell lymphoma at sub-nanomolar concentrations was 
comparable to what has been described in several human lymphoid malignancies, where IC50 
doses range from 5.6 to 31.5 nM (mean 11.2 nM) (Smith et al., 2009).  
Several studies also report the involvement of non-histone protein acetylation in a diverse 
array of cellular processes including protein traffic, apoptosis and cell motility (Catalano et 
al., 2012; Singh et al., 2010). Therefore, to further investigate HDACi acetylation of non-
histone proteins, we evaluated the effects of panobinostat on tubulin acetylation. Our data 
demonstrated that low doses of panobinostat (5 nM) on CLBL-1 cells led to tubulin 
acetylation, a marker of microtubule stabilization, and bundle formation.  
Apoptosis activation through either the extrinsic or the intrinsic pathway has been shown to 
be one of the main mechanisms by which HDACis induce tumor cell death (Carew, Giles, & 
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Nawrocki, 2008). In this context, activation of caspases is a known feature of HDACi-induced 
apoptosis (Carew et al., 2008; Fulda & Debatin, 2006). In agreement with this, apoptotic cell 
death of CLBL-1 canine lymphoma cells after panobinostat treatment was strongly evidenced 
at 20 nM by the activation of caspase-3 and -7, and by the subsequent increase in the 
percentage of apoptotic cells. These results confirmed that the CLBL-1 canine lymphoma cell 
line used in this study was a good model to investigate the effects of HDACis and 
panobinostat. Additionally, it is worth mentioning that the effects of panobinostat observed in 
this work are attained at concentrations achievable in patient plasma, and are thus highly 
relevant to the clinical set (Catalano et al., 2012). Indeed, in a Phase I clinical study on 
intravenous panobinostat, Cmax reached up to 200 nM (Giles et al., 2006) and preliminary 
results (Beck et al., 2004) from an ongoing Phase I pharmacokinetic study on oral 
panobinostat, conducted in patients with solid tumors and hematologic malignancies, a steady 
state Cmax ranged from 15 to 35 nM.  
Finally, in order to evaluate the pre-clinical efficacy of panobinostat, we performed in vivo 
studies using a SCID xenograft model implanted with CLBL-1 canine lymphoma cells. 
Animal data confirmed the antitumor properties of panobinostat, showing that the drug 
significantly induces apoptosis, while impairing tumor growth. The maximum TGI effect was 
strongly evident at both 10 mg/kg and 20 mg/kg (TGI of 82.9% and 97.3%, respectively). 
Furthermore, enhanced H3 histone acetylation levels on tumor samples confirmed that in vivo 
tumor growth inhibition was correlated with panobinostat mechanism of action as observed in 
the in vitro studies. It is also important to mention that panobinostat treated groups, namely 
animals from the 20 mg/Kg treated group, presented mild toxicity signs, similarly to those 
reported in previously published studies (Catalano et al., 2012). As stated 
by Subramanian and collaborators, HDACis are mostly well tolerated, however, due its potent 
and wide spectrum HDAC inhibition, panobinostat is associated with significant dose-limiting 
toxicities (Subramanian, Bates, Wright, Espinoza-Delgado, & Piekarz, 2010). No previous 
clinical studies have been performed in canine patients using panobinostat and other HDACi 
with similar toxicity profile, such as the FDA-approved vorinostat and romidepsin (Andreu-
Vieyra & Berenson, 2014). For this reason, following preclinical validation of panobinostat, it 
will be important in the future to carry toxicity studies in dogs using single-agent and CHOP 
(cyclophosphamide, doxorubicin, vincristine, and prednisone) combination protocols.  
In conclusion, the anti-cancer activity of panobinostat demonstrated herein validates HDACis 
as a novel cancer therapy for canine B-cell lymphoma. Translational and clinical studies will 
determine the clinical utility and safety of panobinostat as a single/adjuvant agent for the 
treatment of canine lymphoma. In addition, this work opens up perspectives in comparative 
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oncology as it validates the naturally occurring canine B-cell lymphoma model for 
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Canine DLBCL is one of the most common cancers in dogs which shares remarkable 
similarities with its human counterpart, making the dog an excellent model for the 
investigation of novel therapeutic agents. However, the integration of canine lymphoma in 
comparative studies has been limited due in part by the lack of suitable xenograft mouse 
models for preclinical studies. To overcome these limitations, we established and 
characterized a localized subcutaneous bioluminescent canine DLBCL xenograft mouse 
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model. The canine CLBL-1 cell line expressing the luciferase and green fluorescent protein 
reporters was generated and used to establish the xenograft tumor model. A pilot study was 
first conducted with three different cell densities (0.1×106, 0.5×106 and 1×106 cells) in SCID 
mice. All mice presented homogeneous tumor induction within eight days after subcutaneous 
injection, with a 100% engraftment efficiency and no significant differences were observed 
among groups. The tumors were highly aggressive and localized at the site of inoculation and 
reproduced histological features and immunophenotype consistent with canine DLBCL. 
Importantly, xenograft tumors were detected and quantified by bioluminescent imaging. To 
assess response to therapy, a therapeutic study with a histone deacetylase inhibitor, 
panobinostat, was performed. The results demonstrated that panobinostat (20 mg/kg) 
efficiently inhibited tumor growth and that bioluminescent imaging allowed the 
monitorization and quantification of tumor response to therapy. In summary, this study 
provides a bioluminescence canine DLBCL model that offers high engraftment efficiency, 
preservation of tumor features, and noninvasive monitoring of tumor progression, validating 




NHL is a leading cause of cancer-related death in the United States and Europe, and its 
incidence continues to increase (Teras et al., 2016; Tilly et al., 2015). NHL encompasses a 
heterogeneous group of malignancies that usually originates in the lymph nodes, but can 
occur in almost any tissue, resulting from the neoplastic transformation of B and T 
lymphocytes (Shankland et al., 2012). DLBCL is the most common subtype of NHL, 
comprising approximately 30-58% of all NHL cases (Tilly et al., 2015). DLBCL is an 
aggressive form of lymphoma that is initially chemoresponsive, showing favorable responses 
to frontline R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisolone) immunochemotherapy. However, 10-15% of DLBCL patients are primarily 
refractory to this treatment and approximately 20-25% relapse after the initial response, with 
poor survival rates after current salvage therapy regimens (Sehn & Gascoyne, 2015). As such, 
new therapeutic agents and approaches are urgently needed. A multitude of new drugs are 
entering clinical development for NHL treatment; nevertheless the approval of new therapies 
remains low due in part to the scarcity of clinically relevant models for validation (Younes, 
2011). Canine DLBCL, one of the most common neoplasias in dogs, shares genetic, 
biological, molecular and clinical similarities with its human counterpart, making the dog an 
excellent animal model to explore novel therapeutic molecules and approaches for human 
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DLBCL (Curran et al., 2017; Ferraresso et al., 2017; Mudaliar et al., 2013; Richards et al., 
2011; Richards & Suter, 2015). Moreover, dogs diagnosed with lymphoma are frequently 
treated with anthracycline based chemotherapy regimens, similarly to human DLBCL 
patients, providing realistic opportunities to explore therapeutic protocols that may translate to 
human clinical trials (Richards et al., 2011). These initiatives are also encouraged by the 
increasing healthcare standards demanded by pet owners, creating the need for novel cancer 
therapies designed for veterinary applications (Henry & Bryan, 2013; Porrello et al., 2006; 
Weiskopf et al., 2016). Still, the integration of canine lymphoma as an animal model for 
clinical validation of therapeutics has been limited partially by the lack of suitable cNHL 
mouse models for preclinical research (Richards & Suter, 2015). In fact, even though 
comparative oncology studies provide unique information not easily provided by conventional 
preclinical models, the use of the tumor-bearing dog model for innovative drug development 
requires previous controlled toxicokinetic studies in laboratory animals (LeBlanc, Mazcko, & 
Khanna, 2016). 
Mouse models have been critical tools for studying the biology and genetics of cancer as well 
as for predicting efficacy and for evaluating toxicity of anti-cancer therapeutics (Morton & 
Houghton, 2007; Yee, Ignatenko, Finnberg, Lee, & Stairs, 2015). Indeed, the discovery that 
tumor tissue could be xenografted into T-cell deficient nude athymic (nu/nu) mice (Pelleitier 
& Montplaisir, 1975), and later into B-cell-deficient and T-cell-deficient severe combined 
immunodeficient (scid/scid) mice (Paine-Murrieta et al., 1997), started a new era for 
experimental studies in oncology, allowing the routine and efficient transplantation and 
propagation of human tumor tissues in mice. In fact, many human xenograft tumor models 
have been established, especially for human lymphoma, resulting in the identification of 
therapeutic molecules that continue to lead clinical cancer management as chemotherapy 
treatments (Kohnken et al., 2017).  
Despite the increasing investment in canine lymphoma research, there is a paucity of 
validated, well characterized and widely disseminated canine lymphoma preclinical models. 
Possibly due to the low number of available well-characterized canine lymphoid cell lines, the 
majority of in vivo canine lymphoma models described represent T-cell lymphoid 
malignancies (Kisseberth et al., 2007; Nadella et al., 2008; Umeki et al., 2013). Indeed, 
CLBL-1 cell line is the only canine cell line that faithfully represents DLBCL, reproducibly 
inducing tumors and preserving its phenotype in the xenotransplantation setting (Rütgen et al., 
2010, 2012; Weiskopf et al., 2016). Within this context, CLBL-1 xenograft mouse models are 
the most reliable preclinical tool of canine B-cell lymphoma. Although previous studies [11, 
24] paved the way for the development of canine B-cell lymphoma mouse models many 
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questions remained to be answered regarding tumor engraftment efficiency, reproducibility 
and the potential to be used for bioluminescent (BLI) monitoring. Aiming to overcome such 
limitations, we established and characterized a new localized subcutaneous bioluminescent 
canine CLBL-1 DLBCL xenograft mouse model that easily allows monitoring tumor 
progression and treatment response in preclinical studies. 
 
5.3. Material and methods 
 
5.3.1. Cell culture and reagents  
 
The canine CLBL-1 B-cell lymphoma cell line previously established by Dr  Barbara Rütgen, 
(Department of Pathobiology, University of Veterinary Medicine, Vienna, Austria) (Rütgen et 
al., 2010, 2012) was cultured in RPMI-1640 medium (Gibco, Life Technologies, Paisley, UK) 
supplemented with 10% heat inactivated FCS (Gibco) and penicillin 100 U/ml plus 
streptomycin 0.1 mg/ml (Gibco). Cell cultures were maintained at 37°C in a humidified 
atmosphere of 5% CO2 (T75-tissue culture flasks, Greiner Bio-One, Kremsmünster, Austria).   
 
5.3.2. Construction of a CLBL-1GFP+luciferase+ stable cell line 
 
For in vivo live imaging, a CLBL-1GFP+luciferase+ stable cell line was generated using a lentiviral 
system encoding firefly luciferase and green fluorescent protein (GFP) reporters. CLBL-1 
cells were transduced with luciferase-2A-GFP lentiviral particles (Amsbio Cat#LVP020), 
according to the manufacturer’s protocol and as previously described (da Silva et al., 2012). 
Briefly, 5×106 CLBL-1 cells were resuspended in 100 µl of lentiviral particles (1x107 IFU/ml) 
and subject to spinoculation method (O’Doherty, Swiggard, & Malim, 2000). After 6h, 
medium was changed for fresh complete RPMI and after 24h an equal amount of fresh 
medium was added. At 72h, transduction efficiency was assessed by FACS and GFP positive 
cells were sorted, using FACSAria IIu sorter (BD Biosciences), and maintained in the same 
culture medium supplemented with gentamycin 50 μg/ml (Gibco) for 7 days to avoid 
contamination. After 4 weeks in culture, CLBL-1GFP+luciferase+ cells were subjected to a second 
sort to ensure a stable GFP expressing cell line and cultured as previously described above.  
Two weeks after the second cell sort and two months following the cell line maintenance, 
GFP fluorescence was confirmed by FACS analysis. In addition, luciferase activity was 
confirmed using a luciferase assay kit (Promega, Wisconsin, USA) according to the 
manufacturer´s protocol. As a control, non-transduced CLBL-1 cells were analyzed in 
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parallel. To confirm that no alteration of cellular physiology occurred during the construction 
of CLBL-1GFP+luciferase+ cell line, we compared growth patterns of both parental and transduced 
cell lines using a cell doubling time assay as previously described by Rütgen et al, 2010 
(Rütgen et al., 2010). Finally, CLBL-1GFP+luciferase+ cell line was authenticated by short tandem 
repeat testing and compared to the parental CLBL-1 cell line (Eurofins 
Genomics, Ebersberg, Germany).  
 
5.3.3. Mouse and breeding conditions 
 
All animal-handling procedures were performed according to EU recommendations for good 
practices and animal welfare, and approved by the Animal Care and Ethical Committee of the 
Veterinary Medicine Faculty. Female 6–8-wk-old SOPF/SHO SCID mice (Charles River 
Laboratory) were maintained in microisolation individually ventilated cages under pathogen-
free conditions (Tecniplast, Buguggiate, Italy, Boxunsfeu model, with H14 Hepa Filter e 
Prefilter sheet for Smart Flow). Mice were allowed to acclimatize for at least two weeks prior 
to the experiment start. Mice were kept on a 12h light: 12h dark cycle. Room temperature was 
maintained at 24–26°C. Food pellets and water were sterilized and provided ad libitum. 
 
5.3.4. Establishment of a localized subcutaneously bioluminescent canine DLBCL 
xenograft model  
 
To establish the bioluminescent xenograft model, a pilot tumor induction study was first 
conducted with three different cell densities. For that, nine SCID mice were randomly 
assigned to three different groups, according to the cell density used for inoculation: group I - 
1×106 cells (n=3), group II - 0.5×106 cells (n=3) and group III - 0.1×106 cells (n=3). 
Suspensions of CLBL-1GFP+Luciferase+ cells in PBS with matrigel® (Corning, NY, USA, Cat # 
354248) (1:1) were injected subcutaneously into the dorsal interscapular region to induce 
tumors. Tumor volume and body weight were measured three times per week. Tumor volume 
was calculated as (width)2 × length from electronic caliper measurements. Tumor endpoints 
criteria included tumor volume diameter superior to 1.5 cm and/or signs of marked changes in 
locomotion and posture, difficulties in accessing or ingesting food and drink, weight loss 
≥15%, signs of pain (grimace scale ≥1). The tumor load in the mice was also analyzed by 
weekly BLI with IVIS system (Xenogen Corp., Alameda, CA) as described below. After two 
weeks of tumor development, animals reached a humane endpoint and were sacrificed, 
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necropsy was performed by a veterinary pathologist. Tumor and main organs including the 
liver, kidney, lung, spleen, and intestine were harvested and formalin-fixed. 
 
5.3.5. In Vivo Bioluminescence Imaging 
 
In vivo BLI was conducted on a cryogenically cooled IVIS system (Xenogen Corp., Alameda, 
CA) using LivingImage acquisition. Prior to BLI imaging, mice received a 150 mg/kg 
intraperitoneal injection with D-Luciferin (Xenolight, potassium salt). D-Luciferin was 
purchased from PerkinElmer´s and was dissolved to 15 mg/ml in PBS, filter-sterilized. Fifteen 
minutes after substrate injection, animals were anesthetized by intraperitoneal injection with a 
mixture of medetomidine (1mg/Kg) and ketamine (75 mg/Kg). A photographic image of the 
animal was taken in the chamber under dim illumination, followed by acquisition and overlay 
of the pseudocolor image representing the spatial distribution of photon counts produced by 
active luciferase within the animal. An integration time of 1 min with a binning of 100 pixels 
was used for luminescent image acquisition. Acquired images were analyzed using Living 
Image Software version 4.5.5 (Xenogen Corp.). Signal intensity was quantified as the sum of 
all detected photon counts within the region of interest after subtraction of background 
luminescence measured at the dorsal trunk. 
 
5.3.6. Histopathological Analysis 
 
Tissues, including tumors, were fixed in 10% buffered formalin and embedded in paraffin 
using a Leica tissue processor. Three µm sections were cut from paraffin blocks and stained 
with hematoxylin & eosin (H&E). Sections were mounted onto superfrost ultra plus slides 
(Menzel-Glaser, Braunschweig, DE) for immunohistochemistry. 
 
5.3.7. Imunohistochemistry analysis 
 
A representative area of each tumor was selected and tissue sections of 3μm thickness were 
mounted on glass slides (Superfrost glass slides, Thermo Scientific, Braunschweig, 
Germany), deparaffinized with xylene and hydrated in a graded ethanol series to distilled 
water. All protocol steps were carried out using the Novolink Polymer Detection System 
(Novocastra, Leica Biosystems, Newcastle, UK), according to the manufacturer’s 
instructions. The antigen retrieval step was performed by microwave treatment (5 min at 900 
watts plus 15 min at 650 watts) in Tris–EDTA buffer (pH 9.0). The system’s Peroxidase 
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Block Solution and Protein Block Solution were used sequentially to block endogenous 
peroxidase and to prevent unspecific labelling, respectively. Tissue sections were incubated 
30 min at room temperature with two antibodies: polyclonal rabbit anti-human CD20 
(Thermo Fisher Scientific), diluted 1:200, and rabbit polyclonal anti-human CD3 (Dako, 
Glostrup, Denmark), diluted 1:400. For all antibodies, labelling was developed by incubating 
the slides with the system´s chromogen, diaminobenzidine (DAB), and hydrogen peroxide as 
substrate. Nuclear background staining was performed with Gill’s hematoxylin (30 seconds). 
Labelling without the primary antibody was used as negative control. Dog lymph node 
sections were used as positive control.  
 
5.3.8. Assessment of therapeutic response in the bioluminescent mouse model of canine 
DLBCL   
 
To validate the bioluminescent canine DLBCL xenograft model for preclinical studies and its 
potential to investigate the utility of BLI in monitoring response to therapy, a therapeutic 
study was conducted with panobinostat, a HDACi. For this purpose, ten SCID mice were 
injected subcutaneously into the dorsal region with suspensions of 1 × 106 cells of CLBL-
1GFP+Luciferase+ cells in PBS with matrigel® (1:1) to induce tumors. When tumors reached a 
minimum volume of 100 mm3, mice were randomly assigned to one of the two groups: 
control group (vehicle only, n=5) and treatment group (20 mg/kg panobinostat, n=5). Vehicle 
(2% DMSO + 48% PEG300 + 2% Tween 80 + ddH2O) and treatment dose selection were 
based on our previous studies (Dias et al., 2018). Panobinostat (Selleckchem, Houston, TX, 
Cat # S1030) stock solutions were prepared at 67 mg/ml in DMSO (Sigma-Aldrich) and 
stored at -20ºC. Treatment consisted of intraperitoneal injections 5 days per week, over two 
weeks. Tumor volume and body weight was measured three times per week. Tumor volume 
was calculated as (width)2 × length. Compound activity was determined by TGI. TGI was 
determined as the percent change in tumor volume of treated over control animals (%T/C). At 
the end of the study, all animals were examined using in vivo bioluminescence imaging, as 
described above, and were sacrificed for necropsy examination by a pathologist. Tumor and 







5.3.9. Statistical analysis 
 
All data was expressed as mean ± standard error of mean (SEM). Analysis was performed 
using Prism 5 (Graphpad Software). All data normality was analyzed using Shapiro-Wilk’s 
test. For in vitro assays, statistical significance of results was determined by One-way 
ANOVA followed by Tukey Multiple Comparison test to compare individual groups. The 
distribution of the in vivo assays results did not pass the normality test. Therefore, groups 





5.4.1. Generation of a stable CLBL-1GFP+luciferase+ cell line 
 
The CLBL-1 cell line (Rütgen et al., 2010, 2012) was transduced with a bicistronic lentiviral 
vector, as described in the material and methods section, to generate a stable canine DLBCL 
cell line expressing both firefly luciferase and GFP reporters for bioluminescence and 
fluorescence detection. The CLBL-1 cell line was selected for our study because it is the only 
canine cell line that faithfully represents DLBCL, reproducibly inducing tumors and 
preserving its phenotype in the xenotransplantation setting (Dias et al., 2018; Rütgen et al., 
2010, 2012; Weiskopf et al., 2016). As shown in Figure 43A, a stable CLBL-1GFP+luciferase+ cell 
line was generated after two cycles of cell sorting. The luciferase activity was confirmed 
using a luciferase assay kit. As shown in Figure 43B, luciferase activity of CLBL-
1GFP+luciferase+ was confirmed and it was correlated with cell density. In contrast, no luciferase 













Figure 43 - Generation of a stable CLBL-1GFP+luciferase+ cell line. 
 
(A) Histogram of CLBL-1
GFP+luciferase+
 cell line construction, representing GFP expression analysis after 
the first and second cell sort. CLBL-1 cells were transduced with lentiviral particles encoding GFP-
luciferase reports. After 72 h, GFP positive cells were sorted, using FACSAria IIu sorter (BD 
Biosciences), and cultured in RPMI medium. After 4 weeks in culture, cells were subjected to a 
second sort to ensure a stable GFP expressing cell line. The phenotype of the final CLBL-1
GFP+luciferase+
 
stable cell line that was used in further assays, is represented by the right-side histogram. (B) 
Luciferase activity was analyzed in the CLBL-1GFP+luciferase+ cell line using the parental cell line as a 
control (Control 1 – 1×104 cells and Control 2 - 1×106 cells). Indicated cell densities of both cells lines 
were lysed, incubated with D-luciferin and luminescence was measured. Results are expressed as 
mean ± SEM.  *p < 0.05 and ** p < 0.01 from control cells.  
 
Importantly, the evaluation of growth patterns through a cell doubling time assay confirmed 
that the stable CLBL-1GFP+luciferase+ cell line exhibited a similar doubling time compared to the 
CLBL-1 parental cell line (26.45 hour doubling time for CLBL-1GFP+luciferase+, versus 26.52 





Figure 44 - Growth curves of the CLBL-1GFP+luciferase+ cell line versus the 
parental CLBL-1 cell line. 
 
 
The cells were grown for 5 days in the regular cell culture conditions. The total numbers of cells over 
time are plotted in a logarithmic scale. Both cell lines showed similar growth patterns and doubling 
times. 
 
5.4.2. Establishment of a subcutaneously bioluminescent canine DLBCL mouse model  
 
To develop the subcutaneous bioluminescent canine DLBCL xenograft mouse model a pilot 
study was first performed with SCID mice inoculated with three different cell densities. For 
that, mice were randomly assigned to three distinct groups (n=3) according to the number of 
cells administered (group I = 1×106 cells, group II = 0.5×106 cells and group III = 0.1×106 
cells). Suspensions of CLBL-1GFP+luciferase+ cells were inoculated subcutaneously into the 
dorsum of SCID mice. All xenograft mice, regardless of cell density, presented tumor 
development at the site of injection eight days after cell inoculation. Importantly, tumors were 
established with a success rate of 100% (n=9) (Figure 45A). All tumors were efficiently 
monitored and quantified by BLI. No significant differences in tumor growth were observed 
between groups. As shown in Figure 45B, the BLI signal obtained confirmed tumor induction 
and allowed for tumor growth monitoring.  In addition, it is important to mention that apart 
from tumor formation, no clinical abnormalities were observed in any of the transplanted 




Figure 45 - Establishment of a bioluminescent mouse model of canine DLBCL. 
 
SOPF/SHO SCID mice (6-8 weeks-old) were injected subcutaneously with CLBL-1GFP+Luciferase+ cells 
using three different cell densities (1×106 cells (n=3), 0.5×106 cells (n=3) and 0.1×106 cells (n=3)) in a 
matrigel suspension. (A) Tumor volumes were measured three times a week, using a caliper and 
calculated as (width)2 × length (±SEM). There were no significant differences in tumor size between 
groups. (B) Bioluminescent imaging was performed to monitor tumor development. Prior to BLI 
imaging, mice received an intraperitoneal injection with D-Luciferin. Fifteen minutes after substrate 
injection, animals were anesthetized and subjected to in vivo imaging. Representative images of 
bioluminescence imaging at the end of the first and second week are shown.  
 
5.4.3. Characterization of xenograft tumor histopathological features 
 
To assess macroscopic and microscopic characteristics of the bioluminescent canine DLBCL 
xenograft model, necropsy and histopathological evaluation were by a veterinary pathologist. 
Macroscopically, all xenografts were located in the injection site, the dorsal interscapular 
region. Tumors were nodular, soft and hemorrhagic and highly adherent to subcutaneous 
tissue and underlying muscle. No gross macroscopic alterations were identified in the main 
organs examined. Microscopically, tumors corresponded to compact infiltration of the dermis, 
hypodermis, muscle panniculus and skeletal muscle by large lymphoid cells with indistinct 
cytoplasmic borders, finely distributed nuclear chromatin and inconspicuous nucleolus 
(Figure 46A). There were extensive areas of necrosis and mitotic activity was considered 
intermediate (six to seven mitosis per high power field). These microscopic features are 
characteristic of a medium to high grade lymphoma (Rütgen et al., 2012). 
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Immunohistochemistry analysis of the xenograft tumor using CD20 and CD3 labelling was 
positive for CD20 in virtually 100% of the tumor cells confirming the phenotype of the 
CLBL-1GFP+luciferase+ cell line (Figure 46B). Importantly, all these characteristics were 
consistent with data obtained for the parental CLBL-1 xenograft model (Dias et al., 2018; 
Rütgen et al., 2010, 2012).  
 
Figure 46 - Histopathological characteristics of the CLBL-1GFP+Luciferase+ cell line 
as a xenograft tumor in SOPF/SHO SCID mice. 
 
Mouse interscapular region. Xenograft CLBL-1GFP+Luciferase+ tumor. (A) Upper panel - Compact 
infiltration of the dermis, hypodermis, muscle panniculus and skeletal muscle by large lymphoid cells 
(H&E, 20x). Bottom panel – Magnification of the tumor showing lymphoid cells with indistinct 
cytoplasmic borders and finely distributed nuclear chromatin and inconspicuous nucleolus. A muscle 
fiber is surrounded by tumor cells in the insert (H&E, 100x, insert 400x).  (B) Upper panel – 
Immunohistochemistry for B-cells showing positivity in virtually 100% of the tumor cells (anti-CD20 
antibody, Gill’s hematoxylin, 100x, insert 400x). Bottom panel – Immunohistochemistry for T-cells, 





5.4.4. Evaluation of bioluminescence canine DLBCL xenograft model for non-invasive 
monitoring tumor progression and response to therapy  
 
Aiming to evaluate the suitability of the established bioluminescent canine DLBCL xenograft 
model for monitoring tumor progression and therapeutic responsiveness, we conducted an in 
vivo therapeutic study using panobinostat, a HDAC inhibitor. We have recently investigated 
antitumor properties of HDAC inhibitors for the treatment of canine DLBCL (Dias et al., 
2018). Among a panel of HDAC inhibitors studied, panobinostat proved to be the most 
promising compound showing strong in vitro and in vivo antitumor properties against canine 
DLBCL. Therefore, panobinostat was selected to test the treatment response in the 
bioluminescent CLBL-1GFP+luciferase+ xenograft model. Considering that in the pilot study all 
cell densities presented the same engraftment efficiency (100%), the 1×106 cell density was 
used to establish the xenograft model and the therapeutic study, allowing the further 
comparison with the xenograft model established using parental CLBL-1 cell line (Dias et al., 
2018).  As expected and consistent with the pilot study, all inoculated mice presented tumors 
eight days after inoculation. When tumors reached ~100 mm3, mice were randomized into two 
groups: control group (not treated/vehicle, n=5) and treated group (panobinostat at 20 mg/kg, 
n=5). After two weeks of treatment, panobinostat at 20 mg/kg dose inhibited tumor growth by 
93.3% when compared to vehicle control treated mice (p < 0.05) (Figure 48A). This tumor 
growth inhibition was similar to data gathered from the panobinostat efficacy study performed 
on the xenograft model using the parental CLBL-1 cell line (Dias et al., 2018). In addition, 
besides macroscopic dimensions, xenograft tumors of the panobinostat treated group 
presented identical histopathological characteristics to the xenograft tumors of the control 













Figure 47 - Histopathological characteristics of the CLBL-1GFP+Luciferase+ 




Mouse interscapular region. Xenograft CLBL-1GFP+Luciferase+ tumor. (A) Compact infiltration of the 
dermis, hypodermis, muscle panniculus and skeletal muscle by large lymphoid cells (H&E, 20x). (B) 
Magnification of the tumor showing lymphoid cells with indistinct cytoplasmic borders and finely 
distributed nuclear chromatin and inconspicuous nucleolus. A muscle fiber is surrounded by tumor 
cells in the insert (H&E, 100x, insert 400x).  
 
To validate the bioluminescence model for the detection of a therapeutic response, we 
quantified the photon signal intensity from BLI and statistically examined the differences 
between the two groups. As shown in the representative photographs (Figure 47B) and in the 
BLI measurements (Figure 47C) we can observe a significant lower BLI signal, up to 20-fold, 
in treated mice compared to untreated control mice (p < 0.01). Thus, the BLI signal obtained 
showed to be extremely suitable for visualization of tumor localization in mice and to monitor 





Figure 48 - Assessment of therapeutic response of the bioluminescent canine 





SOPF/SHO SCID mice (6-8 weeks-old) were injected subcutaneously with 1 × 106 of CLBL-
1GFP+Luciferase+ cells. When tumors reached ~100 mm3, mice were randomized into two treatment 
groups: not treated (controls/vehicle only) and panobinostat at 20 mg/kg (n = 5 per group). Mice were 
treated with intraperitoneal injections for 2 weeks, 5 days per week.  (A) The tumor growth curve 
showed that treatment group had a statistically significant tumor growth inhibition compared to the 
vehicle group (*p < 0.05). (B) Bioluminescent imaging was performed to monitor therapeutic 
response. Fifteen minutes after D-Luciferin substrate injection, animals were anesthetized and 
subjected to in vivo imaging. Representative images of bioluminescence imaging at the end of the 
therapeutic assay are shown. (C) Quantitative analysis of photon counts derived from CLBL-
1GFP+Luciferase+ xenograft mice between control/vehicle mice and mice receiving panobinostat treatment. 
The treated mice group presented a significant lower BLI signal, up to 20-fold, compared to untreated 




DLBCL is the most common canine aggressive B-cell lymphoma worldwide, sharing similar 
biological, behavioral, genetic, and molecular characteristics with the human counterpart 
(Aresu, 2016; Ferraresso et al., 2017; Mudaliar et al., 2013) Despite having good response to 
multiagent chemotherapy, curative treatment remains elusive for most dogs (Marconato et al., 
2011). As such, collaborative efforts are being made to integrate naturally occurring canine 
lymphoma into novel cancer treatment studies, in order to improve the treatment for dogs 
diagnosed with lymphoma, while accelerating therapeutic development for human lymphoma 
(Ito et al., 2014; Marconato et al., 2013). However, the integration of canine lymphoma in 
comparative studies has been limited due in part by the lack of validated, well-characterized 
and widely disseminated canine lymphoma models for preclinical research (Richards & Suter, 
2015).  
To date, few in vivo canine lymphoma models have been described (Ito et al., 2011; 
Kisseberth et al., 2007; Nadella et al., 2008; Rütgen et al., 2012; Umeki et al., 2013). This is 
mainly due to the low number of available well-characterized canine lymphoid cell lines. In 
fact, canine hematopoietic cell lines have been historically difficult to establish and most cell 
lines are of T-cell origin (Richards & Suter, 2015; Seiser et al., 2013). Therefore, the majority 
of canine lymphoma xenograft murine models described until now represent T-cell lymphoid 
malignancies (Kisseberth et al., 2007; Nadella et al., 2008; Umeki et al., 2013). Notably, only 
four of the available cell lines are reportedly of B-cell origin, including the GL-1 cell line 
derived from a dog with B-cell acute lymphoblastic leukemia (Nakaichi et al., 1996); the 17-
71, a B-cell cell line not initially phenotyped and that does not express typical B-cell 
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lymphoma markers (Steplewski et al., 1987); 3132, a cell line that probably is not of B-cell 
origin despite initial reports of surface immunoglobulin (Strandstrom & Rimaila-Parnanen, 
1979) and CLBL-1, the only available cell line that has been well-characterized both in vitro 
and in vivo (Dias et al., 2018; Roode et al., 2016; Rütgen et al., 2010, 2012; Weiskopf et al., 
2016). As a matter of fact, CLBL-1 appears to be the only exclusive cell line that faithfully 
represents DLBCL, reproducibly inducing tumors and preserving its phenotype in the 
xenotransplantation setting (Rütgen et al., 2010, 2012). Primary canine DLBCL xenografts 
have also been described and are a possible alternative approach, however, these tumors only 
form when implanted intraperitoneally into conditioned NOD scid gamma (NSG) mice and 
their variability in growth makes therapeutic evaluation challenging (Ito et al., 2011; 
Weiskopf et al., 2016). 
The CLBL-1 cell line tumorigenicity, genomic stability, histological and morphological 
properties were initially reported on a xenograft murine model (Rütgen et al., 2012). For that 
purpose, CLBL-1 cell line was subcutaneously injected in the right and left flank of 
Rag2−/−γc−/− mice. This model was highly tumorigenic, and all mice demonstrated liver, 
spleen, bone marrow, ovaries and uterus lymphoma involvement. This was the first study 
demonstrating that CLBL-1 canine lymphoma cell line develops multicentric lymphoma as 
observed in canine patients, making it a highly stable tool for B-cell lymphoma research in 
veterinary and human medicine. Nevertheless, it revealed certain shortcomings related to 
heterogeneous clinical presentation and inability to monitor disease progression through non-
invasive methods (Rütgen et al., 2012). A similar in vivo study with CLBL-1 in murine 
xenograft model has also been reported by Weiskopf et al. to study the synergy of the 
antitumor activity of blocking CD47 and anti-CD20 immunotherapy. This work established 
xenograft models of disseminated, intra-abdominal and subcutaneous disease into NSG mice, 
paving the way for the development of bioluminescent canine B-cell lymphoma mouse 
models. However, many questions remained to be answered regarding tumor engraftment 
efficiency, reproducibility and BLI monitoring (Weiskopf et al., 2016).  
To overcome these limitations, we aimed at establishing and characterizing a localized 
subcutaneous bioluminescent xenograft mouse model of canine DLBCL, which would easily 
allow monitoring of tumor progression and treatment response in preclinical studies. For this 
purpose, we established a SCID xenograft model of canine DLBCL by subcutaneously 
implanting CLBL-1GFP+Luciferase+ cells. The development of a stable cell line of CLBL-1 
expressing luciferase and GFP, allows monitoring and quantifying the disease progression 
noninvasively. Currently, bioluminescent imaging (BLI) is one of the most widely used 
techniques to track target cells in vivo, especially hematopoietic cell lines that disseminate 
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widely in their hosts as xenografts (Xu et al., 2016). This technique relies on the fluorescent 
signal produced by the chemical reaction between the luciferase and its substrate (D-
luciferin), as such it is highly specific and sensitive, allowing to visualize, quantify and 
monitor in real-time the tumor development (Close, Xu, Sayler, & Ripp, 2010). CLBL-1GFP+ 
Luciferase+ cell line implanted in SCID mice induced highly aggressive tumors, with rapid tumor 
growth that requires close monitoring to avoid tumor burden. Three different cell densities for 
tumor establishment were tested (0.1×106, 0.5×106 and 1×106 cells) and all presented 
homogeneous tumor development within eight days after injection, with a 100% engraftment 
success rate. There were no significant differences in tumor growth curve between different 
cell density groups.  
Histological and immunohistochemical analysis revealed that xenograft tumors retained 
similar histological characteristics and B-cell and T-cell markers expression, compared to 
original CLBL-1 cell line xenografts (Rütgen et al., 2010, 2012). Finally, the CLBL-
1GFP+Luciferase+ model, comparable to the parental CLBL-1 model, demonstrated a high 
consistency in disease progression with tumor onset occurring after 8 days of inoculation in 
all animals, providing an intervention window of two weeks that allows the rapid screening of 
a plethora of therapeutic molecules. 
In order to confirm whether the bioluminescent canine DLBCL xenograft model could be a 
reliable preclinical tool for drug investigation, we conducted a therapeutic study. We have 
recently investigated antitumor properties of a panel of seven HDAC inhibitors for the 
treatment of canine DLBCL. Amongst all HDAC inhibitors studied, panobinostat proved to 
be the most promising compound and was selected for further in vitro and in vivo 
investigation. This potent HDACi demonstrated strong antitumor properties against a CLBL-1 
xenograft canine tumor growth, as it efficiently inhibited tumor growth (Dias et al., 2018). As 
such, panobinostat was selected to test the treatment response in our established 
bioluminescent model. The results presented herein, demonstrated that treatment with 
panobinostat (20mg/kg) efficiently inhibited tumor growth and consequently reduced the BLI 
signals, up to 20-fold, when compared with the control mice. Thus, the BLI measurements 
obtained with the established bioluminescence xenograft model were extremely suitable for 
visualization of the tumor localization in the mice, but also highly useful for the quantitative 
detection of the tumor load and response to therapy.  
In conclusion, in this study we established and characterized a novel localized subcutaneous 
bioluminescent canine DLBCL xenograft model that offers high engraftment efficiency, 
preservation of relevant tumor features and reproducible tumor growth. This model 
established with CLBL-1GFP+Luciferase+ cells can be therefore efficiently used to monitor non-
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invasively and quantitatively the outgrowth of canine DLBCL, and be a valuable preclinical 








































Final conclusions and future perspectives 
 
 
The current landscape of cancer research is facing a profound transformation with the 
introduction of immune-oncology as the fourth pillar for cancer therapy. Not only have 
immunotherapies resulted in unprecedented clinical responses, rapid drug development and 
several first-in-class approvals from the FDA in the past few years, but the advent of such 
innovative therapies is also revolutionizing treatment paradigms and algorithms in current 
oncology and hemato-oncology practice (Kelly, 2018). As a result, clinical and translational 
research need to adapt to a rapidly changing scenario to effectively translate novel concepts 
into sustainable and accessible therapeutic options for cancer patients (Golan, Milella, 
Ackerstein, & Berger, 2017). Historically, the success rate in developing new oncology drugs 
has been surprisingly low as compared to other areas of medicine, particularly in late phases 
of development. The complexities and challenges of the new era of immune-oncology 
strongly emphasize the need to identify new strategies, models and paths to develop fast, 
successful, and cost-effective therapies (Golan et al., 2017; Ventola, 2017). 
Advances in cancer immunotherapy relies on faithful predictive preclinical investigation and 
rodent models have been the foundation of preliminary basic research and safety assays 
(Malaney et al., 2014). However, these induced-tumor models underrepresent the 
heterogeneity and complex interaction between the human immune cells and tumors. In fact, 
laboratory mice rarely develop spontaneous tumors, are housed under specific-pathogen free 
conditions that markedly influence immune development, and incompletely model key 
characteristics of the tumor/immune microenvironment, creating challenges for clinical 
translation. As a result, these murine models have failed to correlate with clinical success 
rates (Biemar & Foti, 2013; Kohnken et al., 2017; Kola & Landis, 2004). Thereby, the use of 
alternative animal models is pivotal to bridge the translational gap between murine models 
and human clinical studies. 
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The inclusion of a canine model in the drug development path of cancer immunotherapies is 
being widely recognized as a valid solution to overcome several hurdles associated with 
conventional preclinical models (Decker et al., 2017). Dogs with naturally occurring tumors 
are highly translational models that represent an opportunity to investigate the clinical 
potential of novel immunotherapies in a comprehensive manner. By complementing murine 
studies and human clinical trials, dogs allow monitoring the “scaling up” effects of a 
therapeutic approach that depends on complex interactions between tumor and immune cells, 
while assessing long-term efficacy and toxicity (Park et al., 2016). Taken together, these 
features may allow the establishment of solid foundations to rapidly translate the results 
obtained from canine patients to human patient management, with benefits for both species 
(Barutello et al., 2018). However, the implementation of such canine clinical trials is far from 
being an easy quest. It requires multiple organized efforts to validate the canine model, which 
still lacks a thorough characterization of the canine immune system and its effector cells and 
molecules, the evaluation of common tumor epitopes, the development of canine-
specific/cross-reactive agents and the establishment of preclinical models for veterinary 
oncological settings (Klingemann, 2018). 
Driven by the great success achieved with the application of immunotherapies in the treatment 
of hNHL and by the remarkable similarities of canine lymphoma to its human counterpart, 
canine lymphoma has been one of the main focus of comparative research regarding the 
development of immunotherapeutic approaches for dogs (Ito et al., 2015; Jain et al., 2016; 
Marconato et al., 2015; O’Connor & Wilson-Robles, 2014b; Weiskopf et al., 2016). These 
initiatives are also motivated by the great clinical demand to improve the poor prognosis of 
dogs diagnosed with cNHL, considering that the majority of dogs, regardless of the treatment 
options used, relapse with terminal, drug-resistant disease (Vail et al., 2007). To date, two 
mAbs - CD20-positive B cell (Blontress®) and CD52 positive T cell lymphoma (Tactress®) - 
have been approved by the US Department of Agriculture and are commercially available in 
the USA and Canada (Regan & Dow, 2015). Nevertheless, the reported therapeutic efficacy 
of these mAbs is suboptimal and substantially inferior to results reported in human patients, 
demonstrating an urgent and unmet need to develop effective immunotherapeutic strategies 
for cNHL (Klingemann, 2018). 
Within this context, the present work was designed to establish an innovative and promising 
research line that enables the development of a novel sdAb-based drug delivery system for 
NHL, and the characterization of the immune system of dogs diagnosed with cNHL and 
validation of an animal model of human NHL.  
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In addition to tackling many of the limitations associated with the canine model, this work 
aimed to usher-in a new generation of targeted cancer therapies. For that purpose, a 
multidisciplinary strategy addressing several distinct complemental objectives was carefully 
designed. Altogether achieving the proposed objectives would allow the construction of a 
solid framework that offers a platform that could both support current research and promote 
further developments. Therefore, the present work comprised six different chapters with 
specific goals that have ultimately contributed to the main objective of the study.  
The first chapter begins by covering a general overview of the challenges and prospects of 
today’s cancer immunotherapies and the role that comparative medicine might play in solving 
the limitations brought by this rapidly expanding field. The state of art of both human and 
canine NHL and the rationale behind the use of the canine model to bridge the translational 
gap between murine preclinical studies and human clinical trials were also addressed, 
followed by a review of currently available immunotherapies for cNHL that demonstrates the 
potential contained in these therapeutic options. Finally, a brief synopsis of antibody 
therapeutics was presented, highlighting the latest advances in antibody development, the 
advantages of antibody fragments and the promising use of sdAbs as targeting moieties for 
cancer therapy. By shedding some light on these subjects, the intricate scope of our work was 
unraveled, allowing a better understanding of its outline and specific goals. The following 
chapters (2, 3, 4 and 5) focused on the main achievements and the implications of these 
findings. 
Considering that new knowledge holds the key for innovation, basic and applied research go 
hand in hand when it comes to exploring the full potential of cNHL model. As mentioned 
above, much is still unknown about the cNHL immune status and it has become clear that 
insights into the immune system of these animals can propel the discovery of truly effective 
immunotherapies, either by unveiling new mechanisms/receptors or by improving the clinical 
efficacy of previous therapies. With that in mind, chapter 2 reports an effort to gain a better 
understanding of the systemic and intratumoral cytokine dysregulation/dysfunction in canine 
lymphoma. For that purpose, considering that high quality basic, clinical and translational 
cancer research requires prompt access to well-preserved biological samples, a canine 
lymphoma biobank was established with samples collected from several diagnosed dog 
patients. These samples were used to assess the cytokine mRNA profiles of circulating and 
intratumoral environments in multicentric canine lymphoma. Furthermore, blood count 
analysis and the comparison of putative cytokine serum levels of dogs diagnosed with 
lymphoma with those of healthy control dogs were also performed. Overall, it was concluded 
that, similarly to its human counterpart, local and systemic dysregulation in cytokine response 
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might be involved in cNHL pathogenesis and tumor survival promotion, progression and 
immune escape. By confirming and extending previous investigations, our work contributed 
to identify potential cytokine candidates to be used not only for diagnostic and prognostic 
purposes but also as targets for therapeutic intervention either by cytokine inhibition and/or 
immunomodulatory strategies. Notably, preliminary studies have reported that chemotherapy 
protocols, while prompted complete tumor responses, appeared to fail to restore immune 
response in cNHL, possibly reducing its ability to re-establish control over residual disease 
(Axiak-Bechtel et al., 2014). Also, active immunotherapy strategies suh as cancer vaccines 
have also proven to be successful in mounting an immune response and improving survival in 
dogs with NHL, when in combination with conventional chemotherapy (Marconato et al., 
2014, 2015; Peruzzi et al., 2010). These findings strengthen the concept that harnessing the 
immune system with immunotherapeutic approaches might be the long-waited solution to 
improve the prognosis of cNHL. Importantly, the successful construction of a multicentric 
cNHL biobank was a major output of this work. Maintaining the construction of this biobank 
will ensure the availability of multiple, properly preserved samples for current and future 
research studies. This is will be particulary advantageous for the investigation of common 
targets in human and canine NHL for the development and application of immunotherapeutic 
approaches. Indeed, these samples were used for the evaluation of the gene expression of 
several markers: CD19, CD21, CD22, CD74, and CD80; and assessment of their potential as 
immunotherapy targets for canine B-cell lymphoma. This study was conducted under this 
thesis project and resulted in the master thesis of André Almeida.  
The work described in chapter 3 explored the development of recombinant antibodies for 
cNHL treatment and diagnosis. In the last decade, the scientific community has been reporting 
cases of therapeutic success using mAbs in human lymphoma treatment, encouraging the 
establishment of similar therapeutic options in veterinary settings (Adler & Dimitrov, 2012). 
However, the recently approved mAb-based therapies have presented disappointing scientific 
and clinical results, demonstrating that the discovery of an effective antibody for the treatment 
of cNHL may require a more complex and innovative approach. We have been showing that 
rabbit derived sdAbs can be developed against several targets and that these minimal scaffolds 
show great potential for therapeutic applications (Goncalves & Aires-Da-Silva, 2008; Volker 
et al., 2016). sdAbs are presently the smallest functional antibody fragment, only consisting of 
a VH or VL domain, which  improves their tumor penetration and accessibility to targets not 
easily reached by complete IgGs (Aires da Silva et al., 2008; Corte-Real et al., 2005; Popkov 
et al., 2004; Volker et al., 2016). In addition to the reduced size, complementary-determining 
regions (CDRs; antigen-binding regions) of sdAbs can be easily engineered to develop 
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specific and high-affinity binders. Moreover, sdAbs also present excellent properties such as 
high stability, solubility, low immunogenicity and low manufacturing cost (Aires da Silva et 
al., 2008; Volker et al., 2016). Importantly, rabbit sdAbs also benefit from the unique 
ontogeny of rabbit B cells that promotes vastly distinctive antibody repertories rich in in vivo 
pruned binders of high diversity, affinity and specificity (Weber et al., 2017). Furthermore, 
rabbits are evolutionarily distant from mice and rats, so epitopes that are not immunogenic in 
rodents can be recognized by rabbit mAbs, increasing the targetable epitopes and facilitating 
the generation of mAbs that cross react with other species (Weber et al., 2017) - a key aspect 
for clinical translational.   
As such, it has become clear that rabbit recombinant antibody fragments will become part of 
the new-generation of mAbs and that cNHL, as an animal model to its human counterpart, 
could could serve as a proof of concept and propel the development of novel 
immunotherapies strategies. 
Nevertheless, a critical question remained: should we develop antibodies against a validated 
target or should we pursuit novel immunotherapeutic targets? On one hand, the majority of 
antibody therapeutics have been isolated from target-led drug discovery, where many years of 
target research preceded drug program initiation. On the other hand, as the search for 
validated targets becomes more challenging and target space becomes increasingly 
competitive, alternative strategies are gaining favor (Minter, Sandercock, & Rust, 
2017). Considering the many strengths presented by each approach, we aimed to pursue both, 
as described in chapter 3, by developing sdAbs against canine CD20, a well-known clinically 
validated target in human NHL, and by developing novel sdAbs against other specific cNHL 
antigens using an innovative strategy.  
The anti-CD20 mAb Rituximab has revolutionized the treatment of B-cell malignancies and is 
now used in a growing range of clinical settings (Ito et al., 2015; Motta et al., 2010). This 
unprecedented success has not only substantially changed the mindset of the clinical 
community about the ability of mAb to improve outcomes but has also catalyzed the interest 
in the pharmaceutical industry to develop the next generation of anti-CD20 mAbs (Alduaij & 
Illidge, 2011; Chames et al., 2009). A few 1st generation mAbs targeting canine CD20 were 
recently developed and one has obtained clinical approval, as previously mentioned. 
However, unsatisfactory clinical results have highlighted the need for 2nd and 3rd generation 
mAbs and an urgent demand to gain better understanding of antibody effector functions 
present in the canine immune system  (Ito et al., 2015; Jain et al., 2016; Klingemann, 2018; 
Rue et al., 2015; Sinha, 2014). With this in mind, we have conducted the first comprehensive 
target characterization of canine CD20 using our cNHL biobank. Data obtained under gene 
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and protein expression studies on lymphoma and normal canine cells demonstrated an 
overexpression of this receptor on canine lymphoma cells, validating the canine CD20 as a 
potential target for veterinary immunotherapeutic strategies. Additionally, a new sequence of 
canine CD20 was identified in our biobank samples, diverging from previous published 
sequences. Furthermore, we reported the use of a novel strategy for the generation of 
recombinant anti-CD20 monoclonal antibodies that bind to the canine receptor and presents 
cross-reactivity against the human receptor. This resulted in the selection of a panel of novel 
sdAbs, that may become useful tools for exploring the development of novel therapeutic 
alternatives for comparative oncology. 
Although the addition of Rituximab has altered the therapeutic landscape and improved 
prognosis of hNHL, the mortality rate is still high. Therefore, considerable room for improved 
outcome remains, including the use of novel strategies that act synergistically with CHOP–
based protocols to provide greater tumor specificity and less nonspecific toxicity (Marconato 
et al., 2015). Among mAb-based therapies, ADCs are considered one of the most promising 
strategies, combining the tumor selectivity, pharmacokinetics and biodistribution properties of 
antibodies with the cytotoxic potency of small molecules (Diamantis & Banerji, 2016). The 
selection of the target antigen is the first and most important determining factor for a 
successful ADC, directly affecting its efficacy, therapeutic window and toxicity profile. The 
ideal characteristics of a useful ADC antigen include up regulated expression in the tumor; 
internalization of antigen via endocytosis in the presence of ligand and its recycling back to 
the plasma membrane and homogeneous antigen expression in the tumor microenvironment 
with low antigen abundance in healthy tissues (Sau et al., 2017).  Therefore, CD20 targeting 
does not gather all the recommended criteria to be considered a valuable ADC target, despite 
its upregulation in cancer cells and low expression in normal cells, as the majority of anti-
CD20 mAbs do not internalize upon binding (Klein et al., 2013). Recent studies indicate that, 
depending on the linker and drug combination, this mechanism may not be essential and 
ADCs can be cleaved extracellularly or via other mechanisms, therefore presenting a 
bystander killing effect (Staudacher & Brown, 2017). Nevertheless, during the development 
of sdAbs against novel cNHL targets, we focused in selecting sdAbs with binding and 
internalization properties, in order to develop a highly selective and potent new anti-cancer 
ADC therapeutic molecule. 
To overcome the limitations of current discovery platforms, we have explored a novel 
selection strategy of tumor-specific antibodies against canine lymphoma that relies on 
displaying cancer-restricted antigens that can then be captured using multiple antibody-based 
technologies. Approaching the drug discovery process from this angle — the 
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antibody/therapeutic activity side — provides an opportunity to discover new targets and 
target epitopes, use the antibody as a tool to validate the target, and rapidly evaluate the 
functional characteristics of the antibody itself as a possible therapeutic agent (Loo & Mather, 
2008). 
For that purpose, a highly diverse library of rabbit sdAbs against primary canine NHL cells 
has been successfully constructed, to ensure the presence of antibodies against any potentially 
relevant target that is overexpressed in the disease setting. By coupling subtractive antibody 
selection rounds on whole-cells and a high-throughput screening, we have selected a panel of 
novel sdAbs targeting cNHL. 
The obtained data showed that these selected sdAbs have great promise. In fact, recently a 
final in vivo selection on a human and canine NHL murine model confirmed that these sdAbs 
populations were indeed highly selective and specific against NHL. With this novel approach 
the repertoire of targetable NHL tumor receptors may be expanded, while simultaneously 
confirming the availability of the epitope in vivo and generating new antibodies for targeting. 
In the future, we expect to use these promising sdAbs as tools for the development of a novel 
ADC for NHL, by coupling a potent cytotoxic drug payload to the selected sdAbs. 
Among the main components of an ADC – payload, linker and antibody – the payload is an 
important and crucial constituent of the therapeutic ADC molecule. In broad terms, payloads 
for ADCs can range from small cytotoxic molecules to protein toxins, enzymes, other proteins 
and radionucleotides (Strohl & Strohl, 2012). In the first generation of ADCs, researchers 
used clinically approved chemotherapeutics with known clinical profiles like doxorubicin, 
methotrexate, and 5-flurouracil as payloads, however, this ADC class was underwhelming 
due to the insufficient potency of the payload and/or high toxicity as a consequence of the 
instability of the ADC and systemic loss of the drug (Dan et al., 2018; Vankemmelbeke & 
Durrant, 2016). Since then, the development of second-generation ADCs focused on 
improving linker stability. Moreover, it has resorted to more potent (100–1000-fold) tubulin-
targeting agents such as the auristatins and maytansinoids, or DNA-targeting agents such as 
the calicheamicins. That has led to the relatively recent US FDA approval of two microtubule-
inhibiting ADCs: brentuximab vedotin (SGN-35, Acetris®) for Hodgkin and anaplastic large 
cell lymphoma and ado-trastuzumab emtansine (T-DM1, Kadcyla®) for metastatic HER2-
positive breast cancer. Regardless, the second-generation of ADCs are not without its 
shortcomings. Notably, the heterogeneity of the final ADC with respect to drug–antibody 
ratio (DAR) due to stochastic coupling strategies, the narrow therapeutic index, the limited 
penetration of solid tumors and the development of resistances, continue to drive the field 
toward further improvements.  As such, third generation ADCs focused on site-specific 
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conjugation to ensure homogenous ADCs with well-defined DAR. At the same time, efforts 
are being made to explore payloads with novel modes of action, with special focus on agents 
that present activity against nonproliferating cancer cells, which would widen the target area 
to include tumor-initiating cells and possibly overcome resistances (Vankemmelbeke & 
Durrant, 2016).   
Within this context, a screening of multiple drugs, acting via different mechanisms, was 
conducted to assess their cytotoxic effect on cNHL, aiming to identify potential payloads to 
be coupled with our sdAbs. This allowed the recognition of a few highly potent drugs, among 
which HDACi were particularly effective and gained special interest due to the high efficacy 
they also present in targeted human cancer therapy, namely hematopoietic tumors. Ultimately, 
this culminated on a pioneer investigation of their antitumor properties using a canine B-cell 
lymphoma model, which is described under chapter 4. A panel of seven HDACis was initially 
tested on the well characterized CLBL-1 canine B-cell lymphoma cell line and panobinostat 
was identified as the most promising compound. Panobinostat was therefore thoroughly 
characterized and showed strong in vitro and in vivo antitumor properties.  
The execution of this work prompted the establishment of a murine xenograft model of canine 
B-cell lymphoma using CLBL-1 cell line, required to test the antitumor effect of panobinostat 
in vivo. Despite recognizing all the limitations of conventional murine models, there is no 
question that these models remain fundamentally important and should not be discarded 
mainly to conduct preliminary screening and pre-clinical studies. In fact, the cost, 
reproducibility, well-characterized attributes, and wide biologic variation of these model 
systems still render them extremely valuable for proof-of-concept studies (Decker et al., 
2017). Therefore, this model proved to be highly valuable as a stable tool for B-cell 
lymphoma research. However, it also presents opportunities for improvement. In light of this, 
under chapter 5, we described the establishment and characterization of a novel localized 
subcutaneous bioluminescent cNHL xenograft model that offers high engraftment efficiency, 
preservation of relevant tumor features and reproducible tumor growth. This model 
established with a stable CLBL-1 expressing firefly luciferase and GFP reporters proved to be 
a rather efficient non-invasive and quantitative method to monitor the outgrowth of cNHL. a. 
Thus, it represents an innovative preclinical tool for comparative medicine.  
As conclusion, the approach taken during the course of this thesis allowed not only the 
characterization of new potential therapeutic antibodies for lymphoma treatment, but also the 
establishment of a solid platform for the acceleration of translational research of novel 
immunotherapeutic approaches for comparative oncology. The successful construction of a 
cNHL biobank allowed the characterization of the immune status of dogs diagnosed with 
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NHL with the investigation of the cytokine response present in the disease setting and the 
evaluation of the expression of potential targets for immunotherapeutic strategies, while 
guarantees the availability of properly cryopreserved samples for ongoing and future projects.   
Furthermore, the methodologies applied to identify potential targets, select and characterize 
the best therapeutic antibody, characterize a highly potent payload and to develop and 
characterize a bioluminescent model for in vivo testing, resulted in an innovative workflow 
that can be easily translated to other drug development research projects. In addition, this 
work opens up perspectives in comparative oncology as it contributes for the validation of the 
naturally occurring canine B-cell lymphoma model for translational immune-oncology 
research. As a result, this work has created an avenue to develop fast, successful, and cost-
effective immunotherapies for comparative oncology (Figure 49).   
 




Overall, our research group is particularly interested in the development of innovative mAb-bases therapies. By 
focusing on therapeutic areas with a high unmet medical need, such as cancer, we aim to provide solutions that 
improve patient’s quality of life and prolong lives. At the core of our oncology programme is the validation of 
canine lymphoma as an animal model for immunotherapeutic approaches in comparative medicine. Notably, the 
Canine Lymphoma Project provides an integrated drug discovery platform that maximize interdisciplinary 
cooperation and leverage commonalities across humans and dogs, for the development of novel 
immunotherapies against non-Hodgkin lymphoma, benefiting both species. Currently, this work is actively 
investigating new immunotherapies that mobilize the patient’s own immune system to combat cancer and mAb-
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